LIST OF ACCEPTED ABSTRACTS
Acute liver failure and drug induced liver injury

110
Neddylation inhibition recovers drug-induced liver injury through the stabilization of Tamm41
Poster Presentation
Presenter: Claudia Gil-Pitarch

204
Distinctive cytokine profiles in checkpoint inhibitor-induced liver injury, idiosyncratic drug-induced liver injury and autoimmune hepatitis: a potential mechanistic biomarker panel
Poster Presentation
Presenter: Edmond Atallah

356
E2F2 deficiency protects from acetaminophen-induced hepatotoxicity while E2F1 is required to prevent the devastating effects
Poster Presentation
Presenter: Xabier Buque

476
Acute liver failure, does race affect hospital outcomes?
Poster Presentation
Presenter: Raissa Nana Sede Mbakop

746
Outbreak of unexplained acute hepatitis in children: the role of viral infections
Poster Presentation
Presenter: Yael Gozlan

879
Kelch-like ECH-associated protein-1 deletion rescues cell death associated with glutathione-glutathione peroxidase 4 knockdown in hepatocytes in acute models of liver injury
Poster Presentation
Presenter: Leticia Colyn

937
Noninvasive screening for histological features of autoimmune hepatitis and prognosis of patients with antinuclear antibody-positive drug-induced liver injury
Poster Presentation
Presenter: Feiyu Zhang

1086
Prior drug allergies are associated with worse outcome in patients with idiosyncratic drug-induced liver injury: an analysis from the Spanish DILI registry
Oral Presentation
Presenter: Raul J. Andrade

1092
Forward programming to produce hepatocytes organoids for cell based therapy
Poster Presentation
Presenter: Fabian Bachinger

1240
Clinical determinants of hospital mortality in liver failure: a comprehensive analysis of 62,717 patients
Poster Presentation
Presenter: Sven H Loosen

1409
Soluble and monocyte surface CD206 is a promising indicator of sepsis in patients with acute liver failure
Poster Presentation
Presenter: Anna Cavazza

1442
Impact of plasma exchange and evolution of intensive care management in patients with acute liver failure in a liver transplant center over the past decade
Poster Presentation
Presenter: Octavi Bassegoda

1488
Liver transplantation in acute liver failure in Slovenia
Poster Presentation
Presenter: Marjana Turk Jerovšek

1558
Clinical and histological features of drug-induced liver injury: a retrospective study in biopsy-based cohort
Poster Presentation
Presenter: Ting Zhang

1586
Clinical characteristics of chronic drug-induced liver injury in mainland China: a multicenter retrospective cross-sectional study
Poster Presentation
Presenter: Hong Zhao
Clinical and histological features of porto-sinusoidal vascular disorder in drug-induced liver injury population: a retrospective study in biopsy-based cohort
Poster Presentation
Presenter: Mengqi Li

Stress-driven suppression of the hippo pathway accelerates liver injury
Poster Presentation
Presenter: Na Young Lee

Bio-molecular map of albumin identifies signatures of severity and early mortality in acute liver failure
Oral Presentation
Presenter: Neha Sharma

Microbiome and metabolome analysis outlines circulatory predictors of poor outcomes in ALF
Poster Presentation
Presenter: Sushmita Pandey

Epigenetic modifications implicated in idiosyncratic drug-induced liver injury
Poster Presentation
Presenter: Raul J. Andrade

Mesenchymal stem cell-derived small extracellular vesicles ameliorate liver injury via attenuating macrophage extracellular traps
Poster Presentation
Presenter: Zhihui Li

Dysregulated lipolysis increases intrahepatic concentrations of non-esterified fatty acids in chemotherapy-associated steatohepatitis
Poster Presentation
Presenter: Martina Derler

Exponential increase of paracetamol liver injury over the last decade in a Spanish referral center
Poster Presentation
Presenter: Anna Pocurull
2757
Efficacy of N-acetylcysteine to prevent anti-tuberculosis drug-induced liver injury: a randomized controlled trial
Oral Presentation
Presenter: Kittichai Samaithongcharoen

2806
Stanozolol-induced liver injury: a peculiar biochemical profile in a series of thirteen cases
Poster Presentation
Presenter: Vinicius Nunes

2813
Systematic review: patients with pre-existing chronic liver disease are more vulnerable to the severe sequelae of drug induced liver injury
Poster Presentation
Presenter: Georgia Zeng

2876
An in silico designed receptor antagonizing peptide targeting C-C motif chemokine receptor 8 attenuates monocyte/macrophage recruitment in vitro and in vivo
Poster Presentation
Presenter: Eline Geervliet

3052
Altered intestinal permeability in patients with drug-induced liver injury and other forms of acute liver injury: a sequential analysis of serum levels of LBP, CD14 and CD163
Poster Presentation
Presenter: Daniel E. Di Zeo-Sánchez

3078
Hepatocyte senescence is linked with extrahepatic organ injury, failure of regeneration and mortality in patients with acute indeterminate hepatitis
Oral Presentation
Presenter: Mohsin Hassan

3121
A systems medicine approach for the identification of potential prognostic biomarkers in patients with acute decompensation of cirrhosis
Poster Presentation
Presenter: Estefania Huergo Iglesias

3192
Control compounds used to validate in vitro models of idiosyncratic drug-induced liver injury: a systematic review
Poster Presentation
Presenter: Raul J. Andrade

3412
Determinants of steroid responsiveness in patients with severe acute hepatitis of indeterminate, autoimmune hepatitis and drug induced aetiologies
Poster Presentation
Presenter: Mahdi Saeidinejad

3473
SRT-015, best-in-class apoptosis signal-regulating kinase 1 inhibitor, demonstrates preclinical efficacy in acute models of liver injury
Poster Presentation
Presenter: Kathleen Elias

3534
Chemotherapy-induced hepatotoxic reactions in patients with acute myeloid leukemia: the overweight and obesity role in the pathogenesis
Poster Presentation
Presenter: Igor Skrypnyk

3620
Serum proteomics in American adults with acute liver failure
Poster Presentation
Presenter: Katharina Remih

3676
Gender differences in liver transplantation (LT) for acute liver failure (ALF) in a multicentre ALF-LT Spanish cohort
Poster Presentation
Presenter: Victoria Aguilera Sancho

3700
Autoimmune hepatitis (AIH) or drug-Induced liver injury (DILI) – a diagnostic challenge
Poster Presentation
Presenter: Yaakov Maor

3775
CDK 4/6 inhibitors induced liver injury: 7 cases from REFHEPS registry
Poster Presentation
Presenter: Lucy Meunier
Alcohol-related liver disease

293
Low sphingolipid levels indicate poor survival in patients with alcohol-related liver disease
Poster Presentation
Presenter: Thit Mynster Kronborg

521
Evaluation of histological differences between cirrhosis due to alcoholic-related liver disease and non-alcoholic steatohepatitis using automated fibrosis phenotyping of liver histology
Poster Presentation
Presenter: Masanori Fukushima

532
Potential gut microbial biomarkers for detection of sarcopenia in alcohol-related liver disease patients
Poster Presentation
Presenter: Haripriya Gupta

539
Disentangling the contributions of alcohol and alcohol-related liver disease towards dementia
Poster Presentation
Presenter: Sixian Zhao

612
The prevalence and prognostic impact of bariatric surgery in patients hospitalized with alcoholic liver disease
Poster Presentation
Presenter: Louis Onghena

656
Radiomic data can define phenotypes of acute alcoholic hepatitis
Poster Presentation
Presenter: Nawaz Safdar

702
Hemoglobin is a short-term prognostic factor in decompensated alcohol-associated cirrhosis: a multicenter prospective study
Poster Presentation
Presenter: José Ursic Bedoya

962
Strategies are needed to support people with alcohol use disorder and alcohol-related liver disease to take part in randomised clinical trials: results from the MIRAGE pilot trial of functional imagery training
Poster Presentation
Presenter: Ashwin Dhanda

993
The role of HSD17B13 and MBOAT7 during alcohol detoxification: different effects on fibrosis and inflammation
Poster Presentation
Presenter: Sebastian Mueller

1016
Epidemic within pandemic: alcohol-related hepatitis and COVID-19
Poster Presentation
Presenter: Natalie Marlowe

1075
A prospective study of hepatic fibrosis evaluation in an alcohol withdrawal unit of an university hospital center: role of FIB-4 and elastometry. Fibr'addict study
Poster Presentation
Presenter: Armand Abergel

1308
Risk of alcohol-related liver disease in offspring of individuals with alcohol-related liver disease: a nationwide cohort study in Denmark
Poster Presentation
Presenter: Gro Askgaard

1346
Pyroptotic MAITs link microbial translocation with severity of alcohol-related liver disease
Poster Presentation
Presenter: Li-Ping Zhang

1385
Cause-specific mortality in patients with alcohol-related liver disease: a nationwide Danish cohort study
Poster Presentation
Presenter: Anna Emilie Kann

1418
Alcohol use disorder among patients admitted with non-alcohol related conditions: a retrospective cohort study in secondary care
Poster Presentation
Presenter: Mohsan Subhani

1419
Adverse childhood experiences as a background for alcoholic liver disease – cohort analysis of risk score in ALD and non-ALD cirrhosis patients in comparison with the control group
Poster Presentation
Presenter: Karolina Sulejova

1483
Costs of hospital management of acute alcoholic hepatitis
Poster Presentation
Presenter: Lucy Turner

1564
Low doses of different hepatotoxins induce alcohol-related liver disease and drive hepatocellular carcinoma
Poster Presentation
Presenter: Brisa Rodope Alarcón-Sánchez

1661
Nucleoredoxin-dependent functioning is dysregulated by chronic alcohol consumption and is associated with the establishment of cellular senescence in the liver of aged mice
Poster Presentation
Presenter: Osiris German Idelfonso García

1687
Prognostic role of serum alpha-1 antitrypsin levels for waitlist mortality in patients with alcohol-associated liver disease
Poster Presentation
Presenter: Ronald Samuel

1690
Granulocyte monocyte/macrophage apheresis for corticosteroid-nonresponsive or -intolerant severe alcohol-associated hepatitis: a nonrandomized controlled study
Poster Presentation
Presenter: Ryosuke Kasuga

1697
Plasma lipidomics and meta-proteomics analysis classifies lipid species and microbial peptides associated with poor outcome in SAH patients
Poster Presentation
Presenter: Jaswinder Maras
Diabetes increases risk of mortality in alcohol-related liver disease
Poster Presentation
Presenter: Richard Parker

An increase in the number of activated regulatory T cells is associated with an improvement in liver function of patients with severe alcoholic hepatitis after steroid therapy
Poster Presentation
Presenter: Soon Kyu Lee

Systemic dyslipidemia in Ldr mice accelerates hepatic fibrosis after chronic-binge ethanol feeding
Poster Presentation
Presenter: Constanze Hoebinger

Clinical course of biopsy-controlled alcohol-related liver disease
Oral Presentation
Presenter: Stine Johansen

AKR1B10 as a novel molecular driver of alcohol-associated hepatitis
Poster Presentation
Presenter: Maria Hernandez-Tejero

Increased concentration of 4-hydroxyphenyllactic acid in patients with alcohol-related liver disease could promote the growth of Lactobacillus spp
Poster Presentation
Presenter: Jin-Ju Jeong

Risk factors for acute myocardial infarction in patients with alcohol-related liver cirrhosis - a nationwide register-based nested case-control study
Poster Presentation
Presenter: Emma Celia Herting

Type VII collagen degradation biomarker (C7M): a new marker of alcohol-induced gut injury and bacterial translocation in steatotic liver disease
Poster Presentation
Presenter: Emil Deleuran Hansen
Supplementation of choline attenuates the onset of alcohol-related liver disease
Poster Presentation
Presenter: Victor Sánchez

Risk of primary liver cancer in alcohol-related cirrhosis - Danish and English cohort studies
Poster Presentation
Presenter: Morten Daniel Jensen

Impact of heavy alcohol consumption on mitochondrial metabolism
Poster Presentation
Presenter: Scott Minchenberg

Pharmacological therapy for alcohol use disorder is effective and safe in patients with cirrhosis. Systematic review and meta-analysis
Poster Presentation
Presenter: Jordi Gratacós-Gines

Detrimental association between COVID-19 pandemic stages and alcoholic hepatitis admissions: a Canadian population-based study
Poster Presentation
Presenter: Abdel-Aziz Shaheen

Opportunistic cirrhosis casefinding in alcohol dependent inpatients through alcohol specialist nurse assessment and transient elastography: early detection in a high risk group
Poster Presentation
Presenter: Ann Archer

A cost-comparison of the LiverPRO score with FIB-4, ELF, and FibroScan in 6,032 study participants
Poster Presentation
Presenter: Katrine Prier Lindvig

Recompensation following an episode of alcohol-associated hepatitis mostly occurs in the first year of follow-up and is related to Child-Pugh score, levels of GGT and platelets, and alcohol abstinence
Poster Presentation
Presenter: Jordi Gratacós-Gines
Tumor necrosis factor-inducible gene 6 protein suppresses release of cluster of differentiation 44 intracellular domain, and attenuates alcohol-induced liver damages and activation of hepatic stellate cells
Oral Presentation
Presenter: Jinsol Han

US trends and contribution of metabolic syndrome in alcohol-associated liver disease from 1999-2018
Poster Presentation
Presenter: Brian Lee

Early liver transplantation for acute alcoholic hepatitis in a Spanish liver transplant center
Poster Presentation
Presenter: Victoria Aguilera Sancho

Plasma multi-omics outlines association of urobilinogen with corticosteroid non-response, inflammation, intestinal permeability and outcome in severe alcoholic hepatitis
Oral Presentation
Presenter: Manisha Yadav

Platelets proteome dynamics and its association with liver severity in severe alcoholic hepatitis
Poster Presentation
Presenter: Rupinder kaur Kalra

The beneficial effects of the diet withdrawal and physical exercise on steatohepatitis of DUAL etiology
Poster Presentation
Presenter: Olga Estévez

Cardiovascular events in patients with alcohol-related liver disease and the prognostic value of endotrophin assessed by PRO-C6
Poster Presentation
Presenter: Ida Ziegler Spedtsberg
Bariatric surgery in alcohol dependence and alcohol-related liver disease
Poster Presentation
Presenter: Thomas Williams

2975
Naltrexone is safe and effective in achieving abstinence and reducing alcohol craving in cirrhotic patients: a double blind randomized placebo controlled trial
Oral Presentation
Presenter: Manasa Alla

2976
New patient referrals and alcohol consumption data in an Irish hepatology outpatient setting
Poster Presentation
Presenter: Aoife Moriarty

3076
Alcohol use disorder in patients undergoing bariatric surgery is associated with a worse prognosis
Poster Presentation
Presenter: Edilmar Alvarado-Tapias

3115
Dynamics of oxidized albumin and cognate metabolites are associated with severe inflammation in experimental model of alcohol related liver disease
Poster Presentation
Presenter: Babu Mathew

3125
Multi-omics analysis reveals the therapeutic effect and mechanism of the Chinese herbal JiGuCao capsule on acute alcoholic hepatitis in mice
Poster Presentation
Presenter: Yue Chen

3260
Implementation and outcomes of liver health check clinics in community alcohol services
Poster Presentation
Presenter: Michael Griffiths

3268
In-silico identification and ex-vivo validation in humans of distinct oncogenic potential of aldo-keto reductase AKR1B10 in hepatocellular carcinoma from alcohol induced liver injury
Poster Presentation
Presenter: Michael Waters
Identification of risk factors for alcohol relapse in liver transplant patients with alcohol-related liver disease
Poster Presentation
Presenter: Dilara Turan

Binge drinking acutely induces fatty liver with increased liver stiffness which is readily reversed
Poster Presentation
Presenter: Kristoffer Kjærgaard

Patients with alcohol-related cirrhosis who recompensate on follow-up have a characteristic metabolomic profile with differential concentrations of lipid and amino-acid metabolites
Poster Presentation
Presenter: Helena Hernández-Èvole

Histological inflammation in severe alcohol-related hepatitis is the main pre-treatment factor associated to glucocorticoid response
Poster Presentation
Presenter: Antonio Saviano

Alcohol rehabilitation after alcoholic hepatitis is associated with reduced mortality: results of a 2012-2021 National retrospective study
Poster Presentation
Presenter: Vincent Mallet

Validation of the Lille 4 score on a cohort of romanian severe alcoholic hepatitis patients
Poster Presentation
Presenter: Bumbu Andreea Livia

Characterization of fibrogenesis in severe alcohol-related hepatitis using a 3D model of coculture of organoids and fibroblasts from patients
Poster Presentation
Presenter: Line Carolle Ntandja Wandji

The synergistic impact of food insecurity and alcohol use on mortality in adults with significant liver fibrosis
Poster Presentation
Presenter: Ani Kardashian

3633 Baclofen is effective on abstinence and improvement of Child-Pugh score in patients with cirrhosis: results of a meta-analysis
Poster Presentation
Presenter: Gildas Fantognon

3643 Beneficial effects of a screening programme for alcohol-related liver fibrosis with transient elastography in people with alcohol use disorder promoting alcohol abstinence
Poster Presentation
Presenter: Emma Avitabile

3749 When is the optimal time to collect baseline data for calculating the Lille score in severe alcoholic hepatitis?
Poster Presentation
Presenter: Mina Ignat

3836 Carbohydrate-deficient transferrin is a suitable drinking marker for patients with metabolic dysfunction-associated fatty liver disease
Poster Presentation
Presenter: Kazuyoshi Kon

Cirrhosis and its complications: ACLF and Critical illness

108 Lower free and total serum cortisol levels are associated with higher risk of bacterial infection and acute-on-chronic liver failure in stable outpatients with advanced chronic liver disease
Poster Presentation
Presenter: Lukas Hartl

130 Increased level of presepsin in patients with acutely decompensated cirrhosis predicts development of acute-on-chronic liver failure
Poster Presentation
Presenter: Alberto Zanetto

175 Serum Cytokine and Chemokine profiles and disease prognosis in hepatitis B virus-related acute-on-chronic liver failure
Poster Presentation
Presenter: Bingbing Zhu

638
ACLF grade is not independently associated with 1-year mortality after hospital discharge in cirrhotic patients admitted to ICUs in the Netherlands
Poster Presentation
Presenter: Jubi de Haan

678
Microbial cell-free DNA next-generation sequencing of ascites in acutely decompensated cirrhosis patients: a proof-of-concept study
Poster Presentation
Presenter: Beiling Li

799
Machine learning-based model is superior to CLIF-C ACLF score for predicting ICU mortality in critically ill patients with acute-on-chronic liver failure
Poster Presentation
Presenter: Maike Rebecca Pollmanns

831
Parvovirus B19 infection associated with adverse outcomes in decompensated cirrhosis patients
Poster Presentation
Presenter: Changze Hong

840
Predictors of clinical courses in patients with acutely decompensated cirrhosis. An external validation of the PREDICT study
Poster Presentation
Presenter: Enrico Pompili

1071
ACLF course profiles over screening period in the phase IIb DHELIVER study
Poster Presentation
Presenter: Frederik Nevens

1119
Outcomes, clinical trajectories and risk factors of acute kidney injury (AKI) in critically-ill patients with liver cirrhosis
Poster Presentation
Presenter: Martin Schulz

1316
Increased serum IL-6 and IL-8 are associated with echocardiographic signs of diastolic dysfunction in patients admitted for acutely decompensated cirrhosis
Poster Presentation
Presenter: Victor Dragan

1319
Acute on chronic liver failure is associated with prolonged clot initiation in rotational thromboelastometry as compared to acute decompensation, but clot formation time and firmness are similar
Poster Presentation
Presenter: Tian Yu Qiu

1478
Frequency of ACLF and predictors of in-hospital mortality in cirrhotic patients in a tertiary care hospital of Pakistan
Poster Presentation
Presenter: Sulhera Khan

1567
Impaired pituitary-thyroid signaling and low free triiodothyronine indicate increased risk for ACLF and mortality in cirrhosis
Poster Presentation
Presenter: Lukas Hartl

1694
VSIG4 as a biomarker for the diagnosis and prognosis of HBV-ACLF
Poster Presentation
Presenter: Jun Li

1708
Plasma thrombomodulin as a candidate biomarker for the diagnosis and prognosis of HBV-related acute-on-chronic liver failure
Poster Presentation
Presenter: Jun Li

1789
The risk factors for poor prognosis according to the clinical course after first acute decompensation in cirrhotic patients
Poster Presentation
Presenter: Sung-Eun Kim

1899
Albumin use in acute-on-chronic liver failure in a large national cohort
Poster Presentation
Presenter: Nadim Mahmud

1989
Long-term outcome following liver transplantation for patients with acute on chronic liver failure grade 3 (ACLF-3): a retrospective matched-controlled study
Oral Presentation
Presenter: Florent Artru

2261
The prognostic impact of each organ failure is different than that of acute-on-chronic liver failure according to the major clinical presentation in acutely decompensated cirrhosis
Poster Presentation
Presenter: Jung Hee Kim

2307
Even small amounts of alcohol consumption can worsen the prognosis in acutely decompensated patients with viral hepatitis
Poster Presentation
Presenter: Jung Hee Kim

2467
Spur cells in liver cirrhosis are predictive of ACLF and liver-related mortality regardless of severe anaemia
Poster Presentation
Presenter: MICHELE BEVILACQUA

2471
Performances of the CLIF-consortium acute-on-chronic liver failure (ACLF) score are gender specific
Poster Presentation
Presenter: Sophie-Caroline Sacleux

2710
Nosocomial infections in cirrhosis are unpredictable and vary based on region of the world: CLEARED study
Poster Presentation
Presenter: Jasmohan S Bajaj

2793
Metabolic biomarkers significantly enhance the prediction of HBV-related acute-on-chronic liver failure prognosis
Poster Presentation
Presenter: Yan Zhang
3139
Real-world evidence of reversibility in patients with acute-on-chronic liver failure that survive hospitalization
Poster Presentation
Presenter: Ahmed Elshabrawi

3143
Incidence, risk factors and outcomes of acute kidney disease in cirrhosis patients with sepsis-related acute kidney injury
Poster Presentation
Presenter: Rakhi Maiwall

3184
Different risk factors of clinical outcomes between variceal bleeding and non-variceal gastrointestinal bleeding in acutely decompensated cirrhosis
Poster Presentation
Presenter: Sung-Eun Kim

3266
Combination of CLIF-C ACLF and ammonia levels as a predictor of in-hospital outcomes in patients with acute-on-chronic liver failure
Poster Presentation
Presenter: gi Biswas

3291
High histamine levels associate with acute-on-chronic liver failure and liver-related death in patients with advanced chronic liver disease
Poster Presentation
Presenter: Michael Schwarz

3528
Disparities in hospital outcomes among patients with end-stage liver disease with palliative care collaboration: a nationwide cohort analysis (2016-2020)
Poster Presentation
Presenter: Sheza Malik

3532
Evaluation of albumin and midodrine versus albumin alone in the outcome of refractory ascites in patients with decompensated cirrhosis: a randomized controlled trial (NCT04816240)
Poster Presentation
Presenter: Priti Jain

3577
Soluble urokinase plasminogen activator receptor is a biomarker for outcome in decompensated liver cirrhosis and acute-on-chronic liver failure
Poster Presentation
Presenter: Sven Lamatsch

3621
Prediction of sepsis in patient of acute on chronic liver failure (ACLF) - a machine learning approach
Poster Presentation
Presenter: Ashok Choudhury

3653
Trajectory of outcome from acute-on-chronic liver failure is determined beyond 48 hours of admission to intensive care
Poster Presentation
Presenter: Thomas Dixon

3709
Detection of 1,3-beta-D-glucan increases with the severity of decompensation stages in liver cirrhosis and is associated with lower survival in patients with acute on chronic liver failure
Poster Presentation
Presenter: Adam Herber

Cirrhosis and its complications: Experimental and pathophysiology

350
Restoration of epithelial and vascular intestinal barriers and splanchnic macrophage function mediates the halting of bacterial translocation by propranolol in cirrhotic rats with ascites
Oral Presentation
Presenter: Elisa Castillo

408
Study of epigenetic control of LSECtin in hepatic antigen presenting cells during experimental cirrhosis
Poster Presentation
Presenter: Enrique Angel

460
Glial transcriptional changes in experimental HE arise early and show similarities with established neuroinflammatory disorders
Poster Presentation
Presenter: Wouter Claeyss

585
Bacterial DNA translocation-induced systemic inflammation is associated with overt hepatic encephalopathy and predicts mortality in patients with cirrhosis
Poster Presentation
Presenter: Kessarin Thanapirom

683
Dysregulation of the FXR-FGF19 pathway indicates impaired gut-liver axis signalling in patients with cirrhosis
Oral Presentation
Presenter: Benedikt Simbrunner

684
Extracellular vesicles carrying oxidation-specific epitopes as effectors in acute hepatic decompensation and acute-on-chronic liver failure – a pilot study
Poster Presentation
Presenter: Benedikt Simbrunner

731
Nitazoxanide counteracts lipopolysaccharide-induced hepatic and renal transcriptomic profile changes to improve systemic inflammation and organ damage in a disease model of acute-on-chronic liver failure
Poster Presentation
Presenter: Vanessa Legry

785
Novel insights on liver endothelial mechanobiology in cirrhosis: role of calcium integrin-binding protein 1
Oral Presentation
Presenter: Cong Wang

1046
Factor VIII synthesis by adipose tissue stromal cells contributes to coagulopathy in chronic liver disease
Poster Presentation
Presenter: Sanal MG

1054
Evaluation of the effect of glucocorticoids on cardiac chronotropic dysfunction in cirrhotic rats, do dopamine receptors also play a role?
Poster Presentation
Presenter: Qamar Niaz

1120
Role of extracellular vesicles in sarcopenia associated to chronic liver diseases
Poster Presentation
Presenter: Simone Di Cola

1176
Effects of β-adrenergic hyperstimulation, liver cirrhosis and acute-on-chronic liver failure (ACLF) on the small intestinal gut-vascular barrier (GVB)
Poster Presentation
Presenter: Marco Felber

1357
Multi-omics reveals the regulation mechanism of the Chinese herbal AnLuoHuaXian formula on reversing liver cirrhosis in the rat
Poster Presentation
Presenter: Ruijia Liu

1525
Platelets from patients with decompensated cirrhosis display pro-inflammatory features
Poster Presentation
Presenter: Simone Di Cola

1707
ETS2 alleviates HMGB1 and LPS triggered excessive inflammation in acute-on-chronic liver failure
Oral Presentation
Presenter: Jun Li

1726
Imperfect maturation in erythroid progenitors leads to severe anemia in cirrhotic patients
Poster Presentation
Presenter: Deepika Lal

1904
Identification of complication-dependent gut microbial biomarkers for early detection of decompensated cirrhosis
Poster Presentation
Presenter: Satya Priya Sharma

2088
Metabolic Derangements in Hematopoietic Stem and Progenitor Cells (HSPCs) underlie monocyte-macrophage dysfunction in cirrhosis
Poster Presentation
Presenter: Deepanshu Maheshwari

2134
Investigating the PD-1/PD-L pathway and macrophage responses in acute-on-chronic liver failure
Oral Presentation
Presenter: Evangelos Triantafyllou

2186
MCC950 reduces glial cell activation and neuroinflammation in an animal model of thioacetamide-induced hepatic encephalopathy
Poster Presentation
Presenter: Syed Afroz Ali

2341
Yaq-001, a non-absorbable, engineered carbon beads of controlled porosity impacts on gut dysbiosis, gut permeability, organ function and reduces mortality in rodent models of cirrhosis and ACLF
Poster Presentation
Presenter: Jinxia Liu

2459
The gene expression profile of skeletal muscle in end-stage liver disease patients undergoing assessment for liver transplantation with muscle wasting
Poster Presentation
Presenter: Sophie Allen

2480
Distinct changes in the inflammatory profile of patients with EASL-CLIF- versus APASL-acute-on-chronic liver failure
Poster Presentation
Presenter: Mona-May Langer

2575
Ascites CD8 T cells express a tissue-resident bystander phenotype that may contribute to disease pathogenesis in patients with decompensated liver cirrhosis
Poster Presentation
Presenter: Christian Niehaus

2667
Constant alcohol consumption exacerbates hepatic encephalopathy and leads to neuronal loss in rats with chronic liver disease
Poster Presentation
Presenter: Farzaneh Tamnanloo

2671
Evaluation of myocardial inflammation and fibrosis in an experimental model of liver cirrhosis by quantitative cardio-hepatic MRI
Poster Presentation
Presenter: Franziska Schneider

2675
Peripheral blood metabolite associations with cardiac diastolic dysfunction in advanced chronic liver disease
Poster Presentation
Presenter: Madeleine Gill

2694
Biological differences between clinically different muscle wasting phenotypes in patients with decompensated ESLD undergoing assessment for liver transplantation: a UK prospective cohort UK study
Poster Presentation
Presenter: Amritpal Dhaliwal

2908
Longitudinal change in the plasma metabotype indicates therapeutic plasma exchange in acute-on-chronic liver failure patients should be done every 12 hours
Oral Presentation
Presenter: Gaurav Tripathi

3036
Single-cell RNA transcriptomics of peripheral blood mononuclear cells revealed altered gene expressions in monocyte and HLA variations in decompensated liver cirrhosis patients with sepsis
Poster Presentation
Presenter: Nirupma Trehanpati

3075
Pathophysiological biomarkers associated with resolution of ACLF in patients treated with the liver dialysis device, DIALIVE
Poster Presentation
Presenter: Fausto Andreola

3091
Development and characterization of novel rodent ACLF models
Poster Presentation
Presenter: Frank Erhard Uschner

3157
Exploration of mechanisms underlying the beneficial effect of long-term albumin in models of cirrhosis and ACLF
Poster Presentation
Presenter: Alexandra Phillips
The pan-PPAR agonist lanifibranor decreases portal pressure in models of both hepatic and prehepatic portal hypertension
Poster Presentation
Presenter: Anneleen Heldens

Placement of a trans-jugular intrahepatic portosystemic shunt (TIPS) modifies the expression of proinflammatory cytokines in circulating monocytes exposed to lipopolysaccaride
Poster Presentation
Presenter: Mirella Pastore

Whole transcriptomic analysis of bone marrow indicates distinct pathways to be at play in different stages of chronic liver disease patients
Poster Presentation
Presenter: Pramod Gautam

Neurological dysfunction is improved after faecal microbiota transplantation in rats with bile duct ligated-induced chronic liver disease
Poster Presentation
Presenter: Alexandre Bourgeois

Targeting myeloid-derived suppressor cells in a carbon tetrachloride-induced murine model of chronic liver injury
Poster Presentation
Presenter: Emilio Flint

Cirrhosis alters receptor mediated clearance of therapeutic antibodies by hepatic sinusoidal endothelial cells
Poster Presentation
Presenter: Bethany James

Resection of mesenteric lymph nodes is associated with increased systemic immunosuppression in experimental cirrhosis following oral salmonella typhimurium challenge
Poster Presentation
Presenter: Pinky Juneja
ε-Lysine-melittin reduces pathological bacterial translocation and enhances gut immunity in experimental decompensated cirrhosis
Poster Presentation
Presenter: Deepika Jakhar

3649
Combination of weekly albumin infusion, personalized nutrition and home-based exercise programme improves outcomes of patients with end stage liver disease (Al-Fit study)
Poster Presentation
Presenter: Sasanka Vangara

3713
The role of Toll-like receptor 4 in ammonia metabolism and as a therapeutic target for hyperammonemia
Poster Presentation
Presenter: Annarein Kerbert

3742
Effect of fibrinogen substitution in hypofibrinogenaemic CTP class C patients on viscoelastic coagulation tests
Poster Presentation
Presenter: Moritz Tobiasch

3757
Distinct patterns of hepatic and systemic inflammation in different types/aetiologies of liver disease
Poster Presentation
Presenter: Benedikt Hofer

Cirrhosis and its complications: Other clinical complications except ACLF and critical illness

148
A virtual reality-driving test to predict car accidents in patients with cirrhosis
Poster Presentation
Presenter: Simon Johannes Gairing

150
Prevalence of minimal hepatic encephalopathy in patients with cirrhosis: a multicenter study
Poster Presentation
Presenter: Simon Johannes Gairing

154
An overview on microbial population in liver cirrhosis: changing paradigm in the known bacteriology of spontaneous bacterial peritonitis
Poster Presentation
Presenter: Shirin Demma

Comparison of coagulation parameters as prognostic markers of decompensation and liver-related death in advanced chronic liver disease
Poster Presentation
Presenter: Maria Pallozzi

Development and external validation of a model to predict multi-drug resistant bacterial infections in patients with cirrhosis
Poster Presentation
Presenter: Sebastián Marciano

Whole body clearance and production of ammonia quantified by constant ammonia infusion—the effects of cirrhosis and ammonia targeting treatments
Poster Presentation
Presenter: Peter Lykke Eriksen

Substitution of even one non-vegetarian meal with plant-based alternatives associate with lower ammoniagenesis in patients with cirrhosis who follow a western diet: a randomized clinical trial
Oral Presentation
Presenter: Jasmohan S Bajaj

The association between angiotensin converting enzyme inhibitor or angiotensin receptor blocker exposure and key cirrhosis-related outcomes
Poster Presentation
Presenter: Roy Wang

Atorvastatin reduces inflammation markers TNF-α, CD62L and MMP2 in a randomised trial
Poster Presentation
Presenter: Thit Mynster Kronborg

Clinical effectiveness of human albumin in liver cirrhosis: a meta-analysis update
Poster Presentation
Presenter: 昭含 刘
470
Nutritional status of patients with advanced chronic liver disease: descriptive baseline of a prospective study
Poster Presentation
Presenter: Jose Miguel Rosales Zabal

522
The impact of a massive transfusion protocol on the outcomes of patients with acute variceal bleeding: propensity score-matched analysis
Poster Presentation
Presenter: Aryoung Kim

621
Effect of kidney injury and hemodynamic effect after moderate abdominal paracentesis: a randomized control study
Poster Presentation
Presenter: Sakkarin Chirapongsathorn

649
Factors related to a shorter survival in patients with liver disease and followed by a specialized palliative care clinic
Poster Presentation
Presenter: Fernando Xavier e Silva

657
Rifaximin plus lactulose is more effective than lactulose alone for the prevention of overt hepatic encephalopathy in patients with or without diabetes
Poster Presentation
Presenter: Jasmohan S Bajaj

730
Development and validation of the AMMON-OHE model to risk stratify cirrhotic outpatients for occurrence of overt hepatic encephalopathy
Oral Presentation
Presenter: María Pilar Ballester

789
Six-fold increased rate of chronic kidney disease after acute kidney injury: a population-based cohort study of 46,946 patients with cirrhosis
Poster Presentation
Presenter: Anna Cederborg
Classification of bleeding risk from invasive procedures in patients with cirrhosis: an expert consensus
Poster Presentation
Presenter: Alix Riescher-Tuczkiewicz

Experiences from a palliative care clinic specialized in liver diseases – utilisation, clinical characteristics of patients and outcomes.
Poster Presentation
Presenter: Fernando Xavier e Silva

Validation of thigh ultrasound for measurement of sarcopenia and fat mass in patient with cirrhosis: correlation with body composition analysis. Higher fat mass, lower muscle mass and reduced functional muscle
Poster Presentation
Presenter: Reza Saeidi

Goals of care and end-of-life for patients with advanced liver disease followed by a specialized palliative care clinic
Poster Presentation
Presenter: Fernando Xavier e Silva

Pregnancy outcomes in women with liver cirrhosis: a prospective UK obstetric surveillance system national cohort study
Oral Presentation
Presenter: Melanie Nana

Serum ammonia levels do not correlate with overt hepatic encephalopathy severity and time to resolution in hospitalized patients with cirrhosis
Poster Presentation
Presenter: Jasmohan S Bajaj

Poorer results in the clinical frailty scale are associated with covert and overt hepatic encephalopathy in patients with cirrhosis
Poster Presentation
Presenter: Eva Maria Schleicher
Impact of intrapulmonary vascular dilatations and hepatopulmonary syndrome on the clinical course of patients after transjugular intrahepatic portosystemic shunt insertion
Poster Presentation
Presenter: Jim Benjamin Mauz

1109
Normalization of psychometric hepatic encephalopathy score and detection of minimal hepatic encephalopathy in patients with cirrhosis (CHESS-NCRCID 2106): a prospective, multicenter study
Poster Presentation
Presenter: Xiaolong Qi

1156
Surgical subtype predicts adverse outcomes and costs among nonalcoholic cirrhotic patients
Poster Presentation
Presenter: Carolyn Catalano

1234
Potentially inappropriate medicine’ use and nonadherence in hepatic encephalopathy: a retrospective real-world cohort study
Poster Presentation
Presenter: Zhen Howe Hong

1249
Vitamin D deficiency associates with gut dysbiosis, endotoxemia and the risk of infectious complications in patients with liver cirrhosis
Poster Presentation
Presenter: Pei-Chang Lee

1296
Anemia in cirrhotic patients is a risk factor for esophagogastric variceal bleeding and mortality
Poster Presentation
Presenter: Elena Santos Perez

1370
The effects of alfapump on ascites control and quality of life in patients with cirrhosis and recurrent or refractory ascites: pivotal trial results
Poster Presentation
Presenter: Florence Wong

1395
Booster SARS-CoV-2 vaccination elicits robust antibody response to wild type but not Omicron subvariants BA.4/5 in patients with cirrhosis
Poster Presentation
Presenter: Qian Zhu
1448
Safety and efficacy of continuous infusion terlipressin in acute kidney injury-hepatorenal syndrome: the Infuse study
Poster Presentation
Presenter: K. Rajender Reddy

1457
Prognostic significance of individual decompensating events in stable decompensated outpatients with cirrhosis using a multi-center cohort
Poster Presentation
Presenter: Jasmohan S Bajaj

1461
Real-world experience of long-term albumin treatment in a large cohort of patients with cirrhosis and ascites (Real-Answer study)
Poster Presentation
Presenter: Giulia Iannone

1506
The role of prolonged albumin replacement therapy in correction of its structure and functional properties and management of ascites
Poster Presentation
Presenter: Anastasia Turkina

1528
Gender differences in the patient-reported outcomes and perception of ascites burden amongst outpatients with decompensated cirrhosis and ascites
Poster Presentation
Presenter: Florence Wong

1552
On-treatment factors predict recompensation in entecavir-treated hepatitis B patients with decompensated cirrhosis
Poster Presentation
Presenter: You Deng

1572
Temporal trajectory of the model for end-stage liver disease (MELD) score for prediction of mortality among patients with liver cirrhosis
Poster Presentation
Presenter: Niv Zmora
1647
The relation of serum nesfatin-1 levels with disease severity and complications in patients with liver cirrhosis
Poster Presentation
Presenter: Hasan Eruzun

1696
Efficacy of arginine glutamate injection for the treatment of hepatic encephalopathy and hyperammonemia in cirrhosis: a randomized controlled trial
Poster Presentation
Presenter: Yu Chen

1742
Progression of cirrhosis is not associated with clinically significant alterations in hemostasis assessed by thromboelastography
Poster Presentation
Presenter: Alina Buliarcă

1830
The combination of LACE index, MELD on discharge and a previous history of decompensation defines risk groups for early readmission in patients with liver cirrhosis
Poster Presentation
Presenter: Yolanda Sánchez

1834
Impact of allelic HLA divergence on the risk of bacterial infections in cirrhotic patients awaiting liver transplantation
Poster Presentation
Presenter: Clementine Roger

1888
Clostridioides difficile infection in patients with liver cirrhosis
Poster Presentation
Presenter: Olga Adriana Caliman-Sturdza

1897
Factors associated with inpatient albumin administration and center-level variation in a national cohort
Poster Presentation
Presenter: Marina Serper

1924
Normalisation of the psychometric hepatic encephalopathy score in a Nigerian population
Poster Presentation
Presenter: Mansur Mohammed

2000
Racial disparities in COVID-19 clinical outcomes among patients with cirrhosis in North America and Europe - an international registry study
Poster Presentation
Presenter: Umar Hayat

2051
Randomised controlled trial of intravenous versus oral iron in treatment of iron deficiency anaemia after variceal bleeding in patients with cirrhosis
Poster Presentation
Presenter: Tabish Mohammad

2205
Efficacy and safety of lusutrombopag in a real-world Italian series of cirrhotic patients with severe thrombocytopenia undergoing invasive procedures: the Reality study
Oral Presentation
Presenter: Paolo Gallo

2254
Efficacy and safety of branched-chain amino acids supplementation on muscle cramps in patients with cirrhosis: a randomized double-blinded controlled trial
Poster Presentation
Presenter: Thanapat Atthakitmongkol

2338
Nutritional therapy improves minimal hepatic encephalopathy in cirrhosis by improvement in sarcopenia, proinflammatory cytokines and myostatin: a double blind randomized controlled trial
Poster Presentation
Presenter: Sudhir Maharshi

2389
Correlation between mid-arm circumference and QRS alterations as markers of sarcopenia in patients with decompensated cirrhosis
Poster Presentation
Presenter: Letitia Toma

2488
Uromodulin serum levels are associated with poorer prognosis in patients with cirrhosis and hepatorenal syndrome
Poster Presentation
Presenter: Eva Maria Schleicher
Quickstroop, an App-based strategy that takes <1 minute, predicts time to overt hepatic encephalopathy development and hospitalizations
Poster Presentation
Presenter: Jasmohan S Bajaj

Effects of nutritional therapy on Sarcopenia in patient with liver cirrhosis – a randomised controlled trial
Poster Presentation
Presenter: Sudhir Maharshi

The prevalence and prognostic impact of myosteatosis with and without sarcopenia and its association with age and severity of liver cirrhosis
Poster Presentation
Presenter: Alexandra Alexopoulou

The role of renal impairment on rotational thromboelastometry (ROTEM) parameters in hospitalised patients with cirrhosis – a prospective cohort study
Poster Presentation
Presenter: Louis Wang

Acute kidney injury related to metamizole in advanced chronic liver disease patients undergoing major orthopedic surgery
Poster Presentation
Presenter: Lidia Canillas

Analysis of surgical risk in patients with advanced chronic liver disease and major orthopedic surgery from a gender perspective
Poster Presentation
Presenter: Lidia Canillas

Comparison of prognostic value of sarcopenia and MELD score in assessing 28 days and 3 months mortality in patients with cirrhosis of liver
Poster Presentation
Presenter: shivam gupta
Activation of the kynurenine pathway potentially underlies neurodegeneration in patients with covert hepatic encephalopathy
Poster Presentation
Presenter: Georgia Zeng

2791
24-Hour urinary creatinine excretion (UCE) a marker of muscle mass is associated with mortality in critically ill patients with cirrhosis
Poster Presentation
Presenter: Jaya Benjamin

2820
Availability and affordability of services affects outcome in hospitalized patients with cirrhosis-results from CLEARED consortium
Poster Presentation
Presenter: Ashok Choudhury

2880
Rotational Thromboelastometry (ROTEM) reduces need for pre-emptive transfusion in low-moderate risk procedure in cirrhosis: a randomized controlled trial
Poster Presentation
Presenter: Chin King Tan

2983
Real-world treatment of decompensated liver cirrhosis in Italy: a propensity score-matched analysis of long-term versus acute albumin therapy
Poster Presentation
Presenter: Wim LALEMAN

3005
Liver nutrition clinic improves nutritional outcomes in patients with advanced cirrhosis
Poster Presentation
Presenter: Barbara Leggett

3012
Patients with liver cirrhosis and TIPS are prone to in-hospital falls
Poster Presentation
Presenter: Nada Abedin

3158
Prucalopride: a novel and safe usage for reducing incidence of hepatic encephalopathy in decompensated cirrhosis
Poster Presentation
Presenter: Manasa Alla
Smoking and obesity promote systemic inflammation in patients with compensated and decompensated cirrhosis
Poster Presentation
Presenter: Benedikt Hofer

Long-term cellular immune response to COVID-19 vaccination in patients with chronic liver disease
Poster Presentation
Presenter: Mariana Moura Henrique

Association of polymorphisms in genes of the innate immunity with transplant-free survival of patients with decompensated liver cirrhosis
Poster Presentation
Presenter: Janett Fischer

Efficacy and safety of nalfurafine hydrochloride for pruritus in patients with chronic liver disease in Japan
Poster Presentation
Presenter: TADAMICHI KAWANO

Applicability of EASL clinical guidelines recommendations of empiric antibiotic treatment for spontaneous bacterial infections in patients with cirrhosis in South America
Poster Presentation
Presenter: melisa dirchwolf

Decreased platelet function is an independent predictor of liver-related and all-cause mortality in patients with advanced chronic liver disease
Poster Presentation
Presenter: Benedikt Hofer

Thromboelastography-guided coagulopathy correction in cirrhotic patients decreases blood product transfusion: a systematic review and analysis
Poster Presentation
Presenter: Hamed Komeylian

Decreased platelet function is an independent predictor of liver-related and all-cause mortality in patients with advanced chronic liver disease
Poster Presentation
Presenter: Benedikt Hofer

Thromboelastography-guided coagulopathy correction in cirrhotic patients decreases blood product transfusion: a systematic review and analysis
Poster Presentation
Presenter: Hamed Komeylian
Improvement of the quality of care in patients with liver cirrhosis after a clinical intervention. Quasi-experimental study
Poster Presentation
Presenter: Alberto Amador

3583
A multimodal treatment candidate for sarcopenia in men with decompensated cirrhosis: a randomized, placebo-controlled trial evaluating LPCN 1148
Poster Presentation
Presenter: Benjamin Bruno

3586
Effectiveness and safety of anticoagulant treatment in patients with liver cirrhosis and non-tumoral splenic-portal thrombosis
Poster Presentation
Presenter: Nelson Daniel Salazar Parada

3631
Serum PDL1 levels are associated with increased risk of bacterial infections in non-hospitalised patients with cirrhosis
Poster Presentation
Presenter: Adria Juanola

3715
Validation of automatic cell counting based on impedanciometry and flow cytometry in ascitic fluid
Poster Presentation
Presenter: Aitor Odriozola Herrán

Cirrhosis and its complications: Portal Hypertension

22
The effect of precipitating factors for hepatorenal syndrome on response to terlipressin treatment: a subgroup analysis of a pooled North American database
Poster Presentation
Presenter: Kevin Moore

107
Suppression of the pituitary-adrenal axis in stable outpatients with advanced chronic liver disease increases with disease severity and may be linked to systemic inflammation and bile acids
Poster Presentation
Presenter: Lukas Hartl

109
Application of updated diagnostic criteria for cirrhotic cardiomyopathy: evaluation of its clinical impact in liver transplantation candidates
Poster Presentation
Presenter: Sarah Raevens

125
Secondary prevention of variceal bleeding is often imperfect: a national, population-based cohort study of 5,018 patients
Poster Presentation
Presenter: Hannes Hagström

177
Clinical profile of porto-sinusoidal vascular disorder: experience from tertiary referral hospital in India
Poster Presentation
Presenter: Love Garg

190
Terlipressin has acute effects on systemic inflammation markers in patients with cirrhosis and ascites
Poster Presentation
Presenter: Nikolaj Torp

254
Validation of Baveno-VII criteria regarding non-invasive diagnosis of clinically significant portal hypertension
Poster Presentation
Presenter: Byeong Geun Song

333
Head-to-head comparison of the prognostic performance of the hepatic venous pressure gradient and non-invasive tests in compensated advanced chronic liver disease
Oral Presentation
Presenter: Mathias Jachs

346
Rivaroxaban improves survival and decompensation in cirrhotic patients with moderate liver dysfunction. Double-blind, placebo-controlled trial
Oral Presentation
Presenter: Angela Puente Sanchez

378
Indocyanine green clearance reflects various pathophysiological mechanisms and independently predicts liver-related events in ACLD
Poster Presentation
433
Administration of Lactulose, Rifaximin, or combination therapy for hepatic encephalopathy is associated with a reduction in gastrointestinal cancers
Poster Presentation
Presenter: Mathias Jachs

461
Efficacy of Simvastatin plus non-selective beta blocker in improving survival of cirrhotic patients with variceal bleed: a systematic review and meta analysis
Poster Presentation
Presenter: Ankoor Patel

465
Role of non neoplastic portal vein thrombosis in natural history of patients with cirrhosis and hepatocellular carcinoma
Poster Presentation
Presenter: Jemimah Andrea Fajardo

467
Impact of rifaximin use post-discharge of an overt hepatic encephalopathy (OHE) hospitalization on the annual rates of OHE-related inpatient stays
Poster Presentation
Presenter: Sarah Shalaby

498
Predictors and management of post-banding ulcer bleeding in cirrhosis: a systematic review and meta-analysis
Poster Presentation
Presenter: Brock Bumpass

594
A multimodal deep learning network for non-invasive prediction of the hepatic decompensation risk in compensated cirrhotic people: a multicentre cohort study (CHESS1701)
Poster Presentation
Presenter: Maria De Brito Nunes

675
Study the effect of serum YKL-40 as a risk of variceal bleeding in Egyptian cirrhotic patients
Poster Presentation
Presenter: Abdelfattah Hanno
Bacterial translocation has an early onset in cirrhosis and induces a selective inflammatory response
Poster Presentation
Presenter: Benedikt Simbrunner

Effects of renin angiotensin system inhibition on renal function and the clinical course of patients with decompensated liver cirrhosis and ascites
Poster Presentation
Presenter: Tammo Lambert Tergast

The new diagnostic criteria of portopulmonary hypertension identify a group of patients with cirrhosis at high risk of death
Oral Presentation
Presenter: Luis Téllez

Recently validated non-invasive tests for liver fibrosis assessment have great performance in identifying NASH patients at risk for decompensation
Poster Presentation
Presenter: Vlad Taru

Baveno VII algorithm can avoid endoscopic surveillance in patients with cirrhosis
Poster Presentation
Presenter: Haiyu Wang

Efficacy of long term albumin therapy in treatment of decompensated cirrhosis
Poster Presentation
Presenter: Deepanshu Khanna

Use and impact of transjugular intrahepatic portosystemic shunt: a twelve-year nationwide study in Germany
Poster Presentation
Presenter: Wenyi Gu

Spontaneous portosystemic shunts (SPSS) regress after transjugular intrahepatic portosystemic shunt (TIPS) implantation
Poster Presentation
Presenter: Theresa Bucsics
TIPS increases muscle mass in patients with decompensated cirrhosis
Poster Presentation
Presenter: Theresa Bucsics

Earlier diagnosis of hepatorenal syndrome-acute kidney injury with updated guidelines – review of the Confirm trial
Poster Presentation
Presenter: Richard Frederick

Correlation of lymphangiogenesis and inflammation in patients with ACLD
Poster Presentation
Presenter: Florian Offensperger

MELD 3.0 score in prediction of varices and comparison with its previous versions in patients undergoing esophago-gastro-duodenoscopy for variceal screening or band ligation
Poster Presentation
Presenter: Faiza Sadaqat Ali

Pressure response to TIPS does not depend on stent diameter
Poster Presentation
Presenter: Michael Schultheiss

Symptoms from refractory ascites: contributions from both abdominal pressure and the patient
Poster Presentation
Presenter: Nikhilesh Mazumder

Accuracy of spleen stiffness measurement for the diagnosis of clinically significant portal hypertension in patients with advanced chronic liver disease: an individual patient meta-analysis
Poster Presentation
Presenter: Elton Dajti

Individualized portal pressure gradient threshold based on liver function categories in preventing rebleeding after TIPS
Poster Presentation
Presenter: Guangchuan Wang

1598
Audit assessing real-world incidence of adverse events and mortality rate in patients receiving Terlipressin for hepatorenal syndrome at Royal free hospital
Poster Presentation
Presenter: Naz Kanani Alviri

1729
Single-centre experience of spleen stiffness measurement across the spectrum of chronic liver disease
Poster Presentation
Presenter: Sarah Romero

1745
Comparison of bolus versus continuous infusion of terlipressin in cirrhosis patients with septic shock: a randomized controlled trial (NCT 04819568)
Poster Presentation
Presenter: Priti Jain

1777
Progression of portal hypertension in PBC: doppler ultrasound velocity as a non-invasive assessment
Poster Presentation
Presenter: Aiymkul Ashimkhanova

1809
Sequential BAVENO VI plus dedicated spleen stiffness measurement or a novel spleen-centered algorithm significantly enlarges non-invasive ruling out of high risk varices: results from an international derivation-validation cohort study
Poster Presentation
Presenter: Emma Vanderschueren

1825
TIPS under-dilation strategy with new controlled expansion endoprosthesis: a hemodynamic and imaging confirmation of its feasibility
Poster Presentation
Presenter: Dario Saltini

1826
Clinical practice results of the use of intrahepatic portosystemic shunt for the treatment of refractory hepatic hydrothorax
Poster Presentation
Presenter: Elena Tenorio González
Outcomes of a therapeutic stepwise approach involving low-dose systemic thrombolysis for managing acute portomesenteric thrombosis.
Oral Presentation
Presenter: Ahmed Hashim

Predicting esophageal varices and varices needing treatment in patients with compensated advanced chronic liver disease using Baveno VI Criteria, CHESS-ALARM score, FIB-4 score, and recently proposed FIB-5 score
Poster Presentation
Presenter: Fares Mashal

Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt does not increase mortality in patients with cirrhosis
Poster Presentation
Presenter: SILVIA NARDELLI

Randomised controlled trial of ceftriaxone versus no antibiotic to prevent infection in patients with Child-Pugh A cirrhosis with acute variceal bleeding
Oral Presentation
Presenter: ANANY GUPTA

Novel non-invasive model of clinically significant portal hypertension guides carvedilol therapy in patients with compensated advanced chronic liver disease (CHESS2102): an international multicenter study
Poster Presentation
Presenter: Chuan Liu

Spleen stiffness assessed by point shear-wave elastography predicts portal hypertension better than liver elastography
Poster Presentation
Presenter: Vaclav Smid

Comparison of 1-day vs 3-days intravenous terlipressin in cirrhosis patients with acute variceal bleeding: open-label randomized control trial
Oral Presentation
Presenter: Manas Vaishnav
2393
Adverse outcomes following transjugular intrahepatic portosystemic shunt placement in relation to the underlying cause of portal hypertension
Poster Presentation
Presenter: Sarwa Darwish Murad

2463
Validation of a discrete event simulation model evaluating the cost-effectiveness of long-term albumin administration in real-world UK patients with recurrent ascites
Poster Presentation
Presenter: Kris Bennett

2477
Is elastography needed for diagnosing cACLD and stratifying CSPH risk?
Poster Presentation
Presenter: Georg Semmler

2478
Impact of new ESC/ERS diagnostic criteria for pulmonary hypertension in cirrhotic patients with portal hypertension on the frequency of portopulmonary hypertension
Poster Presentation
Presenter: Hiroki Ono

2479
Validation and refinement of the Baveno VII criteria for risk stratification in compensated advanced chronic liver disease after HCV-cure
Poster Presentation
Presenter: Georg Semmler

2484
A retrospective evaluation of the effectiveness and safety of palliative long-term abdominal drains for the management of refractory ascites in patients with end-stage liver disease, in comparison with large volume paracentesis
Poster Presentation
Presenter: Rodrigo Motta

2491
Collagen-proportionate area determined by semiautomated histomorphometry correlates with HVPG across different liver disease etiologies
Poster Presentation
Presenter: Thomas Sorz

2511
Hepatic venous pressure gradient predicts further decompensation in cirrhosis patients with acute esophageal variceal bleeding
Poster Presentation
Presenter: Manas Vaishnav

2615
Serum procalcitonin and interleukin-6 predict acute-on-chronic liver failure following transjugular intrahepatic portosystemic shunt implantation in patients with refractory ascites
Poster Presentation
Presenter: Lukas Sturm

2725
Predicting post-TIPSS mortality: external validation of the FIPS score in a Canadian cohort
Poster Presentation
Presenter: Shamir Malik

2739
Coagulation profile in adult patients with porto-sinusoidal vascular disease
Poster Presentation
Presenter: Sidharth Harindranath

2843
Clinical features and analysis of serum BMP9 levels in patients with portal pulmonary hypertension
Poster Presentation
Presenter: Xiaoyu Wen

2931
Detection of minimal hepatic encephalopathy: standardization of psychometric hepatic encephalopathy scale for Israeli population
Poster Presentation
Presenter: Helena Katchman

2934
Current prognosis of gastric variceal bleeding in France: preliminary results from a multicenter prospective cohort of 87 cirrhotic patients
Poster Presentation
Presenter: Delphine Weil-Verhoeven

3015
Continuous terlipressin infusion improves muscle function but not muscle mass in patients with cirrhosis and portal hypertension
Poster Presentation
Presenter: Ryma Terbah
Robust identification of patient subgroups in acute decompensated cirrhosis
Poster Presentation
Presenter: Sara Palomino

Outcome of sucralfate vs proton pump inhibitor vs sucralfate and proton pump inhibitor combination post endoscopic esophageal variceal band ligation - A randomized controlled trial
Poster Presentation
Presenter: Arun Vaidya

Adoption of a clinical assessment service in hepatology
Poster Presentation
Presenter: Sarah Clark

Impact of non-selective beta-blockers on first and further hepatic decompensation after transjugular intrahepatic portosystemic shunt insertion
Poster Presentation
Presenter: Anja Tiede

Diabetes impairs the hemodynamic response to non-selective betablockers in compensated cirrhosis and predisposes for hepatic decompensation
Poster Presentation
Presenter: Rafael Paternostro

Real-world practice of pre-emptive tipps: an Asia perspective based on Singapore nationwide variceal bleeding audit
Poster Presentation
Presenter: Yu Jun Wong

Detection of candida species in hospitalized patients with decompensated liver cirrhosis and ascites indicates an unfavorable clinical course and outcome
Poster Presentation
Presenter: Marie Griemsmann

Predicting the efficacy of splenic embolization on refractory ascites using a computational model of portal hypertension
3416
Natural history of patients with NAFLD-associated compensated advanced chronic liver disease stratified according to severity of portal hypertension
Poster Presentation
Presenter: Rafael Paternostro

3423
Clinical utility of liver and spleen elastography in the management of patients living with liver disease
Poster Presentation
Presenter: Carmen Lara Romero

3679
Hemodynamic response determines further decompensation and survival in patients with decompensated cirrhosis
Oral Presentation
Presenter: Claudia Pujol

3704
Ultrasound predictors of hemodynamic TIPS dysfunction: friends or foes?
Poster Presentation
Presenter: Andreea Fodor

3721
Preoperative transjugular intrahepatic portosystemic shunt and in-house mortality in patients with liver cirrhosis undergoing surgery
Poster Presentation
Presenter: Felix Piecha

3735
Systemic inflammation remains a critical determinant of the dynamic component of portal hypertension in abstinent patients with alcohol-related cirrhosis
Poster Presentation
Presenter: Benedikt Hofer

3740
MELD-sarcopenia and clinically significant portal hypertension as independent risk factors in the evolution of liver cirrhosis
Poster Presentation
Presenter: Elba Llop
3771
Refractory hepatic hydrothorax is associated with Increased mortality compared to cirrhosis and refractory ascites
Poster Presentation
Presenter: Binu John

3849
To study effect of the combination of midodrine and tolvaptan versus tovalptan alone in patients with severe hyponatremia in cirrhosis - an open label RCT (TOLMINA Trial-NCT05060523)
Poster Presentation
Presenter: srinivasa reddy golamari

Fibrosis / Stellate cell biology

133
Amelioration of CCl4 induced hepatic fibrosis in-vitro and in-vivo by bone marrow derived mesenchymal stromal cells lysate loaded nanostructured lipid carriers
Poster Presentation
Presenter: Sabeen Malik

167
Novel insights on the contribution of collagen degradative macrophages to liver fibrosis resolution
Oral Presentation
Presenter: Maria Fernandez-Fernandez

255
Atypical Chemokine receptors regulate the induction of 'disease-associated' LSEC by modulating Endothelial-to-Mesenchymal transition (EndMT) during liver fibrosis
Oral Presentation
Presenter: Neil Dufton

304
Novel Pathways implicated in the seladelpar-mediated reductions of established liver fibrosis are identified from RNA-SEQ data using plex search and two independent mouse pharmacology datasets
Poster Presentation
Presenter: Edward Cable

316
Analysis of alpha adrenoblocker as antifibrotic and hepatoprotective agent in a Wistar rat model of cirrhosis
Poster Presentation
Presenter: Mariana Yazmin Medina Pizaño
Bulk and single cell RNA sequencing profiling of human hepatic stellate cells and the potential biomarkers for liver cirrhosis
Poster Presentation
Presenter: Xu Liu

726
Spatial lipidomics reveal dysregulated sphingolipid metabolism in liver fibrosis
Poster Presentation
Presenter: Aleksandra Gruevska

819
Reactive oxygen species-mediated hepatic stellate cell activation via PI3K in liver cancer
Poster Presentation
Presenter: Qi Ruan

847
The proto-oncogene Bmi1 is a novel regulator of the activated hepatic stellate phenotype
Poster Presentation
Presenter: Kim Su

874
Hepatic stellate cells from zone 1 do not transform into myofibroblasts but engage in capillarization in preclinical models of liver fibrosis
Poster Presentation
Presenter: Andreas Friebe

952
Identification of pseudo-immune tolerance for chronic hepatitis B patients: development and validation of a non-invasive prediction model
Poster Presentation
Presenter: Shuo Li

1002
Novel natural killer cell immunotherapy through synthesized Neuroligin-4 peptides improved liver fibrosis
Poster Presentation
Presenter: Johnny Amer

1198
Cathepsin D expressed in hepatocytes does not participate in the development of liver fibrosis after chronic CCl4 administration
Poster Presentation
Presenter: Paloma Ruiz-Blazquez
Advancement of artificial intelligence in digital pathology: from exploratory endpoint to primary endpoint in non-alcoholic steatohepatitis clinical trials
Poster Presentation
Presenter: Dean Tai

Hepatic CD40-mediated natural killer T cell apoptosis stimulates liver fibrosis
Oral Presentation
Presenter: Kyurae Kim

3D engineered perihepatic endothelial cell implants reduce fibrosis and inflammation, boosting liver regeneration in fibrotic hepatectomized mice
Poster Presentation
Presenter: Mireia Medrano-Bosch

Selective RNF41 restoration in hepatic macrophages from thioacetamide-induced fibrotic mice reduces liver fibrosis and inflammation
Poster Presentation
Presenter: Alazne Moreno-Lanceta

Hepatic stellate cell-derived extracellular matrix to model aetiology-and patient-specific matrix remodelling and fibrosis progression
Poster Presentation
Presenter: Sara Campinoti

Role of the hepatocyte Epidermal Growth Factor Receptor (EGFR) pathway on the cellular interactome within the liver fibrotic niche
Poster Presentation
Presenter: Isabel Fabregat

Multimodal decoding of the mesenchymal landscape of human biliary fibrosis
Poster Presentation
Presenter: David Wilson

CLOCKΔ19 circadian disruption primes myofibroblasts for accelerated activation and fibrotic progression
Oral Presentation
Presenter: Elliot Jokl

1599
Gender differences in repair mechanisms of chronic cholangiopathies with progressive fibrosis
Oral Presentation
Presenter: Luca Fabris

1718
Therapeutic effect of recombinant human Cytoglobin against mouse liver fibrosis and stellate cell activation via ROS scavenger function and activation of JAK-STAT1 pathway
Poster Presentation
Presenter: Norifumi Kawada

1947
Repeatability and reproducibility assessment and its acceptable standard error of means for qFibrosis system in multi-site NASH clinical trials
Poster Presentation
Presenter: Pik Eu Jason Chang

2055
Hepatic proteomic analysis identifies proteins linked to hepatic sympathetic neuronal degeneration and disorganization which promotes liver fibrosis in bile duct ligation murine model
Poster Presentation
Presenter: Sadam H Bhat

2086
Liver cell-type specific molecular signatures marking transition from advanced fibrosis to cirrhosis in human non-alcoholic steatohepatitis
Poster Presentation
Presenter: Martin Rønn Madsen

2150
The anti-HIV drug Rilpivirine downregulates migration and proliferation of activated hepatic stellate cells: relevance for the purpose of drug repurposing in liver fibrosis
Poster Presentation
Presenter: Ana Benedicto

2200
MicroRNA-29b involves in the progression of NAFLD to liver fibrosis
Poster Presentation
Presenter: qihua duan
2241
Characterizing the long-term stability of human pluripotent stem cell-derived non-parenchymal liver cells
Poster Presentation
Presenter: Ingrid Wilhelmsen

2249
Is the fibrosis phenotype in pre- and post-menopausal F2/F3 women the same?
Poster Presentation
Presenter: Isabel Fernández-Lizaranzu

2262
MCPIP1 inhibits hepatic stellate cell activation in autocrine and paracrine manner
Poster Presentation
Presenter: Jerzy Kotlinowski

2395
The anti-fibrotic efficacy of Adelmidroi depends in the level of hepatic per par gama
Poster Presentation
Presenter: Huanyu Xiang

2449
X-box binding protein 1(XBP1) in hepatic stellate cells (HSC) mitigates liver fibrosis
Oral Presentation
Presenter: Hanghang Wu

2457
Myeloperoxidase from neutrophile granulocytes accomplish destruction of Schistosoma mansoni eggs
Poster Presentation
Presenter: Ricarda Sölter

2564
Does sex influence the development of sarcopenia in liver fibrosis?
Poster Presentation
Presenter: Katia Sayaf

2578
TLC-3595, a selective acetyl-CoA carboxylase 2 (ACC2) inhibitor, improves steatosis and fibrosis in murine models of NASH via pleiotropic mechanisms
Poster Presentation
Presenter: Archana Vijayakumar
2596
Dual alpha-v/beta-6 and alpha-v/beta-1 integrin inhibitor bexotegrast attenuates profibrogenic gene expression of myofibroblasts in human liver explant tissue with biliary fibrosis
Poster Presentation
Presenter: Johanna Schaub

2722
Artificial Intelligence analysis of liver biopsies in pre-cirrhotic NASH: qFibrosis explained
Poster Presentation
Presenter: Pol Boudes

2933
Functional and mechanistic role of lncRNA-C1 in cholestatic liver diseases
Poster Presentation
Presenter: Joan Blázquez Vicens

3001
Cyclophilin inhibition exhibits preventive and curative antifibrotic effects via extracellular matrix remodelling
Poster Presentation
Presenter: Una Rastovic

3085
An integrative multi-omic approach defines therapeutic pathways associated with altered cell state and chromatin organisation in human liver fibrosis
Oral Presentation
Presenter: Karen Piper Hanley

3198
Perturbation of rhythmicity of the circadian clock-oscillator in hepatic stellate cells is associated with liver fibrosis
Oral Presentation
Presenter: Atish Mukherji

3431
3D Extracellular matrix human liver hydrogels for the investigation of genetic variants in hepatic stellate cells
Poster Presentation
Presenter: Elisabetta Caon

3444
Composition of the bile salt pool critically modulates liver fibrosis – towards humanization of murine models of liver disease
Poster Presentation
Presenter: Jingguo Li

3513
Evaluation of anti-fibrotic compounds effect in 3D human NASH model using quantitative digital pathology
Poster Presentation
Presenter: Radina Kostadinova

3752
Single-cell multiomics defines candidate transcription factors regulating pathogenic macrophage differentiation in murine liver fibrosis
Oral Presentation
Presenter: ELENI PAPACHRISTOFOROU

3778
Discovery of novel small molecule inhibitors of HDAC6 that suppress liver fibrosis
Poster Presentation
Presenter: Derek Mann

Gut microbiota and liver disease / Liver-organ crosstalk

174
Prebiotic activity of lactulose optimizes gut metabolites and prevents systemic infection in liver disease patients
Poster Presentation
Presenter: Matthew Odenwald

559
The gut (and its microbiota)-liver axis in liver disease associated with alpha-1-antitrypsin deficiency
Poster Presentation
Presenter: Francesco Annunziata

921
Lactobacillus protects against leaky gut, future decompensation, and hepatic encephalopathy in patients with cirrhosis
Oral Presentation
Presenter: Patricia Bloom

980
Tissue resident NK NTCP- transplanted to immunosuppressed mice exhibiting liver fibrosis and fed with high fat diet (HFD) alleviate intestinal fibrosis
Poster Presentation
Presenter: Johnny Amer
1138
Faecal microbiota transplant restores gut barrier function and augments ammonia metabolism in patients with advanced cirrhosis: a randomised single-blind placebo-controlled trial
Oral Presentation
Presenter: Lindsey A Edwards

1303
Offspring of obese mothers have a higher risk for hepatocellular carcinoma through the transmission of an altered gut microbiome
Oral Presentation
Presenter: Beat Moeckli

1423
Microbiota-targeted interventions in the gut-liver axis for chronic liver disease of DUAL etiology
Poster Presentation
Presenter: Raquel Benedé

1588
Altered gut microbiome and stool bile acids in sarcopenia in cirrhosis
Poster Presentation
Presenter: Benard Aliwa

1863
Viral like particle analysis shows changes with PPIs and may be more sensitive than metagenomics to study PPI modulation of virome in cirrhosis
Poster Presentation
Presenter: Jasmohan S Bajaj

1957
Association of gut microbiome with prospective risk of hepatocellular carcinoma in chronic hepatitis B patients: a prospective nested case-control study
Oral Presentation
Presenter: Zhixian Lan

1983
Pasteurized Akkermansia muciniphila inhibits fibrosis progression in mouse cirrhosis model and induces changes in the gut microbiome
Poster Presentation
Presenter: Sung-Min Won

2068
The novel class of microbially conjugated bile salts activate the main host bile salt receptors FXR and TGR5
2070
Unexpected function of the cell cycle kinase Cyclin E/CDK2 for control of intestinal barrier: implications for gut-liver communication, liver fibrosis and liver cancer
Oral Presentation
Presenter: Anna Verwaayen

2379
Culturomics study of gut microbiota in NASH patients and healthy controls
Poster Presentation
Presenter: Babacar Mbaye

2401
Impact of human gut microbiota from PSC patients on a mouse model of biliary disease
Poster Presentation
Presenter: Petra Hradicka

2468
Characterization of pattern recognition receptor expression for regulating myeloid cell responses in the gut-liver axis in non alcoholic fatty liver disease and cholangiopathies
Poster Presentation
Presenter: Alix Bruneau

2695
Investigating the correlation of a poly-metabolic risk score to clinical features in non-alcoholic fatty liver disease patients throughout a faecal microbiota transplant clinical trial
Poster Presentation
Presenter: Nadeen Habboub

2723
Gut microbial proteomic changes from commensal bacteria are associated with development of first decompensation in cirrhosis
Poster Presentation
Presenter: Jasmohan S Bajaj

2763
The bile acid chenodeoxycholic acid increases muscle insulin sensitization via FOXO1
Poster Presentation
Presenter: Roshni Rebecca Singaraja

2773
Identification of gut microbiota signature for differentiating between viral- and non-viral related hepatocellular carcinoma
Poster Presentation
Presenter: Pisit Tangkijvanich

2782
Long-term benefit of direct-acting antivirals on gut dysbiosis and microbial translocation in HCV-infected patients with and without HIV coinfection
Poster Presentation
Presenter: Natthaya Chuaypen

2874
Edible exosomes oral administration restores gut homeostasis and reduces systemic ammonia level in rodent model
Poster Presentation
Presenter: P. Debishree Subudhi

2897
The intestinal immune barrier is associated with bile acid pool modifications in mice suffering from non-alcoholic steatohepatitis
Poster Presentation
Presenter: Simon Peschard

2915
Serum villin-1 level – a tell-tale sign of gut barrier failure in patients with cirrhosis and acute decompensation
Oral Presentation
Presenter: David Tornai

3250
Oral microbiome signature associated with liver graft dysfunction
Poster Presentation
Presenter: Shruti Sureshan

3273
Phascolarctobacterium as a predictor for survival in cirrhotic patients
Poster Presentation
Presenter: Rosa Haller

3315
Identifying the role of gut-vascular barrier associated macrophages in liver cirrhosis
Poster Presentation
Presenter: Lena Smets
Pemafibrate modulates microbiota profile in a dietary model of fatty liver in rat
Poster Presentation
Presenter: Roger Bentanachs

Gut viral and bacterial alterations modulate the presence and dynamics of minimal hepatic encephalopathy at baseline and longitudinally
Poster Presentation
Presenter: Jasmohan S Bajaj

Altered levels of secondary bile acids in enterohepatic circulation impairs liver regeneration in a rat model of partial hepatectomy
Poster Presentation
Presenter: Impreet Kaur

Intestinal dysbiosis exacerbates gut barrier dysfunction via inhibiting FXR-FGF15 in intra-abdominal sepsis
Poster Presentation
Presenter: Shuwen Qian

Gut-liver crosstalk in hepatocellular carcinoma and non-selective beta-blockers: is there a link?
Poster Presentation
Presenter: Yasmeen Attia

**Hepatocyte biology**

Magnesium content decreases and transient receptor potential melastatin-subfamily member 7 expression increases in hepatocytes as liver inflammation and cirrhosis worsen in liver transplant candidates
Poster Presentation
Presenter: Simona Parisse

Dickkopf-1 inhibitor enhances the anti-tumor effects of sorafenib through inhibition of PI3K/Akt/Wnt signaling in hepatocellular carcinoma
Poster Presentation
Presenter: Sang Hyun Seo
Liver spheroids engrafted in the anterior chamber of the eye - a novel platform to study hepatic physiology and pathology
Poster Presentation
Presenter: Francesca Lazzeri-Barcelo

Multiomic profiling associated with lipid remodeling in senescent primary human hepatocytes
Poster Presentation
Presenter: Sin-Tian Wang

Integrated metabolomic and transcriptomic analyses implicate specific metabolic pathways in crocin-induced apoptosis of HCC cells
Poster Presentation
Presenter: Amr Amin

With-in patient comparison of single-cell versus single-nucleus sequencing on human transjugular liver biopsies
Poster Presentation
Presenter: Lukas Van Melkebeke

DNA damage induced-senescence shifts the cellular bioenergetics capacity from glycolysis to oxidative phosphorylation in mouse hepatocytes
Oral Presentation
Presenter: Pavitra Kumar

Long-term effects in primary human hepatocytes (PHH) after exogenous exposure to human intestinal microbiome secretome peptides
Poster Presentation
Presenter: Natalia Sanchez-Romero

Accumulation of apical bulkheads and hepatocyte rosettes as adaptive responses upon impaired bile flow in liver diseases
Poster Presentation
Presenter: Carlotta Mayer

Tick-tock – Uncovering new aspects of circadian-regulated liver metabolism by kinetic modeling
Poster Presentation
Presenter: Christiane Körner

2435
3D digital histopathology: a new methodology for morphological characterization of the human liver
Poster Presentation
Presenter: Mathieu de Langlard

2568
Three-dimensional single-cell digital atlas of liver tissue architecture
Poster Presentation
Presenter: Fabián Segovia-Miranda

3241
Insulin determines TGF-β effects on HNF4α transcription in liver injury and hepatocyte epithelial-to-mesenchymal transition
Poster Presentation
Presenter: Steven Dooley

Immune-mediated and cholestatic disease: Clinical aspects

57
Antibodies against multiple post-translationally modified proteins aid in diagnostic work-up of autoimmune hepatitis and associate with complete biochemical response to treatment
Poster Presentation
Presenter: Anna Stoelinga

332
Biliary microbial patterns in primary sclerosing cholangitis are linked to disease outcome
Poster Presentation
Presenter: Burcin Özdirik

404
INTEGRIS-PSC phase 2a study: evaluating the safety, tolerability, and pharmacokinetics of bexotegrast (PLN-74809) in participants with primary sclerosing cholangitis
Poster Presentation
Presenter: Gideon Hirschfield

419
A two-step algorithm avoids corticosteroids in two-thirds of cancer patients with severe immune-mediated hepatitis due to immune checkpoint inhibitors
Poster Presentation
Presenter: Mar Riveiro Barciela
420
Norucholic acid for the treatment of primary sclerosing cholangitis: baseline data from a phase III trial
Poster Presentation
Presenter: Michael Trauner

425
A novel web-based online nomogram to predict advanced liver fibrosis in patients with autoimmune hepatitis-primary biliary cholangitis overlap syndrome
Poster Presentation
Presenter: Zhiyi Zhang

500
Long-term prospective follow-up of a primary biliary cholangitis (PBC) multicenter cohort treated with Obeticholic Acid (OCA). Interaction effect of triple therapy with fibrates
Poster Presentation
Presenter: Conrado Fernandez-Rodriguez

506
Autoimmune hepatitis (AIH) in Greece: first results from the Hellenic autoimmune liver diseases study group of the Hellenic association for the study of the liver (HASL)
Poster Presentation
Presenter: Nikolaos Gatselis

565
Peri-procedural complications in people with primary sclerosing cholangitis undergoing endoscopic retrograde cholangiopancreatography - evaluating a high-volume programme
Poster Presentation
Presenter: Kristel Leung

583
Prognostic significance of liver stiffness progression in primary biliary cholangitis
Oral Presentation
Presenter: Christophe Corpechot

603
Risk of cancer and subsequent mortality in primary biliary cholangitis: a population-based cohort study of 3,052 patients
Oral Presentation
Presenter: Axel Wester

631
Clinical significance of F-actin IgA and gliadin IgA antibodies in primary sclerosing cholangitis
Poster Presentation
Presenter: Ewa Wunsch

858
Patient reported gaps between current practice and new practice guidelines for primary sclerosing cholangitis
Poster Presentation
Presenter: Annika Bergquist

877
The association between cholestatic biochemical markers and clinical symptoms in patients with non-end-stage primary sclerosing cholangitis
Poster Presentation
Presenter: Tim Middelburg

888
Impact of maralixibat on cholestatic pruritus in adults aged 16 years and older with Alagille syndrome
Poster Presentation
Presenter: Gideon Hirschfield

893
Results of the prospective multicentre European R-LIVER registry reveal the unmet clinical needs of autoimmune hepatitis
Oral Presentation
Presenter: Ida Schregel

898
Maralixibat leads to significant reductions in pruritus and improvements in sleep for children with progressive familial intrahepatic cholestasis: data from MARCH-PFIC
Poster Presentation
Presenter: Richard J. Thompson

903
Maralixibat leads to significant reductions in bilirubin for patients with progressive familial intrahepatic cholestasis: data from MARCH-PFIC
Oral Presentation
Presenter: Lorenzo D'Antiga

907
Analysis of safety in maralixibat-treated participants with progressive familial intrahepatic cholestasis: data from MARCH-PFIC
Poster Presentation
Presenter: Alexander Miethke
922
Development and validation of a score predicting response to obeticholic acid in primary biliary cholangitis: the OCA response score (ORS)
Oral Presentation
Presenter: Antonio De Vincentis

931
May symptom combinations at initial diagnosis of primary biliary cholangitis implicate distinct natural history?
Poster Presentation
Presenter: Atsumasa Komori

972
Change in serum bile acids correlates with improvement in itch in patients with primary biliary cholangitis receiving linerixibat
Poster Presentation
Presenter: Brandon Swift

1004
Exploring the impact of ursodeoxycholic acid therapy on COVID-19 in a real-world setting
Poster Presentation
Presenter: Christophe Corpechot

1041
Increased risk of osteoporotic fracture in patients with autoimmune hepatitis
Poster Presentation
Presenter: Jihye Lim

1142
Investigating the cholestatic pruritus of primary sclerosing cholangitis (ItCh-PSC): a study of patients participating in the consortium for autoimmune liver disease (CALiD)
Poster Presentation
Presenter: Richard Dean

1143
The changing clinical phenotype of autoimmune hepatitis across the millennium. A 40 year cohort study in Bologna, Italy
Poster Presentation
Presenter: Marco Ferronato

1189
Spleen stiffness measurement predicts decompensation risk in primary biliary cholangitis
Poster Presentation
Presenter: Giulia Francesca Manfredi
1210
Rechallenge with anti-PD1 monotherapy after checkpoint inhibitor hepatitis is associated with low rates of recurrence: a single centre study
Poster Presentation
Presenter: Lucy Walker

1284
The devastating impact of severe pruritus in primary biliary cholangitis
Poster Presentation
Presenter: Helen Smith

1344
Prognostic value of serum ALP levels during additional treatment in Japanese patients with primary biliary cholangitis treated with ursodeoxycholic acid and bezafibrate
Poster Presentation
Presenter: Akihito Takeuchi

1420
Transient elastography measurements of spleen stiffness are associated with treatment response to ursodeoxycholic acid in primary biliary cholangitis
Poster Presentation
Presenter: Ilkay Ergenc

1440
Associations between patient-reported outcomes, liver inflammation and fibrosis in patients with primary sclerosing cholangitis
Poster Presentation
Presenter: Emilie Eifer Møller

1484
Variation in maintenance therapy practices in a large U.S. cohort of patients with autoimmune hepatitis
Poster Presentation
Presenter: Therese Bittermann

1496
Non-adherence to standard pharmacotherapy in autoimmune hepatitis is associated with over-the-counter medication and steroid treatment. Results from the ERN online survey
Poster Presentation
Presenter: Ewa Wunsch
Modulation of alkaline phosphatase levels by obeticholic acid in clinical trials and cultured human hepatocytes
Poster Presentation
Presenter: Kris Kowdley

1522
Risk of death, liver transplant or hepatic decompensation in primary biliary cholangitis increases with increased duration and degree beyond established clinical thresholds for hepatic biomarkers and fibrosis scores
Poster Presentation
Presenter: Kris Kowdley

1573
Accuracy of controlled attenuation parameter (CAP) measurement for the detection of steatosis in autoimmune liver diseases
Poster Presentation
Presenter: Silja Steinmann

1763
Clinicopathological features and prognosis of early primary biliary cholangitis with clinically significant portal hypertension
Poster Presentation
Presenter: Qi Zheng

1770
Non-invasive evaluation of progression to primary biliary cholangitis in patients with positive antimitochondrial antibodies
Poster Presentation
Presenter: ALVARO DIAZ GONZALEZ

1835
Predicting the current and future prevalence of primary sclerosing cholangitis with inflammatory bowel disease (PSC-IBD): a nationwide population-based study
Poster Presentation
Presenter: Palak Trivedi

1844
Risk of decompensated cirrhosis in patients with primary biliary cholangitis under first, second and third-line therapies
Poster Presentation
Presenter: Ana Lucena

1878
Clinical characteristics, hospitalization, and mortality outcomes of Coronavirus Disease 2019 in primary sclerosing cholangitis liver transplant patients
Poster Presentation
Presenter: Stela Celaj

1942
Impact of the metabolic profile on the response to ursodeoxycholic acid in patients with primary biliary cholangitis: results of the ColHai registry
Poster Presentation
Presenter: Andrea González Pascual

1946
Improved survival with regular surveillance imaging in patients with primary sclerosing cholangitis
Poster Presentation
Presenter: Natassia Tan

2003
Clinical, demographic, laboratory characteristics and disease progression of autoimmune hepatitis patients, asymptomatic at diagnosis, in a tertiary medical center in Israel
Poster Presentation
Presenter: Ehud Zigmond

2082
Dominant strictures in patients with primary sclerosing cholangitis: comparison between old and new definition
Poster Presentation
Presenter: Andrea Tenca

2136
Outcome and prognostic factors of primary biliary cholangitis in South Korea
Poster Presentation
Presenter: Kyung-ah kim

2158
Lack of biochemical response after diagnosis is associated with cirrhosis development during follow-up in autoimmune hepatitis
Oral Presentation
Presenter: Charlotte Slootter

2161
Mitochondrial dysfunction and lipid alterations in primary sclerosing cholangitis
Poster Presentation
Presenter: Mette Vesterhus
2190
Hepatic steatosis in patients with autoimmune hepatitis: relationship with corticosteroid treatment and long-term outcome
Poster Presentation
Presenter: Sarah Flatley

2237
Improving the diagnosis of primary biliary cholangitis through immunology protocols
Poster Presentation
Presenter: Mario de Bonis Encinoso

2256
Does fibrosis regression in autoimmune hepatitis require histological as well as biochemical remission?
Poster Presentation
Presenter: Sarah Flatley

2487
Prevalence and risk factors of osteoporosis in patients with primary biliary cholangitis in Chinese population
Poster Presentation
Presenter: Jialiang Chen

2495
Results from a planned interim analysis of a randomized, double-blind, active-controlled trial evaluating the effects of obeticholic acid and bezafibrate on serum biomarkers in primary biliary cholangitis
Oral Presentation
Presenter: Frederik Nevens

2513
Chronic pruritus is associated with altered nerve fiber function and anatomy in patients with cholestatic hepatobiliary diseases
Poster Presentation
Presenter: Miriam Düll

2565
Seladelpar treatment resulted in correlated decreases in serum IL-31 and pruritus in patients with primary biliary cholangitis (PBC): post-hoc results from the phase 3 randomized, placebo-controlled ENHANCE study
Poster Presentation
Presenter: Andreas E Kremer
2577
Vitamin D associates with clinical outcomes in patients with primary sclerosing cholangitis
Poster Presentation
Presenter: Aldo J Montano-Loza

2611
The socioeconomic status, epidemiology, and outcomes of people living with primary sclerosing cholangitis - inflammatory bowel disease in Ontario, Canada: a two-decade analysis
Poster Presentation
Presenter: Kristel Leung

2636
Long-term real-world experience with obeticholic acid in primary biliary cholangitis: the Italian recapitulate study
Oral Presentation
Presenter: Francesca Terracciani

2653
Vibration-controlled transient elastography predicts clinical outcomes in patients with autoimmune hepatitis
Poster Presentation
Presenter: Aldo J Montano-Loza

2655
Symptom burden in people living with primary biliary cholangitis does not associate with transient elastography measures
Poster Presentation
Presenter: Inbal Houri

2682
Burden, impact and variability of pruritus in primary sclerosing cholangitis (PSC) over time: a prospective observational study
Poster Presentation
Presenter: Nasir Hussain

3008
Relative enhancement and spleen volume predict clinical outcomes in primary sclerosing cholangitis
Poster Presentation
Presenter: Laura Cristoferi

3101
Collagen proportionate area is associated with adverse clinical outcomes and allows risk stratification of patients with autoimmune hepatitis
Poster Presentation
Presenter: Neil Halliday

3147
Prevalence of celiac disease in adult patients with cryptogenic liver disease
Poster Presentation
Presenter: Aditya Vikram Pachisia

3264
Drug-induced autoimmune hepatitis or drug-induced liver injury with autoimmune features: two faces of the same coin?
Poster Presentation
Presenter: Pinelopi Arvaniti

3317
To assess response to steroids and validate SURFASA score in Indian autoimmune hepatitis patients
Poster Presentation
Presenter: Harsh Gandhi

3320
The natural history and prognosis of primary sclerosing cholangitis: a multi-center, retrospective cohort study in China
Poster Presentation
Presenter: Xiong Ma

3327
Predictive models of treatment benefit in patients with autoimmune hepatitis and decompensated cirrhosis at diagnosis
Poster Presentation
Presenter: Pinelopi Arvaniti

3388
Elevated GGT levels as predictor of non-response to ursodeoxycholic acid in patients with primary biliary cholangitis
Poster Presentation
Presenter: Flor M Fernandez-Gordón Sánchez

3436
RESIST criteria accurately rule-out high-risk esophageal varices in patients with primary biliary cholangitis and compensated advanced chronic liver disease
Poster Presentation
Presenter: Ciro Celsa

3442
Variation in the presentation pattern of primary biliary cholangitis (PBC) in Spain according to the diagnostic period: data from the Spanish registry of cholestatic and autoimmune liver diseases (COLHAI)
Poster Presentation
Presenter: Sergio Rodriguez-Tajes

3489
Baseline characteristics and risk profiles of 1111 patients with primary biliary cholangitis (PBC) in need of second-line therapy
Poster Presentation
Presenter: Gideon Hirschfield

3510
Celiac disease in patients with autoimmune hepatitis is associated with a milder liver disease course and a better chance of immunosuppressive treatment withdrawal
Poster Presentation
Presenter: Francesco Pezzato

3589
Anti-Saccharomyces cerevisiae antibodies predict severe liver disease and advanced fibrosis in patients with primary sclerosing cholangitis and inflammatory bowel disease
Poster Presentation
Presenter: Lian Bannon

3656
Budesonide is associated with less weight gain than Prednisolone amongst patients with autoimmune hepatitis: results from long term follow-up in routine clinical care
Poster Presentation
Presenter: Josh Orpen-Palmer

3669
Unexpected high incidence of AMA positive primary biliary cholangitis in a northern Italian region
Poster Presentation
Presenter: Davide Bitetto

3795
Presence of metabolic associated liver disease in autoimmune hepatitis is associated with advanced liver fibrosis
Poster Presentation
Presenter: Alvaro Urzúa

3814
Health-related quality of life and medication adherence in adult patients after liver transplantation due to autoimmune hepatitis: a pilot, single centre study
Immune-mediated and cholestatic: Experimental and pathophysiology

165
Associations of fecal bile acids, diet, and intestinal microbes with markers of disease progression in primary sclerosing cholangitis disease
Presenter: Maciej K. Janik

224
Golexanolone, a GABA receptor-modulating steroid antagonist, improves peripheral inflammation, fatigue, locomotor gait, motor incoordination and short-term memory in rats with cholestasis and hepatic encephalopathy due to bile duct ligation
Presenter: Connie Chan

541
Results of pharmacological treatment of Mcpip1 knock-out mice which develop symptoms of primary biliary cholangitis
Presenter: Vicente Felipo

623
Blockade of IL-18 via long-acting IL-18 binding protein attenuates experimental diet-induced cholestatic disease
Presenter: Katarzyna Trzos

778
The significance of patatin-like phospholipase domain-containing protein-3 I148M genetic variant in autoimmune hepatitis
Presenter: Nikolaos Gatselis

810
HSD17B13 inhibitors are hepatoprotective and anti-inflammatory in a mouse model of autoimmune hepatitis
Presenter: Manuel Roqueta-Rivera
A3907, a systemic ASBT inhibitor, improves cholestasis in mice by inhibiting multi-organ bile acid transport and shows translational relevance to human
Oral Presentation
Presenter: Francisco J. Caballero

1085
The cell cycle protein Cyclin E1 mediates pro-inflammatory signals in a mouse model of acute hepatitis and in primary macrophages
Poster Presentation
Presenter: Christian Penners

1112
Anti-nucleosome antibodies as an important marker to distinguish between autoimmune hepatitis and drug-induced liver injury
Poster Presentation
Presenter: Nasser Semmo

1151
Differential activation of regulatory CD4+ T cells via the JAK-STAT-pathway in Primary sclerosing cholangitis
Poster Presentation
Presenter: Leona Dold

1171
Non-invasive imaging method demonstrates anti-fibrotic efficacy of a dual integrin alpha-v/beta-6 and alpha-v/beta-1 inhibitor in a rat model of biliary fibrosis
Poster Presentation
Presenter: Johanna Schaub

1179
Bacteriophage therapy against pathological Klebsiella pneumoniae that determine the clinical course of primary sclerosing cholangitis
Poster Presentation
Presenter: Masataka Ichikawa

1267
The role of Type II and III Interferons in primary biliary cholangitis
Poster Presentation
Presenter: Yooyun Chung

1668
Cytotoxic activity of peripheral NK cells is decreased in primary sclerosing cholangitis
Poster Presentation
Presenter: Leona Dold
1879
Elevated JAG1-NOTCH Signaling is Associated with Fibrosis Stages in Patients with PSC
Poster Presentation
Presenter: Michael Trauner

1927
Pyroptosis plays a key role in primary biliary cholangitis of humans and mice
Poster Presentation
Presenter: Linxiang Huang

2001
Molecular signatures of treatment response in autoimmune hepatitis
Poster Presentation
Presenter: Bastian Engel

2044
Depletion of excess liver copper ameliorates liver damage in a mouse model of chronic cholestatic liver disease
Poster Presentation
Presenter: Dennis Koob

2048
Proteomics and metabolomics of bile reveal molecular insights and classify signatures predictive of carcinoma of gallbladder
Poster Presentation
Presenter: Nupur Sharma

2080
Loss of innate and adaptive effector lymphocytes is associated with diminished globe score prognosis in patients with primary biliary cholangitis
Poster Presentation
Presenter: Hussain Syed

2174
Cholestatic liver disease is alleviated by colitis-induced inhibition of bile acid synthesis
Poster Presentation
Presenter: Wenfang Gui

2178
Serum proteomics reveals association of CCL24 with key aspects of primary sclerosing cholangitis
Poster Presentation
Presenter: Raanan Greenman
2230
CD44 reduces fibrosis development in chronic cholestatic liver injury in Mdr2 knock-out mice
Poster Presentation
Presenter: Franziska Ihli

2419
Combination of intestinal bile salt uptake inhibition with pharmacological repression of bile salt synthesis improves liver health in cholestatic mice
Poster Presentation
Presenter: Stan van de Graaf

2504
The role of bile salts in cholestasis associated pruritus
Poster Presentation
Presenter: Frank Wolters

2579
scRNA transcriptomics reveal the role of cholangiocytes and neutrophils cross talk in PKHD1-KO mice
Poster Presentation
Presenter: Mario Strazzabosco

2590
Combination of ileal bile acid transporter inhibitor and a non-steroidal Farnesoid X receptor agonist for reversal of cholestatic liver injury in Cyp2c70 KO mice with a humanized bile acid composition
Poster Presentation
Presenter: Caroline Klindt-Morgan

2697
Genetic predisposition for liver inflammation and response to anti-cholestatic therapy in experimental sclerosing cholangitis
Poster Presentation
Presenter: Alexander Miethke

2909
In vitro modulation of fibrogenesis and inflammation in patient-derived cholangiocyte organoids
Poster Presentation
Presenter: Anna Katharina Frank

2910
Spatial transcriptomics reveals shared gene and cellular composition in recurrent and primary sclerosing cholangitis
Poster Presentation
Temporal characteristics of cell compartments in immune-mediated cholestatic disease
Poster Presentation
Presenter: Markus Jördens

Oxazolone-mediated bile duct inflammation reveals specific natural killer T cell-dependent inflammatory pathways
Poster Presentation
Presenter: Markus Jördens

Development of an in vitro bile-duct-on-a-chip-platform using patient-derived cholangiocytes
Poster Presentation
Presenter: Anna Katharina Frank

Production of reactive oxidant species and fatty acid uptake is increased in regulatory T-cells in autoimmune hepatitis, and associated with down-regulation of markers linked to suppressor function
Poster Presentation
Presenter: Scott Davies

Phenotypic diversity and regeneration in a model of Alagille syndrome recapitulate patient heterogeneity
Poster Presentation
Presenter: Linde Sevenants

The effect of the combination of metformin with propionic acid on the indicators of oxidative stress in liver tissue of rats with type 2 diabetes mellitus
Poster Presentation
Presenter: Olena Khokhliuk

Laminin 511-E8 is an autoantigen in IgG4-related cholangitis patients that protects cholangiocytes against T lymphocyte-induced epithelial barrier dysfunction
Oral Presentation
Presenter: David Trampert
Identification of potential targets amenable to novel therapeutics to treat symptoms in primary biliary cholangitis  
Poster Presentation  
Presenter: Aaron Wetten

Cholestatic liver disease enhances sociability and leads to significant adaptative changes in amygdala neural circuits regulating social behavior in mice  
Poster Presentation  
Presenter: Wagdi Almishri

Liver development and regeneration

Autologous skeletal myoblast cell-sheet transplantation for liver regeneration  
Poster Presentation  
Presenter: Keisuke Toya

Excessive proliferation after extended hepatectomy compromises liver function in mice  
Poster Presentation  
Presenter: Maxime De Rudder

Insights into DNA damage in regenerating young and aged mice livers  
Poster Presentation  
Presenter: Ainhoa Asensio Aldave

Autophagy regulates the generation and differentiation of chemically derived hepatic progenitors (CdHs)  
Poster Presentation  
Presenter: Hayoon Kim

IGF1 specifically rescues peripheral intrahepatic biliary organoids from a mouse model of Alagille syndrome  
Poster Presentation  
Presenter: Afshan Iqbal

Conditioned medium from human allogeneic liver-derived progenitor cells protects against LPS-induced endothelial hyperpermeability via shingosine-1 phosphate
1114
Liver innervation is dysregulated in a mouse model of Alagille syndrome
Presenter: Mustapha Najimi

1220
Endothelial autophagy is not required for liver regeneration after partial hepatectomy in mice with fatty liver
Presenter: Elisabeth Verboven

1298
Liver regeneration is regulated by intestinal sirtuin-1
Presenter: Adel HAMMOUTENE

1304
The silencing of Sox9 impairs ductular reaction expansion while enhancing the differentiation of DR cells into hepatocytes
Presenter: Sian Seaman

1354
Hepatic progenitor cell activation through the interaction of mesenchymal stem cells and liver sinusoidal endothelial cells
Presenter: Su jung Park

1375
Development of intrahepatic bile ducts during liver progenitor cell-driven liver regeneration is associated with epithelial cell adhesion molecule function
Presenter: Eun Young Cho

1711
Transcriptomics confirm the establishment of a liver-immune dual-humanized mouse model after transplantation of a single type of human bone marrow mesenchymal stem cell
Presenter: Jun Li
1873
Neutrophils promote chronic liver injury resolution
Oral Presentation
Presenter: Silvia Ariño

2090
Lineage tracing of hepatic stellate cells with ultrasound-guided in utero nano-injection
Poster Presentation
Presenter: Jingyan He

2116
Role of GATA4 in the modulation of hepatic progenitor cell fate
Poster Presentation
Presenter: Laura Villamayor

2392
Tunable host senescence determines the success of hepatocyte transplantation in a mouse model of liver injury
Poster Presentation
Presenter: Victoria Gadd

2951
Hepatic nerve endings are rewired by cholestatic injury to connect inflamed lymphatics to sites of ductular remodelling
Oral Presentation
Presenter: Luke Noon

3228
Skin-decellularized matrix-derived microgels accelerate 3D cultures of functional primary hepatocyte spheroids in vitro
Poster Presentation
Presenter: Ashwini Vasudevan

3496
A novel organoid model of human liver bud development
Poster Presentation
Presenter: Charlotte Grey-Wilson

3760
Rescue mechanism of hHIL-6 after partial hepatectomy
Poster Presentation
Presenter: Julia Ettich
Liver immunology

93
RIPK3-mediated XBP1-Foxo1 axis controls NOD1 function and Calcineurin/TRPM7-induced cell death in liver inflammatory injury
Poster Presentation
Presenter: Bibo Ke

537
Intermediate monocytes and associated chemokines allow differentiation of idiosyncratic drug-induced liver injury (DILI) and autoimmune hepatitis (AIH)
Poster Presentation
Presenter: Stuart Astbury

625
Immune characterization of the melanocortin-4-receptor mouse model for non-alcoholic steatohepatitis using mass cytometry and imaging mass cytometry
Poster Presentation
Presenter: Fabienne Birrer

964
Kupffer cell activation enhances systemic anti-bacterial immunity
Poster Presentation
Presenter: Christian Zwicker

1035
Comprehensive phenotypical and molecular characterization of B lymphocytes in patients affected by intrahepatic cholangiocarcinoma
Poster Presentation
Presenter: Giulia Milardi

1135
Interplay between hepatitis B virus replication and intrahepatic expression of VISTA and TIM-3 immune checkpoint markers in chronic hepatitis B patients
Oral Presentation
Presenter: Marianne Tuefferd

1362
Characterisation of invariant natural killer T cells in human hepatic biopsies
Poster Presentation
Presenter: Elena Jiménez-Martí

1391
Mast cell activation index as a novel prognostic marker in a pan-analysis of gastrointestinal cancers
1476
The ascitic environment in cirrhosis upregulates the expression of the immune checkpoint CD155 on peritoneal macrophages
Presenter: Nataliya Rohr-Udilova

1959
The Ninj1/Dusp1 axis contributes to liver ischemia reperfusion injury by regulating macrophage activation and neutrophil infiltration
Presenter: Joseph Delo

2062
The effect of testosterone on human T cells in health and autoimmune liver disease
Presenter: Yuanchang Hu

2085
TIGIT inhibits the cytotoxic effects of NK cells towards biliary epithelial cells in autoimmune hepatitis
Presenter: Amber Bozward

2105
ILT2 as a biomarker of impaired natural killer cells expressing excess lipid peroxidation in patients with hepatocellular carcinoma
Presenter: Toshihiro Sakata

2112
Developing highly pure, functional GMP grade Treg for the treatment of autoimmune liver disease
Presenter: Naomi Richardson

2159
Osteopontin serves as a potential regulator of T cell immunity in patients with hepatocellular carcinoma
Presenter: Tengfei Si

2280
Selective activation of the IL-2 pathway in CD8+ T cells drives antiviral activity to Hepatitis B Virus (HBV)
Oral Presentation
Presenter: Matteo Iannaccone

Liver immunity index: circulating HBV-specific CXCR6+ CD8 T cells mirror intrahepatic anti-viral T cell immunity and predict immune control in models of chronic hepatitis B
Oral Presentation
Presenter: Hannah Wintersteller

Distinct immunometabolic signatures in circulating immune cells define disease outcomes in acute-on-chronic liver failure
Poster Presentation
Presenter: Rita Furtado Feio de Azevedo

Phenotypical and functional sub-classification of Kupffer cells and liver monocyte-derived macrophages in mice
Poster Presentation
Presenter: Hiroyuki Nakashima

CXCL9 does not ameliorate murine macrophage activation syndrome hepatitis
Poster Presentation
Presenter: Tamir Diamond

Single-cell atlas of liver myeloid cells with cure of chronic viral hepatitis
Oral Presentation
Presenter: Ang Cui

2D-interactome of the tumor immune-microenvironment reveals immunosuppressive T cells in primary sclerosing cholangitis-associated cholangiocarcinoma
Oral Presentation
Presenter: Jenny Krause

AAV-HBV mouse model replicates immune exhaustion patterns of chronic HBV patients at single-cell level
Poster Presentation
Presenter: Ren Zhu
Liver-on-chip platform for studying recruitment and differentiation of circulating monocytes
Oral Presentation
Presenter: Aleksandra Aizenshtadt

The decrease of HCV-specific neutralizing antibody responses after DAA therapy is associated with weak envelope-specific CD4 T cell immunity
Poster Presentation
Presenter: Jill Werner

“Swarm hunting” of virus-specific CD8 T cells together with auto-aggressive CD8 T cells to achieve efficient killing of virus-infected hepatocytes
Poster Presentation
Presenter: Ariane Eceiza Tenreiro

Rheostat function of liver sinusoidal endothelial cells and macrophages limiting antiviral CD8 T cell immunity in the liver
Poster Presentation
Presenter: Anna Fürst

Liver sinusoidal scavenger cells eliminate betaherpesvirus from the blood stream
Poster Presentation
Presenter: Anett Kristin Larsen

Metabolic landscape of intrahepatic regulatory T cells in health and disease
Poster Presentation
Presenter: Elena Perpinan

Epigenetic conversion of CD4+ T cells to stable and functioning induced regulatory T cells via cyclin-dependent kinase inhibition and CD28 signal deprivation in patients with primary biliary cholangitis
Poster Presentation
Presenter: Vincenzo Ronca

Liver transplantation and hepatobiliary surgery
139
Access to liver transplant for women in Spain: a national registry analysis
Poster Presentation
Presenter: Marta Tejedor Bravo

140
Validation of MELD3.0 in two centres from different continents
Poster Presentation
Presenter: Marta Tejedor Bravo

161
Primary sclerosing cholangitis as an indication for liver transplantation. Results and conditioning factors: relationship with associated intestinal pathology
Poster Presentation
Presenter: Ainhoa Fernandez

208
Defective efferocytosis by aged macrophages promotes STING signaling mediated inflammatory liver injury
Poster Presentation
Presenter: Haoran Hu

209
Risk factors associated with surgical morbidities of laparoscopic living liver donors
Poster Presentation
Presenter: Jinsoo Rhu

210
Pre-transplant mycophenolate mofetil may be associated with reduced intrahepatic cholangiopathy in ABO-incompatible liver transplantation
Poster Presentation
Presenter: Jinsoo Rhu

343
A multi-center, stratification-randomized, double-blind, placebo-controlled, phase III clinical trial of topical recombinant human thrombin for intraoperative hemostasis
Oral Presentation
Presenter: Jun Yu

352
Liver transplant recipients with autoimmune hepatitis in the Swiss transplant cohort study have a higher risk of graft loss and vascular complications
Poster Presentation
Presenter: Aurélie Rosat
In vitro model of liver ischemia/reperfusion injury identifies iRhom2 as new target of disease
Poster Presentation
Presenter: Giovanni Zito

Use and outcomes of hepatitis B virus positive grafts for renal or heart transplantation in the US (1999-2021)
Poster Presentation
Presenter: Ashwani Singal

Increased left ventricular dimensions are the new risk factor for acute kidney injury after living donor liver transplantation (cardio-renal interaction)
Poster Presentation
Presenter: Dheapak V

Outcomes in patients with new-onset atrial fibrillation after liver transplantation using the national readmission database
Poster Presentation
Presenter: Induja Nimma

Long-term survival after liver transplantation in patients with common variable immunodeficiency
Poster Presentation
Presenter: Ina Andersen

The growing prevalence and impact of type 2 diabetes among liver transplant candidates in the United States
Poster Presentation
Presenter: Zobair Younossi

The influence of immunosuppression and recipient geography on non-melanoma skin cancer risk after liver transplantation
Poster Presentation
Presenter: Therese Bittermann

Incidence and risk factors for de-novo NAFLD after liver transplantation: real-world data
989
Clinical impact and treatment of veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) after liver transplant (LT): the role of transjugular intrahepatic porto-systemic shunt (TIPS)
Poster Presentation
Presenter: Katharina Luise Hupa-Breier

999
Comorbidities and complications of patients hospitalized for liver transplantation evaluation, transplant and post-LT: a fourteen-year nationwide study in Germany
Poster Presentation
Presenter: Michela Triolo

1019
The impact of statin utilization on mortality in liver transplant recipients independent of underlying cardiovascular risk
Poster Presentation
Presenter: Wenyi Gu

1129
Donor outcomes incidence after living-donor liver transplantation: meta-analysis and systematic review
Poster Presentation
Presenter: Megan Ghai

1147
Deep learning prediction modeling of major adverse cardiovascular events following liver transplantation
Poster Presentation
Presenter: Cui Tao

1207
Liver transplantation as treatment option for cholangiocellular carcinoma
Poster Presentation
Presenter: Gabriela Berlakovich

1259
C105SR, a novel non-peptidic small-molecule cyclophilin inhibitor with potent mitoprotective and hepatoprotective properties in the context of hepatic ischemia/reperfusion injury
Poster Presentation
Presenter: Fatima TEIXEIRA-CLERC
The evolution of the muscle compartment from the listing to six-month post-transplantation: a longitudinal monocentric study
Poster Presentation
Presenter: Delorme Alicia

Neoadjuvant PD-1 blockade with Pembrolizumab combined with Lenvatinib therapy in patients with hepatocellular carcinoma beyond Milan criteria before liver transplantation (PLENTY): a single-site pilot randomized controlled trial
Poster Presentation
Presenter: Hao Feng

Polycystic disease: a cumbersome benign indication for transplantation
Poster Presentation
Presenter: Alberto Calleri

Type of calcineurin inhibitor versus long-term outcome following liver transplantation for primary biliary cholangitis – an ELTR study
Oral Presentation
Presenter: Maria van Hooff

Two-year follow-up of liver grafts from COVID-19 donors
Poster Presentation
Presenter: Margherita Saracco

Body composition and MAFLD are associated with prognosis after resection of intrahepatic cholangiocarcinoma
Poster Presentation
Presenter: Isabella Lurje

Prevalence of renal dysfunction is higher in patients that receive a liver transplant for non-alcoholic steatohepatitis
Poster Presentation
Presenter: Rubén Sánchez-Aldehuelo
Assessment of silent coronary artery disease with functional and anatomic tests in liver transplantation: analysis of the diagnostic and prognostic capacity of a risk-adapted protocol
Poster Presentation
Presenter: Giulia Pagano

1778
Perfusate composition of transplanted and not transplanted livers during normothermic machine perfusion
Poster Presentation
Presenter: Jule Dingfelder

1805
Sex-based differences and comparative predictive value of MELD 3.0 in simultaneous liver-kidney transplantation waitlist outcomes after standardization of listing criteria in the United States
Poster Presentation
Presenter: Emily Leven

1813
Safety of coronary angiography with consecutive dual antiplatelet therapy in patients with liver cirrhosis and esophageal varices as part of an evaluation for liver transplantation
Poster Presentation
Presenter: Moritz Passenberg

1900
Effect of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on post-liver transplant mortality and major adverse cardiovascular events
Poster Presentation
Presenter: Kelli Kosako Yost

1972
Application of human chemically-derived hepatic progenitors organoids (hCdHO) in regenerative medicine, hepatotoxic and disease modeling
Poster Presentation
Presenter: Elsy Soraya Salas Silva

1977
Liver transplantation in patients with cystic fibrosis: 30 years of experience in Australia and New Zealand
Poster Presentation
Presenter: Thomas Wilson

2045
Evaluation of a delayed liver transplant strategy for patients listed for hepatocellular carcinoma treated with resection or thermo-ablation as a bridge to liver transplantation; the DELTAS-HCC study
Poster Presentation
Presenter: Catherine Lamarque

2197
Quantification of remnant liver ischaemia after hepatectomy for hepatocellular carcinoma (HCC)
using advanced 3D software analysis and its impact on disease recurrence
Poster Presentation
Presenter: ACIDI Belkacem

2238
Long-term outcome following liver transplantation for chronic liver disease in intensive care unit: the
French nationwide experience
Poster Presentation
Presenter: Magdalena Meszaros

2251
Graft steatosis and donor diabetes mellitus additively increase the risk of retransplantation and
death in adult liver transplantation - data from the Eurotransplant registry
Poster Presentation
Presenter: Milan Sonneveld

2367
Primary sclerosing cholangitis recurrence after liver transplantation: a nationwide survey in Italy
Poster Presentation
Presenter: Maria Cristina Morelli

2506
Coronary computed tomography angiography in pre-liver transplant cardiac work-up
Poster Presentation
Presenter: Chiara Manuli

2691
Safety and efficacy of glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2
inhibitors compared with the standard of care in a cohort of liver transplanted patients: a
retrospective study
Poster Presentation
Presenter: Aida Rebiha

2849
Long-term outcomes following donation after cardiac death (DCD) liver transplantation in primary
sclerosing cholangitis (PSC)
Poster Presentation
Presenter: Arul Suthananthan
2854
De novo cancers after liver transplantation: a French nationwide cohort
Poster Presentation
Presenter: Ilias Kounis

2855
Cytomegalovirus reactivation is associated with lower hepatocellular carcinoma recurrence rates after liver transplantation
Poster Presentation
Presenter: Victoria Aguilera Sancho

3102
Long-term benefit of mTOR inhibitors for dropping calcineurin inhibitors in liver transplant recipients
Poster Presentation
Presenter: Yael Milgrom

3162
Development of metabolic disorders in transplant recipients
Poster Presentation
Presenter: GİZEM ERDEMİR

3190
CMV reactivation after liver transplantation (LT) in HIV infected is similar to non-HIV patients: a single center comparative study
Poster Presentation
Presenter: Sonia García-García

3200
Statins and metformin after liver transplantation: a nationwide cohort
Poster Presentation
Presenter: Cyrille Feray

3209
Incidence of de novo tumors after liver transplantation (LT) in HIV infected is similar to non-HIV patients: a single center comparative study
Poster Presentation
Presenter: Isabel Terol Cháfer

3237
Sarcopenia at listing for liver transplantation is a negative predictor for post-transplant survival, but not for graft survival
Poster Presentation
Presenter: Guido Stirnimann
3277
Influence of marginal organs on the drug metabolism in liver transplantation
Poster Presentation
Presenter: Laura Bülow

3301
Liver Transplantation outcomes in patients following COVID-19 infection
Poster Presentation
Presenter: Dinesh Jothimani

3319
Prehabilitation intervention to maximize early recovery (PRIMER) in liver transplantation: a randomized, controlled trial
Oral Presentation
Presenter: Marina Serper

3410
Comparing clinical outcomes of robot-assisted versus open hepatectomy for liver cancer: a systematic review and meta-analysis
Poster Presentation
Presenter: Muhammed Elfaituri

3447
APRI+ALBI score is superior to Indocyanine Green (ICG) clearance and LiMAx test in the prediction of posthepatectomy liver failure – an international multicenter study of 14581 patients
Oral Presentation
Presenter: Jonas Santol

3449
Endothelial glycocalyx damage marker Syndecan-1 measured during hypothermic oxygenated machine perfusion can predict early allograft dysfunction after liver transplantation
Poster Presentation
Presenter: Laurin Rauter

3530
Liver transplantation in patients with schistosomiasis in a reference hospital in Sao Paulo, Brazil
Poster Presentation
Presenter: Martina Zannini

3557
Liver transplantation for alcohol-related-liver disease in the era of acute on chronic liver failure-single center experience
3606
Porto-pulmonary hypertension in patients considered for liver transplantation: a cohort study
Poster Presentation
Presenter: Declan Lewis

3632
The GALAD score allows early detection of recurrent hepatocellular carcinoma after orthotopic liver transplantation
Poster Presentation
Presenter: Magdalena Hahn

3685
Biliary strictures in liver transplant recipients: novel strategies for identifying therapeutic targets of biliary fibrosis
Poster Presentation
Presenter: Alex Bofill

3691
Tailored immunosuppression with LCPT extended release Tacrolimus based on NFAT-regulated gene expression
Poster Presentation
Presenter: Judith Kahn

3708
Inequity in access to liver transplantation for critically ill patients with cirrhosis across U.S. transplant centers
Poster Presentation
Presenter: Thierry Artzner

3732
HBV re-infection or de-novo infection in the course of liver transplantation in patients chronically infected with HBV, HBV/HDV, or HCV
Poster Presentation
Presenter: Daniele Lombardo

3751
Use of von Willebrand factor antigen for surgical decision making in patients with hepatocellular carcinoma
Poster Presentation
Presenter: David Pereyra
MicroRNA based prediction of posthepatectomy liver failure and mortality outperforms established markers of preoperative risk assessment
Oral Presentation
Presenter: Anna Kern

Which is the best therapy for not transplantable patients with multinodular early HCC?
Poster Presentation
Presenter: Alessandro Vitale

Management in hepatology: cost analysis of two opposite options for pretransplantation evaluation
Poster Presentation
Presenter: Gloria Sánchez Antolín

Association between waiting time and post-transplant survival in recipients with hepatocellular carcinoma outside Milan criteria after downstaging with locoregional therapy
Poster Presentation
Presenter: Zoljargal Lkhagvajav

Reassessing BCLC stage at transplant to predict risk of mortality and HCC recurrence in HCC liver transplant recipients
Poster Presentation
Presenter: George Cholankeril

Post reperfusion syndrome in liver transplant after normothermic perfusion: experience of a reference center
Poster Presentation
Presenter: Luciano Beltrão Pereira

Liver tumours: Clinical aspects except therapy

Targeted surveillance for hepatocellular carcinoma is cost effective in Australia: evidence from a microsimulation study
Poster Presentation
Presenter: Barbara de Graaff
Association of physical activity with risk of hepatocellular carcinoma among patients with diabetes: a nationwide cohort study
Oral Presentation
Presenter: Mi Na Kim

Classification of microvascular invasion of hepatocellular carcinoma: correlation with prognosis and MR imaging
Poster Presentation
Presenter: Dong Ho Lee

A radiogenomics study for hepatocellular carcinoma: distinct transcriptome patterns underlying different radiomics phenotypes in early recurrence
Poster Presentation
Presenter: Weijia Liao

Gadoxetic acid-enhanced MRI-based risk scoring system development and validation for the recurrence-free survival of a single hepatocellular carcinoma after curative surgery
Poster Presentation
Presenter: Bohyun Kim

Exploration of the lack of systematic surveillance for hepatocellular carcinoma for patients with non-alcoholic fatty liver disease
Poster Presentation
Presenter: Theresa Hydes

Exploration of a holistic management procedure for liver cancer surveillance to improve the early diagnosis of liver cancer in Chinese population
Poster Presentation
Presenter: Yong Li

Trajectories of body composition in hepatocellular carcinoma treated with immunotherapy (chance 2215): a longitudinal, multicenter, cohort study
Poster Presentation
Presenter: Zhi-Cheng Jin

Multi-omic large scale risk prediction for hepatocellular carcinoma
827
Survival outcomes of patients with non-alcoholic fatty liver disease-related HCC: a retrospective cohort study
Poster Presentation
Presenter: Anders Mellemkjær

844
Transversal psoas muscle thickness measurement is associated with response and survival in patients with hepatocellular carcinoma undergoing immunotherapy
Poster Presentation
Presenter: Bernhard Scheiner

1011
Predictors of extrahepatic recurrence after transarterial chemoembolization as first-line therapy for hepatocellular carcinoma
Poster Presentation
Presenter: Elisa Pinto

1025
A machine learning enabled score based on large varices predicts 5- and 10-year hepatocellular carcinoma (HCC) development in a 12-year prospective cohort of patients with compensated advanced chronic liver disease
Poster Presentation
Presenter: Sara Ascari

1056
It takes a team for HCC: improvement of outcome with the multidisciplinary ambulatory for systemic therapy
Poster Presentation
Presenter: Andrea Dalbeni

1068
Comparison of clinical manifestations and outcomes between non-viral-related and viral hepatitis-related hepatocellular carcinoma
Poster Presentation
Presenter: Sih-Han Liao

1081
Developing an aptamer biomarker model for the diagnosis of hepatocellular carcinoma
Poster Presentation
Presenter: Mikkel Breinholt Kjær
Validation of the CRAFITY score in patients with hepatocellular carcinoma treated with atezolizumab and bevacizumab
Poster Presentation
Presenter: Bernhard Scheiner

Platelet, elastography, age, sex and etiology for hepatocellular carcinoma surveillance in patients with advanced chronic liver disease: Please algorithm
Oral Presentation
Presenter: Wenyi Gu

Prognostic value of simple non-invasive tests for the risk stratification of HCC development in patients with cirrhosis due to non-alcoholic fatty liver disease
Poster Presentation
Presenter: Amina Abdulle

Epidemiology and characteristics of hepatocellular carcinoma in France: results of the first 2000 patients in real-life situations from the french prospective chief cohort
Oral Presentation
Presenter: Eric Nguyen Khac

Phenotypic characteristics of primary liver cancer in a large French cohort of patients with viral chronic liver disease followed-up before and after viral eradication: an ANRS study
Poster Presentation
Presenter: Alina Pascale

Abbreviated magnetic resonance imaging for secondary surveillance of recurrent hepatocellular carcinoma after curative treatment
Poster Presentation
Presenter: Sun Kyung Jeon

Glycemic control as a modifiable and independent risk factor for the development of liver, biliary tract and pancreatic cancer: a territory-wide study of 273,421 patients with diabetes mellitus
Oral Presentation
Presenter: Xianhua Mao
Comparative study of scoring systems predicting outcome of transarterial chemoembolization for hepatocellular carcinoma: a nationwide cohort study
Poster Presentation
Presenter: Hae Lim Lee

Presence of esophageal varices regardless their size is associated with overall survival in patients with advanced HCC treated with Atezolizumab/Bevacizumab
Poster Presentation
Presenter: Philippe Sultanik

Multidimensional genomic analysis of cell-free DNA for early detection of hepatocellular carcinoma
Poster Presentation
Presenter: Ju Dong Yang

A prospective multicenter study to examine the impact of acquired and genetic predictors on Hepatocellular carcinoma risk in patients with advanced NAFLD: first report
Poster Presentation
Presenter: Serena Pelusi

The apparent diffusion coefficient values predict prognosis and Ki67 expression in intrahepatic cholangiocarcinoma on diffusion-weighted magnetic resonance imaging
Poster Presentation
Presenter: Daiki Hokkoku

Alternative surveillance using CT/MR improves clinical outcomes by detecting early-stage hepatocellular carcinoma in High-risk patients with chronic hepatitis B
Poster Presentation
Presenter: Dong Ho Lee

Similar recurrence after curative treatment of HBV-related HCC regardless of HBV replication activity
Poster Presentation
Presenter: Mi Na Kim

Liver Frailty Index is associated with progression-free survival in patients with advanced HCC treated with Atezolizumab/Bevacizumab
Poster Presentation
Presenter: Philippe Sultanik

1779
Loss of mucosal tolerance to glycoprotein 2 isoform 1 is a novel diagnostic biomarker for cholangiocarcinoma without underlying PSC
Poster Presentation
Presenter: Marcin Krawczyk

1793
Associations of pathologic features with integrated genomic and clinical characteristics of cholangiocarcinoma
Poster Presentation
Presenter: Keun Soo Ahn

1861
Impact of obesity on outcome of hepatocellular carcinoma in an Asian cohort: when should we consider obesity treatment?
Poster Presentation
Presenter: Wei-Lun Liou

1862
Characterization of the imaging signature of hepatocellular carcinoma with enhancement pattern mapping
Poster Presentation
Presenter: Newsha Nikzad

1871
Macrotabecular-massive pattern is associated with aggressive factors, but it is not an independent predictor of tumor recurrence and overall survival in patients with hepatocellular carcinoma treated with liver resection
Poster Presentation
Presenter: Ezequiel Mauro

2035
Characterization and burden of non-hepatocellular carcinoma focal lesions detected during surveillance of patients with cirrhosis
Oral Presentation
Presenter: Pierre Nahon

2274
Implication of patients experience in the liver cancer multidisciplinary approach
Poster Presentation
Presenter: Gemma Iserte
2303
Management of varices but not anticoagulation is associated with improved outcome in patients with hepatocellular carcinoma and macrovascular tumour invasion
Poster Presentation
Presenter: Lorenz Balcar

2331
A new biomarker panel for differential diagnosis of cholangiocarcinoma: results from an exploratory analysis
Poster Presentation
Presenter: Magdalena Swiatek-de Lange

2357
A novel AFP-M2BPGi score has better performance than CRAFITY score in predicting survival for patients with viral hepatocellular carcinoma undergoing immunotherapy
Poster Presentation
Presenter: Pei-Chang Lee

2369
Development, clinical validation and implementation of a novel algorithmic score (GAAD) for the detection of early-stage hepatocellular carcinoma
Poster Presentation
Presenter: Thomas Berg

2609
Sex disparities in presentation and outcome of hepatocellular carcinoma: results of a nationwide study in France
Poster Presentation
Presenter: Charlotte Costentin

2619
GALAD score outperforms aMAP and ALBI scores in the 5- and 10-year prediction of hepatocellular carcinoma (HCC) development in patients with compensated advanced chronic liver disease (cACLD): a 12-year prospective study
Poster Presentation
Presenter: Valentina Baldaccini

2632
CRAFITY score is associated with overall survival in patients with hepatocellular carcinoma treated with transarterial chemoembolisation
Poster Presentation
Presenter: Rhea Veelken
Weakly supervised intrahepatic tumour classification from routine tumour biopsy: a proof of concept
Oral Presentation
Presenter: Beaufrère Aurélie

Collagen proportionate area (CPA) measurement of liver parenchyma and hepatocellular carcinoma (HCC) can predict HCC recurrence after liver resection
Poster Presentation
Presenter: Chiara Sicuro

Artificial intelligence assisted qFibrosis as a pathological “biomarker” to evaluate disease severity in patients with hepatocellular carcinoma
Poster Presentation
Presenter: Kai-Wen Huang

Deep learning-based model in pre-operative computed tomography for prediction of hepatocellular carcinoma recurrence after curative surgery
Poster Presentation
Presenter: Rex Wan-Hin Hui

The association between alcohol consumption and the risk of hepatocellular carcinoma according to glycemic status: a nationwide population-based study
Poster Presentation
Presenter: Su Jong Yu

Addition of des-gamma-carboxy prothrombin to standard of care is effective for HCC surveillance among high-risk patients
Poster Presentation
Presenter: Grishma Hirode

Baveno VI and VII criteria are not suitable for screening of large size esophageal varices and clinically significant portal hypertension in patients with HCC
Poster Presentation
Presenter: Manon Allaire

Cryptogenic non-cirrhotic HCC: clinical, prognostic and immunologic aspects of an emerging HCC etiology
3167  
The Kupffer phase of Sonazoid-enhanced ultrasound as the major imaging feature for diagnosing hepatocellular carcinoma in at-risk individuals

Poster Presentation  
Presenter: Boris Beudeker

3186  
The efficacy of direct-acting antivirals for chronic hepatitis C in patients with the active oncological disease

Poster Presentation  
Presenter: Hyo-Jin Kang

3215  
Natural history and management of recurrent hepatocellular carcinoma after liver transplantation: a multicenter nationwide study

Oral Presentation  
Presenter: Jerzy Jaroszewicz

3246  
Validation of serum biomarker panels for early HCC detection: results from a large prospective European and Latin American multicenter study

Poster Presentation  
Presenter: Massih Ningarhari

3248  
Add-on benefits of AFP-L3, PIVKA-II and GALAD score to ultrasound plus AFP for surveillance of hepatocellular carcinoma

Poster Presentation  
Presenter: Supot Nimanong

3265  
Chemerin protein in hepatocellular carcinomas is related to disease severity in European patients

Poster Presentation  
Presenter: Christa Büchler

3299  
Initial treatment response and short-term mortality of spontaneous bacterial peritonitis in cirrhotic patients with hepatocellular carcinoma

Poster Presentation  
Presenter: Chang Hun Lee
Combined hepatocellular-cholangiocarcinoma: epidemiological, radiological and survival data from a retrospective single-center study
Poster Presentation
Presenter: Guillaume HENIN

Effect of different radiologic modalities for surveillance of hepatocellular carcinoma on survival of high risk cirrhotic patients
Poster Presentation
Presenter: Ahmed El Sabagh

Predicting cardiovascular risk in patients with HCC receiving tyrosine kinase inhibitors: comparison of two different scores
Poster Presentation
Presenter: Bernardo Stefanini

Baseline cirrhosis in addition to the aMAP score, increased the risk of developing hepatocellular carcinoma in patients with hepatitis B
Poster Presentation
Presenter: Supakorn Chaiwiriyawong

Aetiology and outcomes of cirrhosis and hepatocellular carcinoma in Blantyre, Malawi
Poster Presentation
Presenter: Alexander Stockdale

Liver function is a predictor of survival in patients with hepatocellular carcinoma in best supportive care
Poster Presentation
Presenter: Martina Rosi

Liver tumours: Experimental and pathophysiology

Relevance of hypoxia-inducible factor 1 alpha in hepatocellular carcinoma: clinical and pre-clinical analysis
Poster Presentation
Presenter: Tania Payo-Serafín
MAP17 promotes an epithelial-mesenchymal-amoeboid transition in hepatocellular carcinoma by switching one-carbon metabolism
Poster Presentation
Presenter: Claudia Gil-Pitarch

Investigation of optimization model for predicting ICI treatment efficacy on contrast-enhanced CT images of hepatocellular carcinoma using AI
Poster Presentation
Presenter: Yasuhiko Nakao

Potential biomarkers predicting ferroptosis sensitivity in hepatocellular carcinoma
Poster Presentation
Presenter: Wan Seob Shim

Antitumoral activity of the G9a inhibitor EZM8266 in hepatocellular carcinoma: potential for combination with immune checkpoint inhibitors
Poster Presentation
Presenter: Maite G Fernandez-Barrena

Therapeutic targets associated with conserved subtypes of hepatocellular carcinoma
Poster Presentation
Presenter: Ju-Seog Lee

In vivo cancer-associated fibroblast specific gene silencing for anti-stromal therapy in primary liver cancer using novel siRNA loaded polypeptide nanoparticles
Oral Presentation
Presenter: Paul Schneider

Metabolic rewiring by increased mitochondrial respiration drives immunosuppression in liver cancer
Poster Presentation
Presenter: Naroa Goikoetxea

Ductular reaction is mediated by CD24 and regulated by miR-122
Poster Presentation
Presenter: Nofar Rosenberg
496
Sortilin-driven cancer secretome enhances self-renewal and metastasis of hepatocellular carcinoma via de novo lipogenesis
Poster Presentation
Presenter: Kwan Shuen Chan

502
RBCK1 promotes cancer stemness and sorafenib resistance by restoring Numb/Notch1 axis independently of its ubiquitin ligase activity in hepatocellular carcinoma
Poster Presentation
Presenter: Peng Chen

529
Myeloid IL-8 enrichment associates with immunotherapy resistance in advanced hepatocellular carcinoma
Oral Presentation
Presenter: Tsz Tung Kwong

646
Drug screening for hepatocellular carcinoma: automating and miniaturizing organoid assays for drug screening
Poster Presentation
Presenter: Tijmen Booij

733
Positive effects of PARP-1 inhibition in KRAS-mutated intrahepatic cholangiocarcinoma is mediated by CHK1 kinase
Poster Presentation
Presenter: Darko Castven

757
Multiplatform single cell spatial dissection of the invasive front of hepatocellular carcinoma (HCC) reveals molecular insights into tumor progression
Oral Presentation
Presenter: Josephine Zhang

820
Therapeutic potential of targeting protein hyper-SUMOylation in cholangiocarcinoma
Poster Presentation
Presenter: Paula Olaizola

832
Investigation of novel hepatoblastoma chemosensitizers based on the inhibition of ABC pumps-mediated drug efflux
Poster Presentation
Presenter: Rocio IR Macias

835
Scavenger receptor MARCO is associated with an immunosuppressive microenvironment and tumor progression in intrahepatic cholangiocarcinoma
Oral Presentation
Presenter: Aloña Agirre Lizaso

941
Identification and experimental validation of druggable epigenetic targets in hepatoblastoma
Poster Presentation
Presenter: Alex Claveria-Cabello

944
Hepatitis B surface antigen impairs endoplasmic reticulum stress-related autophagic flux via down-regulation of LAMP2, thereby participating in hepatocarcinogenesis
Poster Presentation
Presenter: Ruth Broering

946
Nuclear translocation of YAP drives BMI1-associated hepatocarcinogenesis in hepatitis B virus infection
Poster Presentation
Presenter: Ruth Broering

1007
Nonresolving inflammation in liver cancer; differential regulation of miR-122 signaling by BMP6 and TGFβ
Poster Presentation
Presenter: Mirco CASTOLDI

1008
Novel platinum-based chemotherapeutic agents halt cholangiocarcinoma progression through the induction of inter-strand DNA breaks, preventing DNA repair mechanisms
Poster Presentation
Presenter: Irene Olaizola

1050
Efficacy of HBV-TCR T cell therapy to eliminate circulating HBV-HCC cells in immunosuppressed whole blood
Poster Presentation
Presenter: Anthony Tan

1083
Liquid biopsy protein biomarkers of cholangiocarcinoma risk, early diagnosis and survival mirroring tumor cells
Poster Presentation
Presenter: Ainhoa Lapitz

1106
Poor sorafenib response in hepatocellular carcinoma patients is mediated by hypoxia-related 14-3-3 scaffolding proteins and induces a shift in tumor immune micromilieu
Poster Presentation
Presenter: Jovana Castven

1149
Pediatric liver cancer: Hepatoblastoma and Neddylation post-translational modification
Poster Presentation
Presenter: Leidy Estefanía Zapata-Pavas

1181
Tumor-extrinsic Axl expression shapes an inflammatory microenvironment independent of tumor-cell promoting Axl signaling
Poster Presentation
Presenter: Kristina Breitenecker

1203
Identification of hepatocyte-restricted antigens, epitopes, and T cell receptors to treat recurrent hepatocellular carcinoma after liver transplantation
Poster Presentation
Presenter: Rakké Yannick

1206
Cytokine levels and circulating DNA profiling in plasma as biomarkers of response to immunotherapy in hepatocellular carcinoma
Poster Presentation
Presenter: Elena Vargas Accarino

1231
Association between gadoxetic acid-enhanced MR imaging, organic anion transporters, and farnesoid X receptor in benign focal liver lesions
Poster Presentation
Presenter: Alicia Furumaya
1245
Intermittent fasting improves tumor-directed drug delivery by caveolar-mediated endocytosis
Poster Presentation
Presenter: Svea Becker

1349
Comprehensive analysis of single-cell and bulk RNA sequencing data identifies antioxidant-1 as a novel immune biomarker associated with immune cell infiltration in hepatocellular carcinoma metastasis
Poster Presentation
Presenter: Ruijia Liu

1463
Remodeling of myeloid cells during hepatocellular carcinoma driven by beta-catenin activation
Oral Presentation
Presenter: Camille Joubel

1477
Immunotherapy resistance in NASH-HCC is driven by the dysfunctional liver microenvironment of NASH
Poster Presentation
Presenter: Daniel Geh

1491
Neutrophil degranulation and ageing as potential therapeutic targets in hepatocellular carcinoma?
Poster Presentation
Presenter: Daniel Geh

1500
In vivo MRI characterization of pathological changes in liver microstructures
Poster Presentation
Presenter: xiaoyu jiang

1544
Clinicopathological analysis of polyploidization in human hepatocellular carcinoma and the development of an evaluation methodology
Poster Presentation
Presenter: Takanori Matsuura

1545
Macrophage STING signaling promotes NK cell to suppress colorectal cancer liver metastasis via 4-1BBL/4-1BB co-stimulation
Poster Presentation
Presenter: HAOMING ZHOU
1561
Dual effects of brown-fat activation limit hepatocellular carcinoma (HCC) progress in steatotic liver
Poster Presentation
Presenter: Juan Gao

1610
Intrahepatic cholangiocarcinoma developing in patients with metabolic syndrome is characterized by Osteopontin overexpression in the tumor stroma
Poster Presentation
Presenter: Luca Fabris

1746
Genetic variant in the hepatic sterol transporter is associated with increased gallstone risk in obese patients and with higher odds of developing gallbladder cancer in general
Poster Presentation
Presenter: Marcin Krawczyk

1748
RBCK1 promotes the stabilization of HBx by linear ubiquitination to drive the progression of HBV-associated hepatocellular carcinoma
Poster Presentation
Presenter: Zheyu Dong

1814
Circular RNA hsa_circ_0062682 promotes oncogenesis in hepatocellular carcinoma and binds to YBX1
Poster Presentation
Presenter: Tadeja Rezen

1892
TAK1 deficiency promotes liver injury and tumorigenesis via ferroptosis and macrophage cGAS-STING signaling
Poster Presentation
Presenter: HAOMING ZHOU

1966
CRISPR-engineered cholangiocarcinoma tumoroids generation from chemically-derived hepatic progenitor organoid for disease modelling
Poster Presentation
Presenter: Michael Adisasmita

2025
Deciphering the cellular and molecular determinants of immunotherapy resistance in NASH-associated hepatocellular carcinoma by single-cell analysis
Poster Presentation
Presenter: Lingyun Zhang

2043
The rs72613567: TA polymorphism in hydroxysteroid 17-beta dehydrogenase 13 (HSD17B13) is associated with survival benefit after development of hepatocellular carcinoma
Poster Presentation
Presenter: Stephan Buch

2087
Development of new personalized therapies targeting VDAC1 in intrahepatic cholangiocarcinoma using patient-derived liver organoids
Poster Presentation
Presenter: Silvia De Siervi

2115
Myeloid-derived cells suppress CD8+ T cells by arginase-1 through interaction with stellate cells in the microenvironment of hepatocellular carcinoma
Oral Presentation
Presenter: Sung Eun Choi

2140
Epigenetic reprogramming synergizes with PD-1/PD-L1 inhibition for cell-targeted therapy in hepatocellular carcinoma
Poster Presentation
Presenter: Caecilia Sukowati

2201
Pegazafermin inhibits NASH-induced hepatocellular carcinoma in the STAM™ mouse model
Poster Presentation
Presenter: Maya Margalit

2211
Modelling hepatocellular carcinoma in precision-cut liver slices for therapeutic screening and as a precision medicine tool
Poster Presentation
Presenter: Amy Collins

2224
Differential hepatoprotective effects of semaglutide and lanifibranor in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH with advanced fibrosis and HCC
Poster Presentation
2225
PD1-negative CD45RA effector-memory CD8 T-cells are essential for response to checkpoint inhibition in advanced hepatocellular carcinoma
Poster Presentation
Presenter: Malte H. Nielsen

2267
Chromosome engineering and CRISPR-Cas9 viability screening reveals increased metastatic capacity targetable by patient-specific synthetic lethality
Poster Presentation
Presenter: Sarah Cappuyns

2276
NLRP3 and IL-1, but not IL-18, are drivers of hepatocellular carcinoma in two independent murine models
Poster Presentation
Presenter: Stephanie Roessler

2286
Determination of human polyploid hepatocellular carcinoma by pathological image diagnosis utilizing artificial intelligence
Poster Presentation
Presenter: Mona Peltzer

2411
Capillarization of tumor endothelial cells within tumor associated with T cell exclusion in an autochthonous mouse HCC model
Poster Presentation
Presenter: Tomonori Matsumoto

2453
Morphological architectures of patient-derived hepatocellular carcinoma organoids with GSK3-beta expression dependent variability according to lenvatinib resistance
Poster Presentation
Presenter: Pin-Hung Lin

2608
Silencing CNNM4 in cholangiocarcinoma inhibits tumoral progression by means of non-canonical ferroptosis
Poster Presentation
Presenter: Kyung Joo Cho

Presenter: Maria Mercado-Gómez
2647
KLF5 upregulation is a common event in cholangiocarcinoma, acting as an oncogene and constituting a bad prognostic factor
Poster Presentation
Presenter: Pedro Miguel Rodrigues

2673
Selective inhibition of human β-catenin DNA transactivation activity using splice switching oligonucleotides for an improved therapeutic window in treating hepatocellular carcinoma
Poster Presentation
Presenter: Jin Hong

2857
CD40 expression in liver cancer cells is upregulated by CD4+T cells through IFN-gamma and ERK 1/2 pathway
Poster Presentation
Presenter: Hanh Ngo Vinh

2873
The mutated ENTPD6 as neoantigen in hepatocellular carcinoma
Poster Presentation
Presenter: Dongbo Chen

2883
PSMP inhibits HCC progression by regulating the polarization of tumor-associated macrophages via the PI3K/Akt pathway
Poster Presentation
Presenter: Shaoping She

2923
Targeting the E2F/MCM axis in cholangiocarcinoma halts disease progression in experimental models by rewiring lipid metabolism
Poster Presentation
Presenter: Mikel Ruiz de Gauna

2950
Characterization of the immune tumor microenvironment in HCC
Poster Presentation
Presenter: Charlotte Hoffmann

2963
Prognostic and genomic portrait of hepatocellular carcinomas with bi-allelic inactivation of RB1 gene
Poster Presentation
Presenter: Jihyun An

2987
Infiltrating suppressive myeloid cells dominate the pediatric hepatoblastoma tumor immune microenvironment
Poster Presentation
Presenter: Yvonne Vercoulen

3024
Genetic biomarkers for sorafenib response in patients with hepatocellular carcinoma
Poster Presentation
Presenter: Lydia Giannitrapani

3034
Molecular determinants of period-specific recurrences in patients with surgically resected hepatocellular carcinoma
Poster Presentation
Presenter: Jihyun An

3044
Bacterial exosomes cargo vaccine with EpCAM aptamers for targeting hepatocellular carcinoma
Poster Presentation
Presenter: Pushpa Yadav

3061
Exploiting RuvBL1 as a target to improve mTOR-driven hepatocarcinogenesis in mice
Poster Presentation
Presenter: Alice Guida

3080
Interleukin 10-mediated signaling dampens antitumor immunity and promotes liver metastasis
Poster Presentation
Presenter: Tao Zhang

3111
Lysosomotropic PIP5K inhibitors sensitize hepatic cancer to reactive oxygen species by inhibiting proliferative and adaptive pathway
Poster Presentation
Presenter: Shantanu P.A.

3114
RuvBL1 is required for mitochondrial integrity and supports the metabolic reprogramming of HCC cells
3116
Dynamic evolution of the serum metabolome reflects human hepatocarcinogenesis
Poster Presentation
Presenter: Tommaso Mello

3134
Constitutive signaling from an engineered IL-21 receptor programs long-lived effector TCR-T cells for HCC therapy
Poster Presentation
Presenter: Johann von Felden

3240
Monitoring the local HCC immune landscape by fine needle aspiration
Poster Presentation
Presenter: Wei Zhu

3245
A patient-derived hepatocellular carcinoma multicellular spheroid system modeling the tumor microenvironment for drug development and precision medicine
Poster Presentation
Presenter: Emilie Crouchet

3267
PD-L1 small molecule inhibitors and Paclitaxel orchestrating CD8+ cell cytotoxicity via tumor-associated macrophages: a personalized HCC immunotherapeutic approach
Poster Presentation
Presenter: Israa Helal

3349
Oncostatin M promotes a pro-tumorigenic inflammatory response in NASH-related HCC
Poster Presentation
Presenter: Beatrice Foglia

3408
Anti-CD122 antibody restores specific CD8+ T cell response in non-alcoholic steatohepatitis and prevents hepatocellular carcinoma growth
Poster Presentation
Presenter: Stéphanie Lacotte

3629
Immunomagnetic enrichment of hepatocyte-specific extracellular vesicles using magnetic beads and click chemistry
Poster Presentation
Presenter: Richell Booijink

3686
Fibroblast growth factor 19 cooperates with Myc to promote liver carcinogenesis
Poster Presentation
Presenter: José Ursic Bedoya

3724
Combining non-selective beta-blockers with sorafenib in HCC: targeting the culprits of metastasis
Poster Presentation
Presenter: Tasnim Mahmoud

3766
Functional and mechanistic role of IncRNA-A1 in cholangiocarcinoma
Poster Presentation
Presenter: Alberto Tinahones

3776
Carbohydrate restriction inhibits tumor progression in a hepatocellular carcinoma mouse model
Poster Presentation
Presenter: Merve Erdem

3790
Expression and role of the metabotropic glutamate receptor type 3 in hepatocarcinoma
Poster Presentation
Presenter: Isabel Méndez

3797
Immunological impact of Axl/TGF-beta signaling in hepatocellular carcinoma
Poster Presentation
Presenter: Gregor Ortmayr

3800
Fatty Acid Synthase expression promotes the malignant features of cholangiocarcinoma cells and predicts shorter survival in patients
Poster Presentation
Presenter: Mirella Pastore

Liver tumours: Therapy
240  
Salvage hepatectomy for recurrent hepatocellular carcinoma after radiofrequency ablation  
Poster Presentation  
Presenter: Jai Young Cho

330  
Efficacy of Atezolizumab/Bevacizumab combination therapy in BCLC-C cirrhotic patients with hepatocellular carcinoma according to the type of disease progression and liver disease severity  
Poster Presentation  
Presenter: SPYRIDON PANTZIOS

351  
Outcomes between surgical resection and transarterial chemoembolization in patients with multifocal BCLC-A and Child-Pugh B  
Poster Presentation  
Presenter: Ji won Yang

468  
Prognostic impact of metastatic site in patients receiving first-line sorafenib therapy for advanced hepatocellular carcinoma  
Poster Presentation  
Presenter: Luca Ielasi

542  
Risk of bleeding and thromboembolic events with atezolizumab/bevacizumab or lenvatinib in patients with hepatocellular carcinoma: a multicenter, retrospective study  
Oral Presentation  
Presenter: Florian P Reiter

556  
Quality of life in patients with unresectable hepatocellular carcinoma treated with selective internal radiation therapy (SIRT) and Nivolumab: a sub-analysis of the NASIR-HCC trial  
Poster Presentation  
Presenter: Manuel de la Torre

637  
Surgical resection of hepatocellular carcinoma has high feasibility, safety and survival in non-cirrhotic liver: a prospective Spanish multicentre study  
Poster Presentation  
Presenter: Laura Monserrat Lopez Torres

707
Downstaging hepatocellular carcinoma with checkpoint inhibitor therapy safely improves access to curative liver transplantation: a case series
Poster Presentation
Presenter: Margaret Liu

709
Multimodal integrative genomics and pathology analyses in neoadjuvant nivolumab treatment for borderline resectable HCC
Oral Presentation
Presenter: Irene Oi-Lin NG

724
Incidence and risk factors of esophagogastric varices bleeding in patients with advanced hepatocellular carcinoma treated with lenvatinib
Poster Presentation
Presenter: Eleonora Alimenti

783
Genomic characteristics of hepatocellular carcinoma patients with response to sorafenib
Poster Presentation
Presenter: Sun Young Yim

969
Impact of baseline liver function on overall survival (OS) and safety in patients (pts) with unresectable hepatocellular carcinoma (HCC) treated with first-line (1L) tislelizumab (TIS): results from the RATIONALE-301 study
Poster Presentation
Presenter: Masatoshi Kudo

1043
Dipeptidyl-peptidase 4 inhibitors improve survival of patients with diabetes mellitus and hepatocellular carcinoma receiving immunotherapy
Poster Presentation
Presenter: Dorothy Cheuk-Yan Yiu

1047
Impact of clinical evident portal hypertension on hepatocellular carcinoma with transarterial chemoembolization (chance-chess 2301): a multicenter cohort study
Poster Presentation
Presenter: Zhi-Cheng Jin

1077
Association of tumor response with survival in patients with unresectable hepatocellular carcinoma treated with first-line tislelizumab versus sorafenib: results from the RATIONALE-301 study
Poster Presentation
Presenter: Tim Meyer

1089
Atezolizumab plus bevacizumab for patients with unresectable hepatocellular carcinoma and high hepatitis B viral load: focusing on hepatic safety and viral kinetics
Poster Presentation
Presenter: San-Chi Chen

1165
Clinical outcomes of surgical resection vs yttrium 90 radioembolization (Y90) in hepatocellular carcinoma (HCC) patients with macrovascular invasion (MVI)
Poster Presentation
Presenter: Zhaozhen Zou

1172
Impact of statin on the survival of patients with advanced hepatocellular carcinoma treated with sorafenib or lenvatinib
Poster Presentation
Presenter: Ji Eun Han

1266
The ALBI grade refines prognostic prediction in advanced hepatocellular cancer and enables risk stratification for bleeding events following atezolizumab plus bevacizumab
Poster Presentation
Presenter: Antonio D'Alessio

1336
Incidence and risk factors of post-transarterial chemoembolization complications in patients with hepatocellular carcinoma: a single center retrospective cohort analysis in a large tertiary hospital
Poster Presentation
Presenter: Melissa April Pajinag

1436
Application of deep learning auto-segmentation and unsupervised machine learning in developing a radiomic prognostic score to predict disease recurrence post radiofrequency ablation for hepatocellular carcinoma
Poster Presentation
Presenter: Mathew Vithayathil

1493
Impact of radiological response and pattern of progression on overall survival in patients with hepatocellular carcinoma treated by atezolizumab-bevacizumab
Poster Presentation
Presenter: Claudia Campani

1520
Efficacy and safety of atezolizumab and bevacizumab in the real-world treatment of Child Pugh B patients with advanced hepatocellular carcinoma
Poster Presentation
Presenter: Leonardo Stella

1720
Prediction for gastrointestinal bleeding in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma
Poster Presentation
Presenter: Kanghee Park

1771
Risk stratification for early recurrence after resection in patients with intermediate stage hepatocellular carcinoma
Poster Presentation
Presenter: Han Ah Lee

1786
Atezolizumab and bevacizumab for non-resectable or metastatic combined hepatocellular-cholangiocarcinoma: a multicentric retrospective study
Poster Presentation
Presenter: Elia Gigante

1804
Changing treatment landscape associated with improved survival in patients with hepatocellular carcinoma: a nationwide, population-based study
Poster Presentation
Presenter: Najib Ben Khaled

1822
Efficacy and tolerability of atezolizumab and bevacizumab in patients with hepatocellular carcinoma previously treated with systemic therapy: a global, observational study
Poster Presentation
Presenter: Vincent Jörg

1843
Transarterial chemoembolization and systemic treatment in patients with autoimmune liver disease-associated hepatocellular carcinoma: outcome and safety profile
Poster Presentation
Presenter: Louisa Stern
1874
Feasibility of systemic anti-cancer therapy as an alternative to best supportive care in patients with advanced HCC and Child-Pugh B liver dysfunction
Poster Presentation
Presenter: Claudia Fulgenzi

1909
Survival outcomes of hepatocellular carcinoma after yttrium-90 selective internal radiation therapy in an Asian population stratified by tumour volume and distribution
Poster Presentation
Presenter: Kaina Chen

1936
Effectiveness and safety of conversion surgery for patients with initially unresectable hepatocellular carcinoma using lenvatinib combined with TACE plus PD-1 inhibitors: a real-world study
Poster Presentation
Presenter: Xingzhi Li

2023
Prognostic factors of intrahepatic cholangiocarcinoma after radical surgical resection
Poster Presentation
Presenter: Koo Jeong Kang

2026
Interim analysis of the ACTION trial: Cabozantinib for hepatocellular carcinoma patients who discontinued first line treatment other than sorafenib or due to sorafenib intolerance
Poster Presentation
Presenter: Marco Sanduzzi Zamparelli

2167
Comparison of clinical outcome between Nivolumab and Regorafenib as second-line systemic therapy after Sorafenib failure in patients with advanced hepatocellular carcinoma
Poster Presentation
Presenter: Jae Seung Lee

2279
Predicting response to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma using single-cell RNA-sequencing-derived gene signatures
Oral Presentation
Presenter: Sarah Cappuyns

2631
Portal-hypertension parameters are associated with survival and ascites occurrence in patients with hepatocellular carcinoma treated by external radiotherapy
Poster Presentation
Presenter: Heloise Giudicelli-Lett

2641
Fragility index of positive phase 2 and 3 randomized clinical trials of treatment of hepatocellular carcinoma (2002-2022)
Poster Presentation
Presenter: Sabrina SIDALI

2669
Sequential systemic treatment in patients with hepatocellular carcinoma: real-world data in the era of immune checkpoint inhibition
Poster Presentation
Presenter: Jana Pauly

2852
Real-world experience of atezolizumab plus bevacizumab combination treatment in high risk patients with advanced hepatocellular carcinoma
Poster Presentation
Presenter: Jeong Heo

2906
Efficacy and tolerability of stereotactic body radiation therapy in patients with hepatocellular carcinoma: a retrospective cohort study
Poster Presentation
Presenter: Dorothy Liu

2943
A simple characterization of dynamic changes in circulating CD8+PD1+ lymphocytes early predicts response to atezolizumab-bevacizumab in hepatocellular carcinoma
Poster Presentation
Presenter: Fabio Piscaglia

3161
Clinical impact of relative dose intensity over the first four weeks in cabozantinib therapy for unresectable hepatocellular carcinoma
Poster Presentation
Presenter: Kaoru Tsuchiya

3185
Survival outcomes from Atezolizumab plus Bevacizumab versus Lenvatinib versus Sorafenib in Child Pugh B unresectable hepatocellular carcinoma patients
Poster Presentation
Presenter: Margherita Rimini

3297
Balancing efficacy and tolerability of first-line systemic therapies for advanced hepatocellular carcinoma: a network metanalysis
Poster Presentation
Presenter: Ciro Celsa

3465
Clinical profile and outcomes of hepatocellular carcinoma in primary Budd Chiari syndrome
Poster Presentation
Presenter: Ankit Agarwal

3516
IMbrave050: Efficacy, safety and patient-reported outcomes (PROs) for adjuvant atezolizumab (atezo) + bevacizumab (bev) vs active surveillance in hepatocellular carcinoma (HCC) patients at high risk of disease recurrence after resection or ablation
Oral Presentation
Presenter: Pierce Chow

3524
Tolerability of first line systemic therapy in elderly patients with advanced hepatocellular carcinoma
Poster Presentation
Presenter: Davide Di Benedetto

3594
Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments
Poster Presentation
Presenter: Mara Persano

3608
Add-on strategy of Regorafenib plus Nivolumab as second line approach in patients with hepatocellular carcinoma: the GOING trial
Poster Presentation
Presenter: Marco Sanduzzi Zamparelli

3703
Improved identification of good candidates for the treatment of intermediate/advanced hepatocellular carcinoma by Yttrium-90 transarterial radioembolization
Poster Presentation
Presenter: Carole Vitellius
NAFLD: Clinical aspects except therapy

202
Systematic screening for NAFLD-related advanced fibrosis in high-risk population in diabetology using transient elastography: a prospective study
Poster Presentation
Presenter: Cyrielle Caussy

232
Metabolic dysfunction associated fatty liver disease and the risk of hepatocellular carcinoma
Poster Presentation
Presenter: Byeong Geun Song

354
GL0034 (Utreglutide), a novel, long acting, glucagon-like peptide 1 receptor agonist (GLP-1 RA), results of a phase 1 study in healthy individuals
Poster Presentation
Presenter: Rajamannar Thennati

355
Relationship of hepcidin levels to metabolic factors, anthropometric indicators of adiposity and disease severity in NAFLD patients
Poster Presentation
Presenter: Claudia Cravo

369
Risk of bacterial infections in non-alcoholic fatty liver disease: a nationwide population-based cohort study
Poster Presentation
Presenter: Axel Wester

421
Association between consumption of ultra-processed foods and nonalcoholic fatty liver disease in the Framingham heart study
Poster Presentation
Presenter: Natalie Sun

432
The impact of Clostridium difficile on mortality and outcomes in patients with NAFLD vs. NASH
Poster Presentation
Presenter: Ankoor Patel
The growing global burden of non-alcoholic fatty liver disease (NAFLD) among teenagers
Poster Presentation
Presenter: Zobair Younossi

562
Impairment of health-related quality of life among people with type 2 diabetes and advanced fibrosis
Poster Presentation
Presenter: Maurice Michel

567
Stratification of liver fat content in nonalcoholic steatohepatitis patients with significant liver fibrosis using the MEFIB-Index and MRI-PDFF and its association with hepatocellular carcinoma, decompensation, and mortality
Oral Presentation
Presenter: Sung Won Lee

586
Impact of PNPLA3 polymorphism on non-alcoholic fatty liver disease in Japan: a multicenter cohort study
Poster Presentation
Presenter: Yuya Seko

597
Presence and severity of esophageal varices drives portal hypertension-related complications in compensated advanced nonalcoholic fatty liver disease
Poster Presentation
Presenter: Grazia Pennisi

609
Nutritional behavior and food pattern are sex-specific with higher salt intake and consumption of ultra-processed foods in a large cohort of NAFLD patients
Poster Presentation
Presenter: Monika Rau

618
PNPLA3 GG genotype is associated with higher incidence of cirrhosis and liver-related events among patients with nonalcoholic fatty liver disease
Poster Presentation
Presenter: Karn Wijarnpreecha

651
Cognitive impairment is frequent in obesity and not restricted to persons with biopsy-proven NAFLD
Poster Presentation
Presenter: Charlotte Wernberg
A social media listening study of patients’ experiences toward NAFLD (LISTEN-NAFLD)
Poster Presentation
Presenter: Jeffrey Lazarus

Rheological properties of bile in patients with nonalcoholic steatohepatitis with and without obesity
Poster Presentation
Presenter: Olena Barabanchyk

Pilot results for a multidisciplinary community metabolic liver clinic
Poster Presentation
Presenter: Theresa Hydes

Prevalence and mortality of non-alcoholic fatty liver disease (NAFLD) in non-diabetics, pre-diabetics, and diabetics in the United States
Poster Presentation
Presenter: Zobair Younossi

Prevalence of extrahepatic manifestations in nonalcoholic fatty liver disease in lean individuals compared to non-lean individuals
Poster Presentation
Presenter: Majd Aboona

Salivary analytical device (SAD) a good tool for monitoring the metabolic status of patients with fatty liver disease
Poster Presentation
Presenter: Gaia Sinatti

Non-alcoholic fatty liver disease and the longitudinal risks of clinical outcomes: a meta-analysis
Poster Presentation
Presenter: Margaret Teng

Deep dive analysis into the screening failure reasons: combined data from multiple therapeutic clinical trials including more than 5,000 patients (in collaboration with NAIL-NIT consortium)
Poster Presentation
Impact of PNPLA3 rs738409 single nucleotide polymorphism and carbohydrate intake for the personalized management of patients with non-alcoholic fatty liver disease
Poster Presentation
Presenter: Nuria Pérez Diaz del Campo

Interferon gamma-induced protein 10 levels increase across the spectrum of liver disease and are associated with insulin resistant components in subjects with non-alcoholic fatty liver disease
Poster Presentation
Presenter: Marta Guariglia

Influence of chronotype and adherence to the mediterranean diet on the risk of liver fibrosis in patients with non-alcoholic fatty liver disease
Poster Presentation
Presenter: Gabriele Castelnuovo

Poor performance at five times sit-to-stand test, but not at handgrip test, is related to significant liver fibrosis and correlates with major cardiovascular events in non-alcoholic fatty liver disease patients
Poster Presentation
Presenter: Giordano Sigon

Long-term clinical outcomes of adults with metabolic dysfunction-associated fatty liver disease: a single-centre prospective cohort study with baseline liver biopsy
Poster Presentation
Presenter: Wah Loong Chan

Use of antidiabetic and lipid-lowering medications associated with lower scores of liver fibrosis biomarkers in nonalcoholic steatohepatitis (NASH) patients
Oral Presentation
Presenter: Jun Wang

Patatin-like phospholipase domain-containing 3 (PNPLA3) risk allele increases rate of progression to end-stage liver disease outcomes and decreases survival rate over time irrespective of degree of fibrosis
Poster Presentation
Presenter: Javier Armisen
1435
Genetic and metabolic characteristics of lean non-alcoholic fatty liver disease in Asian
Poster Presentation
Presenter: Huiyul Park

1470
Frailty in metabolic dysfunction-associated fatty liver disease is related to the presence of diabetes and the severity of liver fibrosis
Poster Presentation
Presenter: Guillaume Henin

1501
The national audit of non-alcoholic fatty liver disease (NAFLD) identifies variations and shortfalls in delivery of care in the UK
Poster Presentation
Presenter: Wenhao Li

1521
Genetic risk factors for NAFLD and clinically significant fibrosis in persons living with HIV
Poster Presentation
Presenter: Eduardo Vilar Gomez

1533
Prevalence of dysmetabolic iron overload syndrome in non-alcoholic fatty liver disease
Poster Presentation
Presenter: Noel Ravindranayagam

1546
Low-quality muscle mass predicts fibrosis progression in a prospective biopsy-proven nonalcoholic fatty liver disease cohort
Poster Presentation
Presenter: Sae Kyung Joo

1590
Effect of PNPLA3 (rs738409 C>G) and TM6SF2 (rs58542926 C>T) polymorphisms on the prognosis of non-alcoholic fatty liver disease (NAFLD) in patients with type-2 Diabetes Mellitus
Poster Presentation
Presenter: Cristiane Villela-Nogueira

1593
Histological and biopsychosocial predictors of quality of life in Spanish and UK cohorts of patients with non-alcoholic fatty liver disease
Digital pathology using stain-free imaging indices allows direct prediction of all-cause mortality, hepatic decompensation and hepatocellular carcinoma development in patients with non-alcoholic fatty liver disease.

Presenter: Jesús Funuyet-Salas

Causes of death by fibrosis stage in 959 biopsy-proven NAFLD patients

Presenter: Ying Shang

The importance of regular screening for HCC in non-alcoholic steatohepatitis/ non-alcoholic fatty liver disease

Presenter: Taisei Keitoku

Sarcopenia is an independent risk factor for non-alcoholic fatty liver disease regardless of fat mass in men: 1:1 propensity score matching analysis

Presenter: Jun-Hyuk Lee

Diabetes mellitus (DM) is the strongest risk factor of significant inflammation or fibrosis in chronic hepatitis B (CHB) combined with nonalcoholic fatty liver disease (NAFLD)

Presenter: Jie Li

A machine learning-based classification of adult-onset diabetes identifies patients at risk for liver-related complications

Presenter: Lukas Otero Sanchez

Dietary patterns associated with metabolic associated fatty liver disease protection

Presenter: Carolin Victoria Schneider
1979
Altered gut barrier integrity as a mediator of host-microbiome interactions in diabetic patients with advanced Non-alcoholic fatty liver disease
Poster Presentation
Presenter: Roberta Forlano

2042
Significant fibrosis is a risk factor for worse health perception and impaired mental health in people living with HIV
Poster Presentation
Presenter: Jesús Funuyet-Salas

2108
A risk prediction model for hepatocellular carcinoma for non-alcoholic fatty liver disease without cirrhosis
Poster Presentation
Presenter: Gi-Ae Kim

2168
Digital pathology with artificial intelligence analyses provides deeper insights into lifestyle intervention-induced fibrosis regression in NASH
Poster Presentation
Presenter: Haiyang Yuan

2184
Long-term prognosis of patients with non-alcoholic fatty liver disease: a retrospective cohort study to understand the impact of surrogate disease endpoints on long-term outcomes in South Korea
Poster Presentation
Presenter: Sungwon CHUNG

2287
Clinical features of non-obese NAFLD: analysis of health check-up cohort
Poster Presentation
Presenter: Shunsuke Sato

2299
Serum uric acid levels and prognosis of patients with non-alcoholic fatty liver disease
Poster Presentation
Presenter: Yang Xinyi

2358
Risk factors for significant fibrosis in non-obese Asian patients with NAFLD
Poster Presentation
Presenter: Jae Yoon Jeong

2406
Effects of a one-month consumption of different non-alcoholic beers on metabolic and liver health in young men
Poster Presentation
Presenter: Henriette Kreimeyer

2421
PNPLA3 protein levels are increased in liver and decreased in adipose tissue from patients with obesity-associated nonalcoholic steatohepatitis
Poster Presentation
Presenter: Helena Castañé

2442
Stigma in NAFLD and NASH: a global survey of patients and providers
Poster Presentation
Presenter: Zobair Younossi

2532
The rising burden of non-alcoholic fatty liver disease (NAFLD) related HCC: is time running out to contain this silent epidemic?
Poster Presentation
Presenter: Saima Ajaz

2683
NAFLD prevalence in the elderly declines with age and is associated with increased frailty, reduced physical function and social disadvantage status: results from the ASPREE study
Poster Presentation
Presenter: Daniel Clayton-Chubb

2686
Histological classifications versus liver-related events: results from the multicentric, European, hepatic outcomes and survival fatty liver registry (HOTSURFR) study
Poster Presentation
Presenter: Vlad Ratziu

2707
Assessing treatment outcomes in an AIH/NAFLD overlap cohort
Poster Presentation
Presenter: Nancy S Reau

2828
Disparities in the in-hospital mortality among patients with non-alcoholic fatty liver disease admitted with acute myocardial infarction: a nationwide analysis
Poster Presentation
Presenter: Umar Hayat

2853
Differential risk of 23 specific incident cancers and cancer-related mortality in patients with metabolic dysfunction-associated fatty liver disease: a population-based cohort study with 9.7 million Korean subjects
Poster Presentation
Presenter: Su Jong Yu

2954
Glycated hemoglobin as an independent predictor of hepatocyte ballooning in nonalcoholic steatohepatitis: combined data from multiple clinical trials including more than 5,000 patients (in collaboration with NAIL-NIT consortium)
Poster Presentation
Presenter: Stephen Harrison

2961
The impact of glycemic control on progressive forms of nonalcoholic fatty liver disease: combined data from multiple clinical trials including more than 5,000 patients (in collaboration with NAIL-NIT consortium)
Poster Presentation
Presenter: Mazen Noureddin

2967
Metabolic dysfunction–associated fatty liver disease is associated with increased risk of extrahepatic malignancies: a nationwide cohort study
Poster Presentation
Presenter: Min Kyung Park

2970
Comparison of nonalcoholic steatohepatitis severity between Hispanics and non-Hispanics: combined data from multiple therapeutic clinical trials including more than 5,000 patients (in collaboration with NAIL-NIT consortium)
Poster Presentation
Presenter: Sophie Jeannin Megnien

3057
Identification of a new gene signature that accurately predicts the risk of hepatic decompensation in non-alcoholic fatty liver disease
Poster Presentation
Presenter: Maria Jimenez Ramos
Natural history & long-term outcomes of the Newcastle non-alcoholic fatty liver disease cohort
Poster Presentation
Presenter: Jenny Gallacher

Liver fibrosis is associated with cardiovascular disease burden amongst patients with non-alcoholic steatohepatitis: the unCoVer-NASH longitudinal cohort study
Poster Presentation
Presenter: Kathleen Corey

Impact of visceral adiposity for coronary artery calcification progression in patients with metabolic dysfunction-associated fatty liver disease; multicenter cohort study
Poster Presentation
Presenter: KyeWhon Kim

Societal costs and labor market affiliation of histologically confirmed non-alcoholic steatohepatitis – a Danish register-based study
Poster Presentation
Presenter: Henning Grønbæk

Serum vitamin D is strongly associated with liver steatosis but not with liver and spleen stiffness assessed by transient elastography in patients at risk
Poster Presentation
Presenter: Gediz Dogay Us

Evaluation of Google search trends for liver diseases in Europe
Poster Presentation
Presenter: Andreas Teufel

The risk of liver-related long term outcomes is altered by dynamic changes in metabolic dysfunction–associated fatty liver disease status: a nationwide cohort study
Poster Presentation
Presenter: Min Kyung Park

Non-alcoholic steatohepatitis disease progression in participants from the United States TARGET-NASH real world longitudinal observational study
Oral Presentation
Presenter: Philip N Newsome

3417
Effect of semaglutide 2.4 mg on alanine aminotransferase in adolescents with obesity: a post-hoc analysis of the STEP TEENS trial
Oral Presentation
Presenter: Mazen Noureddin

3439
Hepatic steatosis in people with HIV is associated with lower BMI and more liver fibrosis compared to metabolic dysfunction-associated fatty liver disease
Poster Presentation
Presenter: Floriana Santomenna

3505
Ascites is the most frequent decompensating event in stable And strictly compensated NAFLD with advanced fibrosis
Poster Presentation
Presenter: Zouhir Gadi

3522
Metabolic associated fatty liver disease: different impact of the three defining criteria on the hepatic and cardiovascular complications
Poster Presentation
Presenter: Jaqueline Currà

3666
Low rates of fibrosis scoring in the primary care records of 5,987 people living with type 2 diabetes
Poster Presentation
Presenter: James Hallimond Brindley

3683
PNPLA3 I148M polymorphism does not promote liver disease progression in severe alpha1-antitrypsin deficiency
Poster Presentation
Presenter: Ines Volkert

3690
Non-alcoholic fatty liver disease (NAFLD) is associated with an increased risk of type 2 diabetes mellitus
Poster Presentation
Presenter: Christoph Roderburg
Study of an association of the serum iron markers, hepatic iron deposition and severity of nonalcoholic fatty liver disease: a single-centered prospective study
Poster Presentation
Presenter: Shubham Jain

Glucose and lipid metabolism alterations after an oral lipid meal in patients with non-alcoholic fatty liver disease carrying the PNPLA3 rs738409 polymorphism
Poster Presentation
Presenter: Chiara Rosso

Caloric input is inadequate in predicting the presence of liver steatosis and fibrosis in a population adhering to a screening program for metabolic syndrome
Poster Presentation
Presenter: Lucia Brodosi

De novo lipogenesis discriminates advanced hepatic fibrosis after an oral glucose load in non-obese subjects with non-alcoholic fatty liver disease
Poster Presentation
Presenter: Chiara Rosso

Nonalcoholic fatty liver disease mediates the effect of obesity on arterial hypertension
Poster Presentation
Presenter: Carlos Pirola

NAFLD: Diagnostics and non-invasive assessment

Machine learning with routine laboratory tests and clinical features performs similar to current NAFLD clinical pathways
Poster Presentation
Presenter: Mazen Noureddin

Evaluation of serum biomarkers for the diagnosis of nonalcoholic fatty liver disease in the general population: a cross-sectional Spanish population-based study
Poster Presentation
Presenter: Jesús Rivera
The liver worsens in non-alcoholic fatty liver disease patients as diabetes mellitus worsens and lasts longer
Poster Presentation
Presenter: Zülal İstemihan

Serum levels of type IV collagen 7S can predict liver-related mortality and events as well as advanced fibrosis: a multi-center study
Poster Presentation
Presenter: Hiroshi Ishiba

The impact of projected increases in obesity prevalence on incident liver disease in the UK: insights from bayesian-network modelling
Poster Presentation
Presenter: Tom Waddell

A clinical care pathway to detect advanced liver disease in patients with type 2 diabetes through automated fibrosis score calculation and electronic reminder messages: a randomised controlled trial
Oral Presentation
Presenter: Vincent Wai-Sun Wong

A descriptive analysis of transient elastography results and metabolic co-morbidities in people living with HIV mono-infection in an urban clinic in the UK
Poster Presentation
Presenter: Claire Mullender

Imaging and biomarker thresholds to accurately diagnose NASH cirrhosis in a 180 patient biopsy confirmed cohort
Poster Presentation
Presenter: Rohit Loomba

Predicting severe liver outcomes in NAFLD using repeated measurements of biomarkers---a cohort study in 1,260 patients
Poster Presentation
Presenter: Ying Shang
Metabolic profile reflects stages of fibrosis in patients with non-alcoholic fatty liver disease
Poster Presentation
Presenter: Roberta Forlano

Economic modelling of clinical management options of unexplained hyperferritinaemia in the adult general population: a proposed new model of care
Poster Presentation
Presenter: John Olynyk

Early aminotransferase improvement in the phase 2b NATIVE study is predictive of response pattern of liver histology as well as hepatic and cardiometabolic health markers at the end of treatment in patients with non-cirrhotic NASH
Poster Presentation
Presenter: Quentin Anstee

FIB-4 as a screening tool for significant liver fibrosis in a cohort of overweight subjects involved in a weight loss program conducted in a primary care setting
Poster Presentation
Presenter: Charlotte Costentin

Liver stiffness measurements with a new point-of-care device, hepatoscope, using two-dimensional transient elastography showed both very good reproducibility and correlation to fibroscan
Poster Presentation
Presenter: Victor de Lédinghen

AI-enabled virtual hematoxylin & eosin and Masson’s trichrome staining for nonalcoholic fatty liver disease activity scoring from single unstained slide
Poster Presentation
Presenter: Peter Cimermancic

Diagnostic performance of magnetic resonance imaging, vibration-controlled transient elastography and controlled attenuation parameter in predicting steatohepatitis in NAFLD patients
Poster Presentation
Presenter: Sun Young Yim

Performance of non-invasive fibrosis tests for long-term liver and heart outcomes in Europeans with metabolic risk factors from the UK Biobank
1003
A real world experience utilising the FAST score to identify patients with NASH fibrosis
Poster Presentation
Presenter: Federica Tavaglione

1023
Metabolic and adipocytokine disorders as a background cause of the progression of nonalcoholic steatohepatitis in obese patients depending on comorbidity with chronic obstructive pulmonary disease
Poster Presentation
Presenter: Gres Karim

1037
The clinical significance of transient elastografy and cap in the diagnosis and surveillance of non alcoholic fatty liver disease
Poster Presentation
Presenter: Ivanna Rachynska

1192
SAFE score yielded a better performance than FIB-4 and NFS in predicting significant fibrosis among Asian NAFLD patients
Poster Presentation
Presenter: Pimsiri Sripongpun

1251
MorphoQuant, the first fully-automated morphometric software for the assessment of liver biopsy, identified significant differences between non-alcoholic fatty liver disease and steatohepatitis biopsies
Poster Presentation
Presenter: Despoina Vasileiou

1276
A systematic review and meta-analysis of the prevalence and cross-sectional severity of South Asian patients with non-alcoholic fatty liver disease
Poster Presentation
Presenter: Cindy Serdjebi

1309
Dynamic changes in liver stiffness assessed by transient elastography as a prognostic factor in NAFLD patients with prediabetes and type 2 diabetes
Poster Presentation
Presenter: Elias Maleh

1318
Diagnostic performance of fibrosis-4 index and NAFLD fibrosis score in at-risk group from low prevalence population
Poster Presentation
Presenter: Huiyul Park

1324
Sarcopenia is an independent risk factor for non-alcoholic fatty liver disease regardless of fat mass in men: 1:1 propensity score matching analysis
Poster Presentation
Presenter: Huiyul Park

1335
The use of non-invasive tests compared with histological fibrosis stage in predicting liver-related events in metabolic dysfunction-associated fatty liver disease
Poster Presentation
Presenter: Wah Loong Chan

1427
Fatty liver score: a novel fatty liver index based on magnetic resonance imaging-proton density fat fraction
Poster Presentation
Presenter: Chul-min Lee

1437
Impact of age as a confounding factor on non-invasive blood-based tests for the evaluation of non-alcoholic fatty liver disease: comparing NIS2+TM to established tests
Poster Presentation
Presenter: Quentin Anstee

1446
Cost effectiveness analysis of screening for advanced hepatic fibrosis in patients with various ‘at-risk population’ in guidelines
Poster Presentation
Presenter: Hye-Lin Kim

1462
The role of M2BPGi in screening for advanced hepatic fibrosis in diabetic patients
Poster Presentation
Presenter: Mimi Kim
Fibrosis-4 score and liver stiffness measurement by vibration-controlled transient elastography predict risk of liver-related events in non-alcoholic fatty liver disease
Poster Presentation
Presenter: Esteban Urias

Which screening of advanced liver fibrosis in NAFLD?
Poster Presentation
Presenter: Paul Cales

High performance of new multiparametric ultrasound in the non-invasive assessment of liver disease
Poster Presentation
Presenter: Gloria Ruiz-Fernandez

Practical diagnosis of cirrhosis by liver specialists in non-alcoholic fatty liver disease using currently available non-invasive fibrosis tests
Poster Presentation
Presenter: Jerome Boursier

Predictors of liver stiffness changes in consecutive cohorts of patients with non-alcoholic fatty liver disease and longitudinal follow up
Poster Presentation
Presenter: Mirko Zoncapè

The prevalence and predictors of non-alcoholic fatty liver disease by vibration controlled transient elastography among lean adults in the United States
Poster Presentation
Presenter: Ifrah Fatima

Glomerular hyperfiltration: a new marker of fibrosis severity in non-cirrhotic non-alcoholic fatty liver disease
Poster Presentation
Presenter: Marta Garbin

Long-term liver-related outcomes in 1,260 patients with non-cirrhotic NAFLD
Poster Presentation
Presenter: Ying Shang
1639
NIS2+™ as a screening tool for optimizing patient selection in non-alcoholic steatohepatitis therapeutic trials
Poster Presentation
Presenter: Vlad Ratziu

1652
A sequential use of transient elastography followed by Agile 3+ score significantly improves the screening of advanced fibrosis in patients with NAFLD with or without severe obesity
Poster Presentation
Presenter: Cyrielle Caussy

1701
Association of non-high-density lipoprotein cholesterol trajectories with the development of non-alcoholic fatty liver disease
Poster Presentation
Presenter: Jun-Hyuk Lee

1704
High prevalence of compensated advanced chronic liver diseases among patients with type 2 diabetes mellitus (CDL 2301): a prospective community-based study
Poster Presentation
Presenter: Xiaolong Qi

1715
A diagnostic non-invasive model for liver advanced fibrosis and cirrhosis in chronic hepatitis B (CHB) concurrent with nonalcoholic fatty liver disease (NAFLD) based on machine learning (ML)
Poster Presentation
Presenter: Jie Li

1722
The role of M2BPGi for screening of advanced hepatic fibrosis in elderly patients
Poster Presentation
Presenter: Hoon Gil Jo

1724
Fibrosis-4 and M2BPGi combination screening algorithm for screening advanced hepatic fibrosis in diabetes is cost-effective
Poster Presentation
Presenter: Mimi Kim

1725
Effect of diabetes mellitus and fatty liver on hepatic fibrosis
Poster Presentation
Presenter: Byung Ik Kim

ABDA score: a non-invasive model to identify subjects with fibrotic non-alcoholic steatohepatitis in the community
Poster Presentation
Presenter: Shalimar

Cost-effectiveness of screening for advanced hepatic fibrosis by noninvasive test in general population
Poster Presentation
Presenter: Bo-Kyeong Kang

Inclusion of the fatty liver-associated variants in the clinical workup of patients: results of an eight years’ experience in a tertiary referral center with genotyping facility
Poster Presentation
Presenter: Marcin Krawczyk

Establishment and validation of a diagnostic model for liver inflammation in chronic hepatitis B (CHB) patients concurrent with nonalcoholic fatty liver disease (NAFLD) based on machine learning (ML)
Poster Presentation
Presenter: Jie Li

Performance of novel collagen turnover biomarkers in relation to FIB-4 to detect advanced fibrosis in NAFLD
Poster Presentation
Presenter: Hannes Hegmar

Utility of SomaSignalTM panels for drug response and monitoring disease progression in patients with advanced fibrosis due to non-alcoholic steatohepatitis
Poster Presentation
Presenter: Kris Kowdley

Development of ultra-sensitivity enzyme linked immunosorbent assay for hepatitis delta virus antibody detection
Poster Presentation
Presenter: Nomin Ariungerel

1916
ALT/AST ratio: the useful predictive marker for insulin resistance
Poster Presentation
Presenter: Han Seul ki

1998
Serum glycochenodeoxycholic acid-3-sulfate can discriminate non-alcoholic steatohepatitis from steatosis
Poster Presentation
Presenter: Barbora Nováková

2016
Analysis of correlation and predictive ability of oral glucose tolerance tests with insulin assays for liver stiffness measurement in non-cirrhotic overweight and obese patients
Poster Presentation
Presenter: Valentino Osti

2077
Using elevated plasma alanine transaminase to screen for non-alcoholic fatty liver disease in overweight and obese individuals from the Danish general population
Poster Presentation
Presenter: Elias Rashu

2133
Burden of non-alcoholic fatty liver disease and usefulness of non-invasive tests to identify advanced liver disease in patients with type 2 diabetes mellitus: interim analysis of an Italian prospective multicentre study
Poster Presentation
Presenter: Gian Paolo Caviglia

2149
A screening strategy of hidden compensated advanced chronic liver disease in diabetic outpatients using sequential and automatic fibrosis-4 and enhanced liver fibrosis scores
Poster Presentation
Presenter: Clara Amiama Roig

2154
The genetic background of NAFLD patients markedly affects their metabolomic and lipidomic signatures
Poster Presentation
Presenter: Lina Jegodzinski
Accuracy of 100 Hz transient elastography-based spleen stiffness for the identification of advanced fibrosis in biopsy-proven non alcoholic fatty liver disease
Poster Presentation
Presenter: Angelo Armandi

Performance of non-invasive markers in evaluating presence and severity of liver fibrosis in non-alcoholic fatty liver disease: results from a multi-ethnic Asian cohort of biopsy-proven non-alcoholic fatty liver disease patients
Poster Presentation
Presenter: EN YING TAN

Comparison of performance of non-invasive indices in assessing degree of steatosis in non-alcoholic fatty liver disease
Poster Presentation
Presenter: EN YING TAN

Evaluating the role of novel magnetic resonance imaging-based biomarkers in non-invasive assessment of hepatic fibrosis and activity in non-alcoholic fatty liver disease
Poster Presentation
Presenter: EN YING TAN

Biomarkers of hepatocyte basement membrane turnover reflect disease activity in patients with early-stage non-alcoholic fatty liver disease
Poster Presentation
Presenter: Ida Lønsmann

Lower ALT levels are associated with increased all-cause and cardiovascular mortality in patients with NAFLD in the United States population
Poster Presentation
Presenter: Bo Feng

A biomarker of fibrosis resolution, CTX-III, increases after bariatric surgery in early NAFLD patients with histological liver improvements
Poster Presentation
Presenter: Ida Lønsmann
Implementing a clinical care algorithm for screening of liver fibrosis in specialist diabetes care

Poster Presentation
Presenter: Muna Tajudin

Associations of genetic risk panel with enhanced liver fibrosis scores among patients with non-alcoholic fatty liver disease

Poster Presentation
Presenter: Zobair Younossi

A validated tool consisting of bedside variables predicts high-risk NASH (HRN) in individuals with type 2 diabetes

Poster Presentation
Presenter: Eduardo Vilar Gomez

One-step diagnosis: detection and stratification of incidental hepatic steatosis by multiparametric abdominal ultrasound

Poster Presentation
Presenter: Irene GONZALEZ DIAZ

Risk-stratification of patients with non-alcoholic fatty liver disease (NAFLD) in primary care: lessons from the Calgary NAFLD pathway

Poster Presentation
Presenter: Abdel-Aziz Shaheen

Wearable technology utilizing an electrical impedance tomography (EIT) system for hepatic steatosis quantification and the role in ambulatory monitoring

Poster Presentation
Presenter: Lung Yi Loey Mak

Analysis of the diagnostic accuracy of the non-invasive fibrosis indices NFS, HFS, and FIB-4 in the staging of advanced fibrosis in patients with metabolic fatty liver: meta-analysis of comparative studies

Poster Presentation
Presenter: Carmen Lara Romero
Significant dose-dependent reduction in liver stiffness using transient elastography in a phase 3 randomized placebo-controlled trial of obeticholic acid over 48 months in patients with pre-cirrhotic fibrosis due to nonalcoholic steatohepatitis
Poster Presentation
Presenter: Rohit Loomba

2483
MRI-PDFF captures the whole spectrum of lipid composition beyond traditional histological evaluation of macrosteatosis
Poster Presentation
Presenter: David Marti-Aguado

2489
Improvements in liver fibroinflammation (as assessed by corrected T1 [cT1]) with HTD1801 (berberine ursodeoxycholate) treatment in patients with nonalcoholic steatohepatitis and type 2 diabetes mellitus
Poster Presentation
Presenter: Stephen Harrison

2520
Abdominal adiposity and insulin resistance are the main predictors of CAP values in individuals with metabolic dysfunction: the liver-bible cohort
Poster Presentation
Presenter: Cristiana Bianco

2526
Assessment of hepatic fibrosis screening in primary care using the FIB-4 score, followed in second line by an ELF (Enhanced liver Fibrosis) test
Poster Presentation
Presenter: Denis Ouzan

2533
Validation and expansion of the American gastroenterological association clinical care pathway for nonalcoholic fatty liver disease in a prospective cohort of patients with type 2 diabetes
Poster Presentation
Presenter: Veeral Ajmera

2548
LIVERFASGP+ (GP+), a non-invasive blood testing for NAFLD staging, improves risk stratification of patients with indeterminate FIB-4 results
Poster Presentation
Presenter: Naim Alkhouri

2559
Prevalence of NAFLD and advanced fibrosis in Stockholm, Sweden
Poster Presentation
Presenter: Emilie Toresson Grip

2567
A stepwise screening approach using noninvasive tests to identify phenotypic nonalcoholic steatohepatitis (NASH) patients with fibrosis for clinical trials
Poster Presentation
Presenter: Naim Alkhouri

2587
LIVERFAST GP+, first-line screening tool in at-risk MAFLD patients outperforms the standard-of-care (SOC) FIB-4
Poster Presentation
Presenter: Mona MUNTEANU

2597
High performance of serological indexes in the non-invasive assessment of liver steatosis
Poster Presentation
Presenter: Beatriz Pillado Pérez

2600
Prevalence of diagnosed advanced liver fibrosis in high-risk population with metabolic dysfunction associated fatty liver disease screened in diabetology using transient elastography
Poster Presentation
Presenter: Cyrielle Caussy

2602
Velacur ACE outperforms CAP for liver fat quantification using MRI PDFF as the gold standard
Poster Presentation
Presenter: Rohit Loomba

2664
Fully automated approach of machine learning combined with deep learning to forecast the coronary artery disease in patients with nonalcoholic fatty liver disease
Poster Presentation
Presenter: antonio cirella

2677
A gut-mycobiome-derived signature predicts advanced fibrosis in people with diabetes
Poster Presentation
Presenter: Rohit Loomba
2680
Thrombospondin-2 as a new biomarker for at risk NASH and advanced fibrosis in a large multicentric European cohort
Poster Presentation
Presenter: Vlad Ratziu

2706
Development of a novel non-invasive test for prediction of liver fibrosis in patients with clinically severe obesity defined by a BMI over 50 kg/m²
Poster Presentation
Presenter: Maximilian Joseph Brol

2748
Diagnostic efficacy of Mac-2 binding protein glycosylation isomer for predicting liver fibrosis in patients with metabolic associated fatty liver disease: multicenter cohort study
Poster Presentation
Presenter: Se Young JANG

2792
Utility of serum phosphatidylethanol in differentiating NAFLD from alcohol-associated liver disease among individuals with overweight and obesity: the San Diego liver study
Poster Presentation
Presenter: Monica Tincopa

2805
Diagnostic and prognostic performance of the SAFE score in non-alcoholic fatty liver disease
Poster Presentation
Presenter: Guanlin Li

2888
Morphometric analysis of sonic hedgehog in non-alcoholic fatty liver steatohepatitis patients by MorphoQuant: a potential biomarker of disease severity
Poster Presentation
Presenter: Cindy Serdjebi

2892
Detecting early improvements in a NAFLD patient population during diet-induced weight loss
Poster Presentation
Presenter: Pietro Torre

2919
Serological biomarkers of extracellular matrix related disease activity are elevated in patients at risk of NASH with significant liver stiffness
Poster Presentation
Presenter: Thomas Møller

2922
A cost-effective non-invasive serum test for diagnosing NASH-cirrhosis (NC-3) in high-risk metabolic syndrome and/or type 2 diabetes patients
Poster Presentation
Presenter: Shira Shaham-Niv

2971
Standardized non-invasive screening for non-alcoholic fatty liver disease in people with type 2 diabetes identifies a substantial number of individuals with advanced liver disease
Poster Presentation
Presenter: Naomi Lange

2973
Performance of the AGA clinical care pathway in identifying patients with at-risk nonalcoholic steatohepatitis: combined data from multiple therapeutic clinical trials including more than 5,000 patients (in collaboration with NAIL-NIT consortium)
Oral Presentation
Presenter: Naim Alkhouri

2978
Performance of vibration controlled transient elastography and related scores to identify at-risk nonalcoholic steatohepatitis patients: combined data from multiple trials including more than 5,000 patients (in collaboration with NAIL-NIT consortium)
Oral Presentation
Presenter: Mazen Noureddin

2984
Performance of non-invasive tests as exclusion criteria for cirrhosis in trials targeting at-risk nonalcoholic steatohepatitis: combined data from multiple trials including more than 5,000 patients (in collaboration with NAIL-NIT consortium)
Poster Presentation
Presenter: Naim Alkhouri

3077
Development of loop-mediated isothermal amplification assay for detection of hepatitis delta virus
Poster Presentation
Presenter: Odgerel Oidovsambuu

3079
Prediction of outcomes in patients with nonalcoholic fatty liver disease by initial measurements and subsequent changes in magnetic resonance elastography
Oral Presentation
Presenter: Takashi Kobayashi

3107
Head-to-head comparison of Agile 3+, LSM-VCTE, NFS, and FIB-4 scores for detecting advanced fibrosis in patients with type 2 diabetes seen in diabetes clinic
Poster Presentation
Presenter: Laurent Castéra

3132
Low risk FIB-4 results in patients under 50 years accurately risk assessed patients for adverse liver outcomes over a follow-up of up to 35 years
Poster Presentation
Presenter: Jenny Gallacher

3142
Prognostic value of the Enhanced Liver Fibrosis (ELF) test to predict long-term outcomes in a NAFLD cohort with up to 35 years follow-up
Poster Presentation
Presenter: Jenny Gallacher

3176
Shortcomings of “FIB-4 First” strategy in screening for non alcoholic fatty liver disease (NAFLD) patients at risk for disease progression in a real life setting: will we be detracting therapeutic opportunities from patients?
Poster Presentation
Presenter: Simone Cappelli

3179
Developing a risk stratification tool for advanced NAFLD fibrosis using routinely measured clinical variables in a diabetes clinic annual review
Poster Presentation
Presenter: Hamish Miller

3314
Screening for advanced fibrosis due to NAFLD in patients with type 2 diabetes in a retina scanning facility
Poster Presentation
Presenter: Andrea Lindfors

3332
FIB-4 predicts the risk of hepatocellular carcinoma in patients with type 2 diabetes: a longitudinal multicentre study
Poster Presentation
Presenter: Vincent Mallet
Assessing the feasibility of AI-based Hamaguchi score estimation for NAFLD diagnosis using ultrasound images
Poster Presentation
Presenter: Alessia Visintin

Diagnostic performance of non-invasive fibrosis markers in patients with immune-mediated disease and hepatic steatosis
Poster Presentation
Presenter: María Del Barrio Azaceta

Evaluation of the performance of a novel single-nuclei digital pathology method for the continuous quantification of steatosis and inflammation in liver biopsies and its correlation with NASH-CRN scores in patients with NASH
Poster Presentation
Presenter: Mathieu Petitjean

Non-alcoholic fatty liver disease made easy for diabetologists: the automated fibrosis-4 index
Poster Presentation
Presenter: Mona Ismail

Comparison between EASL and AGA algorithms for hepatology referral in 1572 outpatients with type 2 diabetes and suspected NAFLD seen in a diabetes clinic
Poster Presentation
Presenter: Laurent Castéra

Impact of obesity on transient elastography accuracy among patients with non-alcoholic fatty liver disease
Poster Presentation
Presenter: María Del Barrio Azaceta

Assessing the role of organokines as biomarkers for diagnosing non-alcohol related liver disease
Poster Presentation
Presenter: Andrea Jiménez Franco
Non-Alcoholic Steatohepatitis impacts on visceral adipose tissue proteomic signature
Poster Presentation
Presenter: Cristian Martínez Navidad

3504
Are non-invasive tests of fibrosis effective in patients with metabolic associated fatty liver disease? Comparative study between liver biopsy and non-invasive scores or fibroscan
Poster Presentation
Presenter: Annalisa Cespiati

3508
Patients with risk factors for liver diseases associated with hepatic steatosis constitute the target population for liver fibrosis assessment in primary care
Poster Presentation
Presenter: Rosario Hernández

3561
Two steps algorithm for the diagnosis of advanced liver fibrosis in general population. Real-life data
Poster Presentation
Presenter: Ana Pérez

3579
Validation of elastography criteria and cACLD risk model for diagnosis of compensated advanced chronic liver disease (cACLD) in NAFLD patients
Poster Presentation
Presenter: Antonio Liguori

3603
The sequential use of liver stiffness measurement and direct biomarkers of fibrosis is able to identify patients with severe non-alcoholic steatohepatitis
Poster Presentation
Presenter: filippo gabrielli

3615
Validation of Baveno VII criteria in NAFLD patients according to body mass index
Poster Presentation
Presenter: María Del Barrio Azaceta

3616
Evaluating the prevalence of liver fibrosis in children with non-alcoholic fatty liver disease using transient elastography, Dutch Fibrokids cohort
Poster Presentation
Presenter: Jalina Rooseboom
Free light chains: novel serum biomarkers for NASH stratification, an update
Poster Presentation
Presenter: Francesca D'Ambrosio

Soluble TREM2 and PRO-C3 as efficacy of intervention markers in NASH
Poster Presentation
Presenter: Charlotte Wernberg

Echocardiography-based markers for subclinical cardiac dysfunction in patients with non-alcoholic fatty liver disease and significant fibrosis with preserved ejection fraction: preliminary data from a prospective monocentric Italian cohort
Poster Presentation
Presenter: Daphne D'Amato

Correlation between serial Fibrosis-4 scores and liver stiffness measurements in patients with low-risk non-alcoholic fatty liver disease
Poster Presentation
Presenter: Tanvi Goyal

AGILE 3+ and AGILE 4 scores for the diagnosis of advanced fibrosis and cirrhosis in patients with non-alcoholic fatty liver disease
Poster Presentation
Presenter: Kamela Gjini

Incorporating artificial intelligence in portable infrared thermal imaging for the diagnosis and staging of nonalcoholic fatty liver disease
Poster Presentation
Presenter: Yana Davidov

Utilization of fibroscan-AST scoring system to risk-stratify non-alcoholic steatohepatitis patients for clinical trials and novel therapies
Poster Presentation
Presenter: Phillip Leff
Novel artificial intelligence-assisted digital pathology quantitative image analysis predicts the occurrence of liver-related clinical events in the multicentric, European, hepatic outcomes and survival fatty liver registry (HOTSURFR) study
Poster Presentation
Presenter: Vlad Ratziu

NAFLD: Experimental and pathophysiology

119
Gamma-muricholic acid inhibits steatosis-dependent peroxidative impairment to attenuates nonalcoholic steatohepatitis by activation of FXR/SHP/LXRα/FASN signaling
Poster Presentation
Presenter: Qin Pan

231
Effect of vitamin D receptor signaling on endoplasmic reticulum stress in non-alcohol related steatohepatitis: exploring potential autophagy dependence
Poster Presentation
Presenter: Basma Alaa

257
Loss of mitochondrial adaptation associates with deterioration of mitochondrial turnover and structure in obesity-related progressive fatty liver disease
Poster Presentation
Presenter: Theresia Sarabhai

259
Improvement of liver fibrosis by a novel long acting Glucagon/GLP-1/GIP triple agonist, efocipegtrutide (HM15211) in carbon tetrachloride-induced mouse model of liver injury and fibrosis
Poster Presentation
Presenter: Jong Suk Lee

331
Dissecting NAFLD pathomechanisms using primary mouse liver and blood cells in a microfluidic perfusible compartmentalized liver-on-a-chip model
Oral Presentation
Presenter: Hanyang Liu

338
Novel role of macrophage Foxo1-mediated YAP-Notch axis in NASH progression
Poster Presentation
Presenter: Bibo Ke
Selective modulation of mitochondrial complex I ameliorates steatosis and hepatic inflammation in MCD-diet fed rats
Poster Presentation
Presenter: Laura Giuseppina Di Pasqua

359
Single-cell transcriptomics depicts metabolism reprogramming and immune landscape of bariatric surgery intervened nonalcoholic fatty liver
Poster Presentation
Presenter: Hanyang Liu

373
Uncovering a novel potential target in non-alcoholic fatty liver disease
Poster Presentation
Presenter: Stine Marie Praestholm

391
Preclinical characterization of HPG7233, a potent, liver-target and highly selective thyroid hormone receptor beta agonist for nonalcoholic steatohepatitis
Poster Presentation
Presenter: Que Liu

399
mTORC1 response to glucose via dihydroxyacetone phosphate is regulated by MAT1A. Role in NAFLD
Poster Presentation
Presenter: María de los Reyes Luque Urbano

439
Efficacy and reproducibility of AI-assisted Gubra Histopathological Objective Scoring Technique (GHOST) in preclinical rodent models of NASH
Poster Presentation
Presenter: Susanne Pors

477
Combination therapy of TERN-501, a selective agonist of thyroid hormone receptor (THR) beta with TERN-101, a farnesoid X receptor (FXR) agonist improves nonalcoholic steatohepatitis (NASH) in a GAN diet-induced and biopsy-confirmed mouse model
Poster Presentation
Presenter: Christopher Jones

538
The E2F2-miR34a-5p axis is involved in the biliary metabolism dysregulation in NASH
Poster Presentation
Presenter: Maider Apodaka-Biguri
Programmed cell death 1 genetic variant and liver damage in nonalcoholic fatty liver disease
Poster Presentation
Presenter: Grazia Pennisi

Novel bariatric surgery models in mice – differential effects on body weight loss and fatty liver disease
Poster Presentation
Presenter: Louis Onghena

APB-R3, a novel long-acting IL-18 binding protein, inhibits IL-18 activity, and thereby ameliorates NASH progress with reduced liver fibrosis
Poster Presentation
Presenter: Eun-Bi Song

Intestinal Angptl4 perturbs gut barrier function in NAFLD
Oral Presentation
Presenter: Damien Chua

Inhibition of NLRP3 inflammasome activation by MK571, an multidrug resistance-associated protein (MRP) inhibitor
Poster Presentation
Presenter: Oh Seung Seok

Cannabidiolic acid (CBDA) regulates energy homeostasis and protects against non-alcoholic fatty liver disease (NAFLD) in mice
Poster Presentation
Presenter: Albert Giralt

A N-acylethanolamines mixture counteracts hepatic dysmetabolism induced in high-fat diet-fed obese mice
Poster Presentation
Presenter: Claudio Pirozzi
Unravelling an autophagy-dependent role of vitamin D in preserving gut integrity in experimental NASH
Poster Presentation
Presenter: Andrew Hakeem

Unravelling the role of iron-catalysed ferroptotic cell death in non-alcoholic steatohepatitis
Poster Presentation
Presenter: Cédric Peleman

Macrophage-derived osteopontin protects from non-alcoholic steatohepatitis
Oral Presentation
Presenter: Natalia Nieto

mir-22 inhibition as glp1 agonist orthogonal mechanism for nafl and nash treatment
Poster Presentation
Presenter: Riccardo Panella

Antagonism of C-C motif chemokine receptor 2 (CCR2) using a novel in silico designed peptide attenuates macrophage infiltration and non-alcoholic steatohepatitis in vivo
Poster Presentation
Presenter: Eline Geervliet

Preclinical efficacy and clinical translatability of resmetirom in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH
Poster Presentation
Presenter: Michael Feigh

NAFLD is a night-time disease driven by nocturnal hepatic, adipose, and skeletal muscle insulin resistance
Poster Presentation
Presenter: Thomas Marjot

Light cytokine-deficiency effects in immune cells subpopulations in a murine non alcohol-related steatohepatitis model
Poster Presentation
Presenter: María Aguilar Ballester
A new nuclear-erythroid-2-related factor 2 activator for the treatment of nonalcoholic steatohepatitis: evidence of metabolic and anti-fibroinflammatory effects in human precision cut liver slices
Poster Presentation
Presenter: Adel HAMMOUTENE

In vitro investigation of the role of adipocyte-derived exosomes in the development of non-alcoholic steatohepatitis
Poster Presentation
Presenter: Robim M Rodrigues

Plasma short chain fatty acids are associated with non-alcoholic fatty liver disease and fibrosis severity
Poster Presentation
Presenter: Mira Thing

GTX-011 improves fibrosis and hepatic stellate cells phenotype in human precision cut liver slices
Poster Presentation
Presenter: Jordi Gracia-Sancho

A formulation of palmitoylethanolamide and phenolic compounds improves NAFLD-associated hepatic lipid dysmetabolism and oxidative stress in obese mice
Poster Presentation
Presenter: Stefania Melini

The NRF2/b-TrCP axis: new therapeutic target in non-alcoholic steatohepatitis (NASH)
Poster Presentation
Presenter: Raquel Fernández Ginés

Novel image analysis and immunohistochemistry advances to accompany pathologist driven non-alcoholic fatty liver disease diagnosis
Poster Presentation
Presenter: Maroua Tliba

Utilization of multicellular liver-on-chip to study non-alcohol-related fatty liver disease
1283
Obeticholic acid administration increases hepatic eNOS levels counteracting lipid accumulation and fibrosis in a diet-induced ob/ob mouse model of NASH
Poster Presentation
Presenter: Laura Giuseppina Di Pasqua

1287
Longitudinal ultrasound imaging assessment of murine liver fibrosis in a high fat, fructose, cholesterol (FFC) model and its response to therapy
Poster Presentation
Presenter: Ryan Gessner

1340
High-fat diet exacerbates lipopolysaccharide-induced liver injury in obese KK-Ay mice
Poster Presentation
Presenter: Satoshi Sakuma

1341
Hepatic Apolipoprotein J facilitates metabolic disease progression by promoting mTOR-mediated suppression of autophagy
Poster Presentation
Presenter: Duan Shuangdi

1343
Loss of gut barrier integrity in nonalcoholic fatty liver disease is associated with severe vibriosis
Poster Presentation
Presenter: Punnag Saha

1368
Brain-derived neurotrophic factor knock-out mice develop nonalcoholic steatohepatitis
Poster Presentation
Presenter: Mayuko Shimizu

1390
Deletion of no-sensitive guanylyl cyclase protects from metabolic obesity but not from fibrosis in murine non-alcoholic fatty liver disease
Poster Presentation
Presenter: Muhammad Ashfaq-Khan

1394
A translational rat model to study metabolic associated fatty liver disease with fibrosis and portal hypertension
Poster Presentation
Presenter: María Martell

1428
Statins regulate PNPLA3 through a mechanism that requires SREBF2 in human liver cells
Poster Presentation
Presenter: Osman Ahmed

1445
Cholesterol-free ketogenic diet feeding improves experimental non-alcoholic fatty liver disease (NAFLD)
Poster Presentation
Presenter: Alessia Provera

1452
Co-stimulatory signals mediated by inducible T-cell co-stimulator (ICOS) influence the hepatic expansion auto-aggressive CD8+T-cells in non-alcoholic steatohepatitis (NASH)
Poster Presentation
Presenter: Cristina Vecchio

1466
The PNPLA3 I148M variant aggravates inflammation through dysfunctional LXR and PPAR gamma signalling in macrophages
Poster Presentation
Presenter: Emmanuel Dauda Dixon

1490
The PNPLA3 I148M variant initiates metabolic reprogramming in macrophages
Poster Presentation
Presenter: Emmanuel Dauda Dixon

1508
Toll-like receptor 5 signalling mediates pro-inflammatory and fibrogenic responses in non-alcoholic steatohepatitis (NASH)
Poster Presentation
Presenter: Wenhao Li

1535
Effects of HSD17B13-targeting siRNA - R0737072 on Liver Fibrosis and Steatosis in a mouse model of NASH
Poster Presentation
Presenter: Li Ming Gan
1537
The disturbance of intracellular chloride induces the development and progression of nonalcoholic fatty liver disease
Poster Presentation
Presenter: Biguang Tuo

1571
Characterization of extracellular vesicles derived from human precision-cut liver slices in non-alcoholic fatty liver disease
Poster Presentation
Presenter: Ke Luo

1625
Deletion of mixed lineage kinase domain like pseudokinase aggravate chronic alcohol induced liver injury via increasing apoptosis
Poster Presentation
Presenter: Hyo Young Lee

1629
Discovery biomarker to optimize obeticholic acid treatment for non-alcoholic fatty liver disease
Poster Presentation
Presenter: Eileen Yoon

1752
Artificial neural networks predict via label-free imaging analysis cellular injury in a human steatohepatitis model
Poster Presentation
Presenter: Julian Weihs

1845
Empagliflozin improves non-alcoholic fatty liver disease in a new translational mice model even without impact on weight loss
Poster Presentation
Presenter: Katharina Luise Hupa-Breier

1850
Secretomics identifies IGFBP1 as a stress signaling marker in human models for NAFLD
Poster Presentation
Presenter: Ruth Walker

1893
Mice lacking Cyclophilin B, but not Cyclophilin A, are significantly protected from the development of major features of NAFLD/NASH in a diet and chemical-induced model
Presenter: Winston Stauffer

1990
Validation and utility of artificial intelligence-based zonal annotations as an additional assessment tool for the histopathologic review of fibrosis in non-alcoholic steatohepatitis patients
Presenter: Gwyneth Soon

1994
IFI16 expression and its genotype variant are associated with NAFLD progression
Presenter: Hyun Goo Woo

2011
Quantification of vessel and bile duct parameters using Second Harmonic Generation in patients with NAFLD across fibrosis stages
Presenter: Jörn Schattenberg

2013
Anti-inflammatory and anti-fibrotic effects by simultaneous activation of glucagon, GIP, and GLP-1 of efocipegtrutide (HM15211) in thioacetamide-induced mouse model of liver injury and fibrosis
Presenter: Jung Kuk Kim

2019
Collagen co-localized with macrovesicular steatosis better differentiates fibrosis progression in non-alcoholic fatty liver disease mouse models
Presenter: Xiaoxiao Wang

2041
Knockdown of a novel target gene enhances liver regeneration and attenuates chronic liver damage related liver fibrosis
Presenter: Shainan Hora

2064
The potential role of Omentin-1 in metabolic associated fatty liver disease (MAFLD): evidence from translational studies
Presenter:
Presenter: Noel Salvoza

2076
Growth differentiation factor 15 in plasma and liver is associated with hepatic oxidative stress in non-alcoholic fatty liver disease
Poster Presentation
Presenter: Mikkel Werge

2081
The PNPLA3 p.I148M risk variant was fixed in Neanderthals and segregates neutrally in humans
Poster Presentation
Presenter: Andreas Geier

2104
The effects of lipopolysaccharides on inducing nonalcoholic fatty liver disease in human precision-cut liver slices
Poster Presentation
Presenter: Mei Li

2177
Hepatic lipid flux, and not lipid amount, damages the liver during starvation-induced steatosis
Poster Presentation
Presenter: Sumeet Singh

2179
Quantitative ultrasound for liver steatosis assessment: benefits of measurements over a large two-dimensional region of interest on the performance of image-brightness-based parameters
Poster Presentation
Presenter: Adrien Besson

2188
Two-dimensional versus one-dimensional transient elastography: benefits of ultrasound imaging-based processing for liver stiffness measurements
Poster Presentation
Presenter: Adrien Besson

2207
Serum exosomal mir-4668-5p in Non-alcoholic Fatty liver Disease (NAFLD) patients with significant liver fibrosis
Poster Presentation
Presenter: Jong Eun Yeon
Rilpivirine as an anti-inflammatory agent in non-alcoholic fatty liver disease: evidence from human hepatocytes, hepatic stellate cells and blood cells
Poster Presentation
Presenter: Isabel Fuster-Martínez

2277
The effect of cholesterol and its metabolites on human pluripotent stem cell-derived hepatic stellate cells
Poster Presentation
Presenter: Ingrid Wilhelmsen

2289
A guinea pig model of pediatric non-alcoholic steatohepatitis
Poster Presentation
Presenter: Kamilla Pedersen

2295
Opposite correlations between hepatic β-oxidation activity and triglyceride levels in male and female rats after a high-fat diet supplemented with liquid fructose
Poster Presentation
Presenter: Roger Bentanachs

2304
Inhibition of CCAT/enhancer-binding protein beta - serpinB3 axis by 1-piperidin propionic acid: a new targeted therapy for non-alcoholic steatohepatitis
Poster Presentation
Presenter: Francesca Protopapa

2309
Zebrafish larvae as a model system to characterize effects of metabolic, drug and genetic perturbations on liver fat accumulation
Poster Presentation
Presenter: Endrina Mujica

2375
Oral antibiotic treatment protects mice against the development of diet-induced non-alcoholic fatty liver disease but not against diet-induced intestinal barrier dysfunction
Poster Presentation
Presenter: Katja Csarmann

2382
Pemafibrate abrogates lipid liver accretion in a dietary model of fatty liver in rat
Poster Presentation
Presenter: Roger Bentanachs
2388
Improvement of NAFLD by Totum-448: effects in the liver, adipose tissue and gut in western-diet fed hamsters
Poster Presentation
Presenter: Vivien Chavanelle

2391
Evaluation of genetic risk score of a dysmetabolic and obese population of southern Italy
Poster Presentation
Presenter: Benedetta Maria Motta

2417
PNPLA3 I148M substitution exacerbate NAFLD under a long-term high fat diet
Poster Presentation
Presenter: Huan Su

2418
Exploring transcriptome profiles to combat non-alcoholic fatty liver disease
Poster Presentation
Presenter: Eva Kocar

2424
Modelling the biological mechanisms of a PNPLA3 polymorphism in a 3D human liver spheroid for NASH progression and drug efficacy
Poster Presentation
Presenter: Francisco Verdeguer

2469
Biomarkers identifying hepatic inflammation in non-alcoholic fatty liver disease (NAFLD)
Poster Presentation
Presenter: Elisabeth Galsgaard

2472
Senescence sensitizes hepatocytes for fatty acid-induced cytotoxicity by compromising the mitochondrial function
Poster Presentation
Presenter: Lilli Rausch

2512
Prophylactic and therapeutic hepatoprotective effects of lanifibranor in the CDAA-HFD mouse model of advanced NASH with progressive fibrosis
Poster Presentation
The transcriptional function of TCF7L2 is spatially restricted in liver and regulates zonated metabolic pathways that contribute to NAFLD
Oral Presentation
Presenter: Luke Norton

Characterization of portal inflammation and hepatic fibrosis in non-alcoholic fatty liver disease
Poster Presentation
Presenter: Zobair Younossi

Cyclophilin inhibition with rencofilstat shifts the liver transcriptome and lipidome in preclinical models toward resolution of nonalcoholic steatohepatitis
Poster Presentation
Presenter: Daren Ure

A functional interaction between hepatic estrogen receptor-α and PNPLA3 p.I148M inherited variant drives fatty liver disease susceptibility in women
Poster Presentation
Presenter: Alessandro Cherubini

Uncovering the role of ISOC1 in non-alcoholic fatty liver disease
Poster Presentation
Presenter: Nicolas Goossens

Development of a target engagement biomarker for HSD17B13: preclinical pharmacodynamic studies of small molecule inhibition of HSD17B13 by INI-822
Poster Presentation
Presenter: Heather Hsu

Characterizing the histologic implications of resmetirom-induced liver volume reduction using artificial intelligence-powered digital pathology
Poster Presentation
Presenter: Janani Iyer
A heterozygous N559Y mutation in Semaphorin 7A promotes nonalcoholic fatty liver disease progression through induction of hepatic ROS production and inflammation
Poster Presentation
Presenter: Yao Tong

2850
Targeting Apolipoprotein J restores autophagy and improves metabolic-associated fatty liver disease and diabetic nephropathy
Poster Presentation
Presenter: Wang Hsin-Tzu

2907
A novel HIF2A mutation causes dyslipidemia and promotes hepatic lipid accumulation
Poster Presentation
Presenter: Hongcui Cao

2935
Translational characterization of the temporal dynamics of metabolic dysfunctions in liver, adipose tissue and the gut during diet-induced NASH development in Ldr-/-Leiden mice
Poster Presentation
Presenter: Eveline Gart

2939
Tyrosol reduces steatosis, fibrosis and inflammation in a murine model of NASH by modulating the immune hepatic phenotype
Poster Presentation
Presenter: Daniela Gabbia

2960
Semaglutide has beneficial effects on non-alcoholic steatohepatitis in Ldr-/-Leiden mice
Poster Presentation
Presenter: José A. Inia

2964
Spatial proteotranscriptomics identifies macrophage heterogeneity in patients with at-risk non-alcoholic steatohepatitis
Oral Presentation
Presenter: Olivier Govaere

2982
Biomarkers of endothelial dysfunction in patients with non-alcoholic fatty liver disease (NAFLD)
Poster Presentation
Presenter: Rocío Montero-Vallejo
Liver-associated dysmetabolism is related to brain structure and perfusion changes in obesity: the BARICO study
Poster Presentation
Presenter: Florine Seidel

Endothelial and platelet-derived microvesicles as a biomarker of cardiovascular risk in patients with metabolic dysfunction-associated fatty liver disease (MAFLD)
Poster Presentation
Presenter: Sheila Gato Zambrano

Single-cell RNA sequencing in DIAMOND mice reveals differentially regulated pathways specifically associated with the transition from simple steatosis towards NASH
Poster Presentation
Presenter: Rocío Gallego-Durán

MicroRNA as novel biomarker for disease severity evaluation and therapeutic target in NAFLD
Poster Presentation
Presenter: Yoonseok Lee

Peroxisome proliferator-activated receptor alpha and estrogen related receptor alpha ligand combinations ameliorate nonalcoholic fatty liver disease
Poster Presentation
Presenter: Milton Antwi

Bridging the gap - how human microphysiological systems improve the translatability of NASH drug discovery
Poster Presentation
Presenter: Raul Silva

Adipose tissue macrophage dysfunction and depletion are associated with a breach of vascular integrity in non-alcoholic steatohepatitis
Poster Presentation
Presenter: Schalk van der Merwe
Increasing gut microbiota produced secondary bile acids to protect against non-alcoholic steatohepatitis
Poster Presentation
Presenter: Justine Gillard

3247
Decoding hepatocyte transcriptional responses in murine non-alcoholic steatohepatitis using single-nucleus RNA-sequencing
Poster Presentation
Presenter: Juliet Luft

3256
Circadian sleep-wake rhythms in non-alcoholic fatty liver disease
Poster Presentation
Presenter: Christine Bernsmeier

3272
E2F2-promoted DNA damage in NASH worsens the metabolic scenario
Poster Presentation
Presenter: Beatriz Gómez Santos

3309
A novel autophagy inducer attenuated nonalcoholic steatohepatitis by regulating the adénylate cyclase 6 in hepatocytes
Poster Presentation
Presenter: Jung Ho Hwang

3322
A novel orally available type IV autotaxin inhibitor, IOA-289, ameliorates steatosis and fibrosis in a preclinical model of non-alcoholic steatohepatitis
Poster Presentation
Presenter: Marit ten Hove

3330
Combined hepatic and adipose tissue transcriptomics highlights circulating NASH biomarkers
Poster Presentation
Presenter: Marica Meroni

3345
The role of chronic ER stress and calcium signalling in NASH associated carcinogenesis
Poster Presentation
Presenter: Muhammad Umair latif
PNPLA3, MBOAT7 and TM6SF2 modify mitochondrial dynamics in NAFLD patients: dissecting the role of cell-free circulating mtDNA and copy number
Poster Presentation
Presenter: Miriam Longo

A novel ALK5 inhibitor (TLR-X) attenuates steatosis and fibrosis in non-alcoholic steatohepatitis in vivo
Poster Presentation
Presenter: Marit ten Hove

Perivascular macrophages contribute to adipose tissue angiogenesis in patients with advanced non-alcoholic fatty liver disease
Poster Presentation
Presenter: Celia Martínez Sánchez

Thermoacoustic assessment of fatty liver disease - an early clinical feasibility study
Poster Presentation
Presenter: Michael Thornton

b-Klotho deficiency in hepatic stellate cells (HSCs) prompts inflammation, oxidative stress and a pro-fibrotic phenotype
Poster Presentation
Presenter: Giada Tria

The overexpression of TM6SF2 and/or MBOAT7 wild-type genes restores the mitochondrial lifecycle and activity in an in vitro NAFLD model
Poster Presentation
Presenter: Erika Paolini

Development of a 2D nonalcohol-related steatohepatitis (NASH) model
Poster Presentation
Presenter: Esther Arnaiz Gonzalez

Evaluating the hepatic efficacy and cardiometabolic profile of PNPLA3, TM6SF2, and other therapeutic targets for NALFD: a drug-target Mendelian randomization analysis
Poster Presentation
Presenter: Daniel Rosoff

3443
A functional investigation of NASH-associated gene polymorphisms in human liver tissue
Poster Presentation
Presenter: Jelena Mann

3452
NAT10-mediated N4-acetylcytidine of hepatic lipogenesis-associated mRNA contributes to maternal high-fat diet-induced non-alcoholic fatty liver disease in juvenile offspring
Poster Presentation
Presenter: Qianren Zhang

3477
BMP-SMAD pathway upregulation in hepatocytes delays NAFLD-NASH development
Poster Presentation
Presenter: Laura Silvestri

3480
Hepatic inactivation of the epigenetic regulators Suv420h1-h2 mitigates NAFLD development and progression in mice
Poster Presentation
Presenter: Alessia Pagani

3537
Role of TGR5 in fat-to-liver communication during NAFLD
Poster Presentation
Presenter: André L. Simão

3547
The pan-PPAR agonist Lanifibranor improves increased portal pressure, endothelial dysfunction and liver histology in a rat model of early NAFLD
Poster Presentation
Presenter: Shivani Chotkoe

3597
Metabolic effects of n-3 fatty acids administered as Calanus oil to transgenic mice lacking functional peroxisome proliferator-activated receptor alpha
Poster Presentation
Presenter: Martin Rossmeisl

3607
Effect of housing temperature on nonalcoholic fatty liver disease development in C57BL/6N mice
3628
Unraveling the individual contributions of the PPAR isotypes to the pan-PPAR agonist Lanifibranor-induced improvements of the vascular alterations and liver histology in a rat model of early NAFLD
Presenter: Shivani Chotkoe

3645
Caspase 8 reverses progression of NASH after hepatocyte-specific JNK deletion
Presenter: Ines Volkert

3658
Peculiar monocyte bioenergetic profile in nonalcoholic steatohepatitis (NASH)
Presenter: Moris Sangineto

3664
Beneficial effect of extravirgin olive oil on hepatic fatty acid accumulation and fibrogenesis: oleocanthalic acid as a promising compound for the treatment of NAFLD and NASH
Presenter: Martina Colognesi

3675
Human skin stem cell-derived hepatic cells with genetic predisposition for liver fat accumulation mimic susceptibility to develop metabolic dysfunction-associated fatty liver disease
Presenter: Alexandra Gatzios

3684
Ageing rates and oxidative stress in patients with non-alcoholic fatty liver disease and profound insulin resistance
Presenter: Anastasiia Radchenko

3780
Hepatocyte depletion of ERK5 impairs the response to lipotoxic oxidative stress resulting in defective insulin receptor signaling
Presenter: Armando Curto
Type I NKT cells are involved in exacerbation of steatohepatitis in aged mice
Poster Presentation
Presenter: Kazuyoshi Kon

NAFLD: Therapy

Hepatic fat and liver volume reductions – impact on non-alcoholic steatohepatitis trials and potential solutions using concomitant fibrosis with ballooning with fibrosis
Poster Presentation
Presenter: Stephen Harrison

CVI-301, a potent and selective thyroid hormone receptor beta full agonist, demonstrates profound total cholesterol and LDL-cholesterol reductions in a hyperlipidemic mouse efficacy model
Poster Presentation
Presenter: Jingwen Liu

HPG1860 in patients with NASH: a phase II double-blind, placebo-controlled, dose-ranging study
Poster Presentation
Presenter: Naim Alkhouri

Primary results from MAESTRO-NASH a pivotal phase 3 52-week serial liver biopsy study in 966 patients with NASH and fibrosis
Oral Presentation
Presenter: Stephen Harrison

A randomized controlled trial of kalmegh supplementation on non-alcoholic fatty liver disease
Poster Presentation
Presenter: Sanket Nandekar

Phase 1 study of the RNA interference therapeutic ALN-HSD in healthy adults and patients with nonalcoholic steatohepatitis
Oral Presentation
Presenter: John Gansner

The effects of a structured dietetics intervention in patients with non-alcoholic fatty liver disease
Poster Presentation
Presenter: Dominic Crocombe

782
The effects of a novel online app (Noom Weight) on weight loss and liver biomarkers in patients with NAFLD: a single arm proof-of-concept study
Poster Presentation
Presenter: Naim Alkhouri

814
Efficacy of digital health-supported lifestyle modification on patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis
Poster Presentation
Presenter: JOO HYUN OH

818
A novel prescription digital therapeutic for the treatment of non-alcohol related fatty liver disease: feasibility study
Poster Presentation
Presenter: Naim Alkhouri

881
Safety, tolerability, and preliminary efficacy of ascending doses of Human Allogeneic Liver-derived Progenitor Cells (HepaStem®) in patients with cirrhotic and pre-cirrhotic non-alcoholic steatohepatitis (NASH)
Poster Presentation
Presenter: Sven Francque

913
Efficacy and safety of LPCN 1144 in hypogonadal and eugonadal subjects for the treatment of nonalcoholic steatohepatitis (NASH) with fibrosis
Poster Presentation
Presenter: Benjamin Bruno

917
Resmetirom improves the lipid/lipoprotein profile in patients with nonalcoholic fatty liver disease
Poster Presentation
Presenter: Naim Alkhouri

930
Resmetirom helps regulate thyroid hormone levels within the liver in patients with nonalcoholic fatty liver disease
Poster Presentation
Presenter: Stephen Harrison
1300
Multicenter, randomized, double-blind, placebo-controlled trial of Fatty Acid Synthase (FASN) inhibitor, denifanstat, versus placebo in the treatment of biopsy-proven NASH: A 26-week interim analysis of the FASCINATE-2 Phase 2B trial
Oral Presentation
Presenter: Rohit Loomba

1504
A deep exploration of bridging fibrosis evolution and individual septa parameters in NASH using quantitative second harmonic generation imaging reveals fibrosis changes in natural history and treatment-induced not seen with conventional histology
Poster Presentation
Presenter: Nikolai Naoumov

1568
Prospective, multi-center, open-label, randomized, omega-3-acid ethyl ester-controlled trial to assess the impact of the pemafibrate on liver function in hypertriglyceridemia patients with non-alcoholic fatty liver disease (Portrait study)
Poster Presentation
Presenter: Yoshio Sumida

1669
Noninvasive tests of liver injury, inflammation and fibrosis are improved by efruxifermin and correlate with histological improvements in F2-F3 NASH patients: secondary analysis of Ph2b HARMONY study
Poster Presentation
Presenter: Jörn Schattenberg

1922
Semaglutide improves non-alcoholic steatohepatitis: a 10-year retrospective study
Poster Presentation
Presenter: Parth Shah

1928
Correlation between severity of hepatic steatosis and markers of cardiometabolic health, and effect of lanifibranor therapy in patients with non-cirrhotic NASH
Poster Presentation
Presenter: Michael Cooreman

1934
SNP-630, a novel compound with multiple mechanisms, reverses liver inflammation and fibrosis in preclinical model and NASH phase 2 clinical trial
Poster Presentation
Presenter: Shin-Wei Chen

1954
Effects of a novel tetra-specific drug (OGB21502) in the obese mice model of liver disease
Poster Presentation
Presenter: Yunki Kim

1986
Barriers for regular exercise in people with non-alcoholic fatty liver disease
Poster Presentation
Presenter: Kedar Deshpande

2196
The effect of standard of care lifestyle advice by a hepatologist in a routine clinical practice on steatosis and fibrosis development among NAFLD patients
Poster Presentation
Presenter: Leen Heyens

2315
A Phase 2a, randomized, active-comparator-controlled, open-label study to evaluate the efficacy and safety of efinopegdutide in individuals with nonalcoholic fatty liver disease
Oral Presentation
Presenter: Manuel Romero Gomez

2321
Incidence and risk of dyslipidemia and hyperglycemia in a phase 3 study of obeticholic acid for the treatment of nonalcoholic steatohepatitis
Poster Presentation
Presenter: Manal Abdelmalek

2325
Impact of oral semaglutide on liver pathology and glucose metabolism in patients with non-alcoholic fatty liver disease complicated by type 2 diabetes mellitus
Poster Presentation
Presenter: TADAMICHI KAWANO

2327
Lessons for the setting of an international integrated research platform to conduct adaptive trials in non-alcoholic steatohepatitis: results of the EU-PEARL project
Poster Presentation
Presenter: Elena de Sena

2349
Incidence and median times to onset and resolution of pruritus adverse events in a phase 3 study of obeticholic acid in patients with nonalcoholic steatohepatitis
Poster Presentation
Presenter: Zobair Younossi

2351
The influence of probiotics on biologic and imagistic alterations in non-alcoholic steato-hepatitis
Poster Presentation
Presenter: Elena Laura Iliescu

2376
Efficacy of pemafibrate in patients with non-alcoholic fatty liver disease complicated by dyslipidemia: a single-arm prospective study
Poster Presentation
Presenter: Hiroki Ono

2394
Treatment monitoring with the Agile 3+ score in patients with non-alcoholic steatohepatitis: analysis of data from a randomised placebo-controlled trial of semaglutide
Poster Presentation
Presenter: Laurent Castéra

2429
Prevalence of, and effect of semaglutide on, features of non-alcoholic steatohepatitis in patients with obesity with and without type 2 diabetes: analysis of data from two randomised placebo-controlled trials using SomaSignal tests
Poster Presentation
Presenter: Jörn Schattenberg

2440
Characterization of the patterns of resolution of histopathology after efruxifermin treatment of patients with NASH fibrosis (F2/3) for 24 weeks
Poster Presentation
Presenter: Cynthia Behling

2539
Endoscopy sleeve gastroplasty is an effective treatment in steatohepatitis patients: a prospective, multicenter, randomized trial
Oral Presentation
Presenter: Javier Abad Guerra

2540
Pemvidutide, a glp-1/glucagon dual receptor agonist, significantly reduces liver fat, fibro-inflammation, and body weight in patients with non-alcoholic fatty liver disease: a 24-week multicenter, randomized, double-blind, placebo-controlled trial
Oral Presentation
Presenter: Stephen Harrison

2581
Fat versus lean tissue loss in short term versus long term weight loss: a dynamic effect with implications for NASH trials
Poster Presentation
Presenter: Lars Johansson

2740
Development of physiologically based pharmacokinetic model to predict liver exposure of SRT-015, a next-generation inhibitor of apoptosis signal-regulating kinase 1
Poster Presentation
Presenter: Artur Plonowski

2881
Serological biomarkers PRO-C3 and PRO-C6 reveal the anti-fibrotic and pro-metabolic effects of MSDC-0602K, an insulin sensitizer, in non-alcoholic steatohepatitis patients during the EMINENCE phase IIb study
Poster Presentation
Presenter: Alejandro Mayorca Guiliani

2932
Different class effects of oral hypoglycemic agents on nonalcoholic fatty liver disease regression and clinical outcomes: a nationwide cohort study
Poster Presentation
Presenter: Heejoon Jang

3023
Similar weight loss with semaglutide regardless of diabetes and cardiometabolic parameters in individuals with non-alcoholic fatty liver disease
Poster Presentation
Presenter: Matthew Armstrong

3376
Comparison of efficacy between liraglutide and phentermine/topiramate in obese patients with nonalcoholic fatty liver disease
Poster Presentation
Presenter: Young Eun Chon

3459
SGLT2 inhibitors improve hepatic fibrosis assessed by Fibroscan in NAFLD patients with type 2 diabetes: a five-year follow-up study
Poster Presentation
Presenter: Rosa Lombardi

3502
Effectiveness of prebiotic treatment in patients with non-alcoholic fatty liver disease (NAFLD) – a randomized trial
Poster Presentation
Presenter: Yaakov Maor

3549
Safety and efficacy of oral semaglutide in overweight diabetic patients with non-alcoholic fatty liver disease: an interim analysis
Poster Presentation
Presenter: Gauri Unithan

3689
Calorie restriction by time restricted intermittent fasting is better than standard calorie restriction in improving the metabolic profile and hepatic fibrosis in patients with non-alcoholic fatty liver disease
Oral Presentation
Presenter: Deepankshi Aggarwal

3743
B-cell activating factor in non-alcoholic steatohepatitis
Poster Presentation
Presenter: Iris Gines Mir

Non-invasive assessment of liver disease except NAFLD

123
Safety and signal intensity of a novel liver-specific MRI contrast agent, Orviglance® (manganese chloride tetrahydrate), in adult subjects with mild, moderate, or severe hepatic impairment
Poster Presentation
Presenter: Andreas Norlin

229
Non-invasive assessment of adult bilirubin based on multispectral reconstruction technology and a smartphone platform
Poster Presentation
Presenter: WenQian Geng

426
Negative and positive predictive values of utilizing a two-stage approach to non-invasive fibrosis testing in patients with hepatitis C virus infection
Poster Presentation
Presenter: Rachel Epstein

Liver elastography is a useful technique to assess the severity of liver congestion in patients with Budd-Chiari syndrome
Poster Presentation
Presenter: MARCOS ANDRES THOMPSON

Screening for hepatic fibrosis in primary care by FIB-4 score, followed in second line f the ELF (enhanced liver fibrosis) test: what are the best thresholds?
Poster Presentation
Presenter: Denis Ouzan

Enhanced detection of cirrhosis and risk of advanced fibrosis with dynamic breath analysis
Poster Presentation
Presenter: Giuseppe Ferrandino

Soluble CD163 as a biomarker of liver fibrosis in liver transplant recipients
Poster Presentation
Presenter: Emilie Høegholm Ernst Lauridsen

Diagnosis and treatment of patients with suspected mucinous cystic neoplasms according to the EASL-guidelines: a retrospective cohort study
Poster Presentation
Presenter: Alicia Furumaya

Liver stiffness can monitor disease severity and changes predict decompensation in alcohol-related liver disease
Poster Presentation
Presenter: Katrine Thorhauge

Hepatobiliary manifestations in pediatric COVID-19
Poster Presentation
Presenter: Tetiana Stoieva
Validation of cut-off values proposed by the society of radiologists in ultrasound liver elastography for diagnosis of compensated advanced chronic liver disease using 2D shear wave elastography
Poster Presentation
Presenter: Ji Hun Kang

Fibrosis-4 score less than 2.67 and normal gamma-glutamyl transferase levels are associated with high negative predictive value for high-risk of liver stiffness in patients with primary biliary cholangitis
Poster Presentation
Presenter: Alan Bonder

Dynamics of liver stiffness measurements provide incremental prognostic information in advanced chronic liver disease
Poster Presentation
Presenter: David JM Bauer

Transient elastography efficiently detects severe fibrosis in patients with chronic hepatitis D
Poster Presentation
Presenter: Dominique Roulot

Hospital discharge after percutaneous liver biopsy – less is more?
Poster Presentation
Presenter: Isabel Garrido

Suitability of Fibroscan, APRI and FIB-4 indexes compared with liver biopsy in the evaluation of liver fibrosis: a single-centre retrospective study
Poster Presentation
Presenter: Alvaro Yagüe

Does methotrexate therapy harm the liver in psoriatic patients?
Poster Presentation
Presenter: Isabel Bessa

Use of magnetic resonance elastography for accurate staging of liver fibrosis in children with autoimmune hepatitis
Poster Presentation
Presenter: Wojciech Janczyk

2545
Performance of the scores diagnosis of autoimmune hepatitis in Moroccan patients
Poster Presentation
Presenter: Sara chbourk

2585
Diagnosis by liver stiffness measurement of sinusoidal obstruction syndrome/veno-occlusive disease after hematopoietic stem cell transplantation: results from the Italian multicentric prospective study (ELASTOVOD)
Oral Presentation
Presenter: Federico Ravaoli

2796
Repeatability of liver stiffness measurement by vibration-controlled transient elastography and controlled attenuation parameter in patients with cirrhosis
Poster Presentation
Presenter: Rohit Loomba

3069
Pattern of transient elastography in Egyptian people living with HIV: predictors of hepatic steatosis and fibrosis
Poster Presentation
Presenter: Ahmed Cordie

3208
Fibrosis-4 index is associated with cardiovascular risk in people living with HIV
Poster Presentation
Presenter: Giulia Morsica

3331
Assessment of international normalized ratio to albumin ratio in predicting mortality in decompensated liver disease at a resource limited medical centre
Poster Presentation
Presenter: Marium Fatima Waqar

3596
Diagnostic accuracy of magnetic resonance elastography, transient elastography and predictive scores in cystic fibrosis related liver steatosis and fibrosis
Poster Presentation
Presenter: Carmen Lara Romero
Liver stiffness measurement Baveno VII rule of 5 and risk of hepatocellular carcinoma after HCV eradication in patients with cirrhosis
Poster Presentation
Presenter: Binu John

Moving toward a more perfect liver function test: the next generation of HepQuant tests
Poster Presentation
Presenter: Michael McRae

Nurses and Allied Health Professionals

Mental health, quality of life, and stigmatization in Danish patients with liver disease
Poster Presentation
Presenter: Nadja Østberg

Analysis of health-related quality of life in the liver transplant patient conducted more than 10 years ago, statewide study
Poster Presentation
Presenter: Fernando García Pérez

Changes in frailty as a predictor of readmission risk in patients with liver cirrhosis. Preliminary results
Poster Presentation
Presenter: Martina Perez

Feasibility of a home-based, virtually-delivered, group exercise intervention in older patients with liver cancer (TELEX-Liver Cancer)
Oral Presentation
Presenter: Kate Hallsworth

Better strategies are needed to increase engagement of patients with cirrhosis with allied health and community services
Poster Presentation
Presenter: Patricia Valery

Who’s testing who? Healthcare professional and patient knowledge of hepatitis delta virus and appropriate testing in an East Midlands hospital
Poster Presentation
Presenter: Rachel Ryder

1514
Quality improvement project: improving early identification of liver disease in diabetic patients in a
district general hospital with opportunistic FibroScan®
Poster Presentation
Presenter: Amy Thatcher

1624
Value based healthcare: patient perception of the liver cancer advanced practice nurse care at the
Barcelona clinic liver cancer
Poster Presentation
Presenter: Neus Llarch

1646
Development of a web-based mobile health application (ReLiver-N App) for patient activation, self-
efficacy, and quality of life in patients with liver cirrhosis
Poster Presentation
Presenter: Ferya Celik

1656
Clinical interdisciplinary development of a home-based enteral nutrition initiation and refeeding
monitoring model of care for patients with chronic liver disease
Poster Presentation
Presenter: Erin Russell

1971
Pharmacist led telemonitoring and titration of carvedilol for ambulatory patients with compensated
cirrhosis and clinically significant portal hypertension
Oral Presentation
Presenter: Eliza Flanagan

2233
Fellowship for hepatology nurses – a new exchange program at Karolinska university hospital
Poster Presentation
Presenter: Pia Loqvist

2381
Refractory ascites in cirrhosis is associated with a major psychological burden in patients with
cirrhosis and caregivers
Oral Presentation
Presenter: Ana Belen Rubio Garcia
2445
Advanced practice nurses’ scope of practice in liver care: evaluation of two different Swiss settings
Poster Presentation
Presenter: Patrizia Kuenzler

2536
Hepatology nursing consultation in a tertiary hospital without liver transplantation: initial experience
Poster Presentation
Presenter: Francisco Jorquera

2603
Hepatitis C education and training for community pharmacists in Ireland
Poster Presentation
Presenter: Miriam Coghlan

2985
Health-related quality of life in a population at-risk of NAFLD or ArLD
Poster Presentation
Presenter: Helle Lindholm Schnefeld

3329
Effectiveness of vaccine education on vaccine awareness and vaccine uptake in patients with cirrhosis of liver of a tertiary care center in South India
Poster Presentation
Presenter: Lt Col (Dr) Ajee K L

3409
Community dispensed hepatitis c virus treatment for 'hard to reach' opiate substitution treatment service users in dublin: an intervention to address hcv infection eradication
Oral Presentation
Presenter: Gillian Farrell

3527
First hepatitis C mass-testing in a category A prison in the United Kingdom
Poster Presentation
Presenter: Alison West

3553
A prospective study to assess medication adherence to systemic therapy among patients with hepatocellular carcinoma
Poster Presentation
Presenter: Suja Kumari
Public Health: Except viral hepatitis

147
Anti-hepatitis B surface antigen negativity can be a risk factor for SARS-CoV-2 infection in SARS-CoV-2 vaccinated healthcare workers
Poster Presentation
Presenter: Tomohide Kurahashi

249
Global, regional, and national burdens of cirrhosis in children and adolescents aged under 19 years from 1990 to 2019: a systematic analysis based on the global burden of disease study 2019
Poster Presentation
Presenter: Chi Zhang

337
Socioeconomic disparities and primary liver cancer incidence between 2006 and 2016: analyze by subtypes, a French population-based study
Oral Presentation
Presenter: Bertille Comoz

437
Socio-economic disparities drive the prevalence of non-alcoholic Fatty Liver Disease (NAFLD) among teenagers in the United States
Poster Presentation
Presenter: Zobair Younossi

613
Identify, screen and treat via electronic pathway (I-STEP): an innovative approach to wait list management for general liver hospital outpatient referrals
Poster Presentation
Presenter: Eliza Flanagan

700
Prevalence and predictors of clinically significant pruritus in patients with non-alcoholic fatty liver disease (NAFLD): data from the global NASH registry™ (GNR™)
Poster Presentation
Presenter: Zobair Younossi

760
Influence of the COVID-19 pandemic on liver cancer-related mortality in the United States
Poster Presentation
Presenter: Zhu Zhan
780
A systematic review of interventions for alcohol use disorder in patients with cirrhosis or alcohol-related hepatitis
Poster Presentation
Presenter: Christopher Oldroyd

833
Increased risk of hepatocellular carcinoma among first-degree relatives of patients with biopsy-proven NAFLD - a multigenerational nationwide cohort study
Oral Presentation
Presenter: Fahim Ebrahimi

1062
Exploring attitudes towards non-invasive liver fibrosis tests in secondary care pathways: comparing national surveys between 2014 and 2021
Poster Presentation
Presenter: Kushala Abeysekera

1164
Global burden of common cancers attributable to metabolic risks from 1990 to 2019
Poster Presentation
Presenter: Qing-Qing Xing

1197
A pilot study to improve the uptake of hepatocellular carcinoma surveillance
Poster Presentation
Presenter: Maria Qurashi

1311
Higher ultra-processed food intake positively associated with non-alcoholic fatty liver disease in both adolescents and adults
Poster Presentation
Presenter: Xuehong Zhang

1320
Vulnerable offspring: a nationwide Danish cohort study of adverse health outcomes in offspring of parents with alcohol-related liver disease compared to controls
Oral Presentation
Presenter: Gro Askgaard

1684
Non-alcoholic fatty liver disease awareness, misperception, and their association with healthcare access in Korean general population: a nationally representative survey
Poster Presentation
Presenter: Jun-Hyuk Lee

1699
Non-alcoholic fatty liver disease prevalence has increased in Australia, particularly amongst women
Poster Presentation
Presenter: Karl Vaz

2347
Multiple vitamin co-exposure and mortality risk in metabolic dysfunction-associated fatty liver disease
Poster Presentation
Presenter: Wang Zilong

2387
Machine learning models are superior to FIB-4 as a first line stratification tool for liver disease in the community
Oral Presentation
Presenter: Huw Pursell

2410
Acceptability and feasibility of a multimodal early detection pilot study for liver disease in high risk groups: “Alright My Liver?”
Poster Presentation
Presenter: Ann Archer

2571
Evidence of significant alcohol-associated mortality in a large population cohort in Uganda
Poster Presentation
Presenter: Cori Campbell

2628
Health economics of the enhanced liver fibrosis test in the detection of advanced liver fibrosis in patients with non-alcoholic fatty liver disease in the UK
Poster Presentation
Presenter: Zobair Younossi

2702
Comparison of the opt in vs opt out policy and its impact on the donation rate of liver transplantation in the Colombian healthcare system
Poster Presentation
Presenter: Andres Gomez Aldana

2711
Socioeconomic disparities and survival in patients with primary liver cancer by subtype: a french population-based study
Poster Presentation
Presenter: Thi Thu Nga Nguyen

2720
Sub-optimal global public health policies and strategies to combat hepatocellular carcinoma
Poster Presentation
Presenter: Luis Antonio Diaz

2884
Healthcare resource use and costs among patients with primary sclerosing cholangitis in Sweden - a retrospective population-based cohort study
Poster Presentation
Presenter: Hannes Hagström

2991
Metabolic dysfunction associated fibrosis-5 (MAF-5) score to identify at-risk liver fibrosis and to predict prognosis in a population-based setting
Oral Presentation
Presenter: Willem Pieter Brouwer

3002
Metabolomic and genomic profiling of alcoholic liver disease and cirrhosis of the liver
Poster Presentation
Presenter: Sini Kerminen

3087
Relationships between education and non-alcoholic fatty liver disease
Poster Presentation
Presenter: Florian Koutny

3454
COVID-19 and excess mortality of patients with liver cancer in France, January 2020 - September 2022
Poster Presentation
Presenter: Stylianos Tzedakis

3497
Detection of potential subjects at risk of liver fibrosis in general population in Spain
Poster Presentation
Presenter: María Del Barrio Azaceta
An explainable artificial intelligence model for prediction of high-risk nonalcoholic steatohepatitis
Poster Presentation
Presenter: Basile Njei

Lifestyle-related population-attributable risk for non-alcoholic fatty liver disease in adolescents and youth
Poster Presentation
Presenter: Vanessa Garcia-Larsen

SIRIUS project: sensing probe exploring liver fibrosis in Slovakia
Poster Presentation
Presenter: Lubomir Skladany

Who is safe from chronic liver disease? A population-based approach for early detection in the US
Oral Presentation
Presenter: Nakia Chung

Impact of coronavirus disease pandemic on hospitalizations due to chronic liver disease in Belgrade, Serbia
Poster Presentation
Presenter: Ivana Pantic

Public Health: Viral hepatitis

Occult hepatitis B virus infection among blood donors in northwestern Greece
Poster Presentation
Presenter: Fotios Fousekis

Hepatitis C seroconversion rates among individuals with repeated testing – Georgia, 2017-2021
Poster Presentation
Presenter: Davit Baliashvili

Micro-elimination of Hepatitis C virus infection in mountainous and remote areas of Taiwan – a multi-center collaborative care model
Poster Presentation
Presenter: Ching-Chu Lo

485
Late presentation of chronic hepatitis C for care in Georgia: data from the national hepatitis C elimination program, 2016-2021
Poster Presentation
Presenter: Tengiz Tsertsvadze

544
Implementation of anti-HDV reflex testing among HBsAg-positive in a tertiary center in South Italy
Poster Presentation
Presenter: Valentina Cossiga

581
Factors associated with HCV reinfection among treated people who inject drugs in the HCV elimination program in Georgia
Poster Presentation
Presenter: Lasha Gulbiani

648
Evaluation of hepatitis B core-related antigen rapid test (HBcrAg-RDT) to identify HBV-infected women eligible for peripartum antiviral prophylaxis in resource-limited countries
Poster Presentation
Presenter: Jeanne Perpétue Vincent

665
Patients with hepatitis B and D are more often linked to medical care than patients with hepatitis C
Poster Presentation
Presenter: Elena Vargas Accarino

708
Burden of hepatitis C in pregnant women and children in the United States
Poster Presentation
Presenter: Paul Wasuwanich

737
HCV screening before endoscopy in hepatogastroenterology outpatient clinic: results of DEPISTC-ENDO study
Poster Presentation
Presenter: André-Jean Remy

745
The impact of hepatitis B and C serologies on the outcomes of non-liver solid organ transplantation
Effectiveness of a direct care action strategy at the drug addiction center (and treat in point of care) for the detection and treatment of hepatitis C in drug users on opioid agonist substitution therapy
Poster Presentation
Presenter: Inés Sáenz de Miera

Screening for hepatitis C virus using rapid diagnostic test (RDT) coupled with mammography in women aged from 50 to 74 years in Montpellier (France). (Mamm’OC NCT05067374)
Poster Presentation
Presenter: Magdalena Meszaros

Improving blood borne virus screening in immigration removal centres in the UK
Poster Presentation
Presenter: Katie Abraham

D-Mongolia: new strategy for hepatitis B, D and C screening and linkage to care in Mongolians living in Spain
Poster Presentation
Presenter: Adriana Palom

Impact of the anti-HDV reflex testing on the reduction of hepatitis D burden in Spain
Poster Presentation
Presenter: Maria Buti

Development of a rapid workflow for detecting HCV RNA from whole blood
Poster Presentation
Presenter: Matthew Pauly

Implementing hepatitis C self-testing (HCVST) among the general population in Georgia: preliminary results
Poster Presentation
Presenter: Ketevan Stvilia
Low prevalence found in HCV micro-elimination program among HIV-negative MSM and TW in a community center in Spain
Poster Presentation
Presenter: Àngel Rivero Calaf

1055
Who is missing? Analysis of the 2021 Georgian seroprevalence survey to identify the population left to be screened for hepatitis C
Poster Presentation
Presenter: Sophia Surguladze

1060
Hepatitis E virus seroprevalence in immunosuppressed patients in Belgium: a prospective study
Poster Presentation
Presenter: Marie Philippart

1082
Retrospective study of hepatitis C virus antibodies and active viral replication in at-risk population with dual diagnosis in a Spanish university hospital
Poster Presentation
Presenter: Cristina del Río-Cubillo

1107
Development of a behaviour-based score predicting hepatocellular carcinoma among patients with chronic hepatitis B virus infection in France (ANRS CO22 HEPATHER)
Oral Presentation
Presenter: Clémence Ramier

1150
Micro-elimination of chronic hepatitis C virus in patients with psychiatric disorders: a multidisciplinary strategy in the outpatient mental health center
Poster Presentation
Presenter: Inés Sáenz de Miera

1183
Engagement of patients with viral hepatitis diagnosed by opt-out universal emergency department testing
Poster Presentation
Presenter: Amy Teague

1199
The impact of hepatitis D virus infection on health-related quality of life and fatigue in patients untreated for HDV: descriptive results from a cross-sectional study across Italy, Germany, Spain and the US
Poster Presentation
Presenter: Pietro Lampertico

1205
Characterization of recent HCV infections and re-infections among the high-risk population from Georgia using global hepatitis outbreak and surveillance technology
Poster Presentation
Presenter: Adam Kotorashvili

1216
Retrospective study of hepatitis C virus antibodies and active viral replication in patients with severe mental illness in a Spanish university hospital
Poster Presentation
Presenter: Cristina del Rio-Cubilledo

1241
Hepatitis D infection in a HBsAg cohorts referred from specialist liver clinics vs. reflex community referred patients in South East London
Poster Presentation
Presenter: Ivana Carey

1271
Late presentation for hepatitis C treatment; prevalence and risk factors in the Swiss hepatitis C cohort
Poster Presentation
Presenter: Nathalie Brunner

1288
Low HBV treatment uptake among Rwandan people with HIV and HCV co-infections: a cohort study from 2016-2019
Poster Presentation
Presenter: Makuza Jean Damascene

1291
Prevalence of chronic hepatitis C on the Swiss organ transplantation list from 2009-2019
Poster Presentation
Presenter: Philip Bruggmann

1302
New and easy strategy for mass screening for hepatitis C in leisure spaces
Poster Presentation
Presenter: Sonia Albertos Rubio
1576
The impact of removing all hepatitis B virus (HBV) testing and treatment restrictions
Poster Presentation
Presenter: Homie Razavi

1614
Simple treatment eligibility score for chronic HBV infection at peripheral health facilities in sub-Saharan Africa
Poster Presentation
Presenter: Nicolas MINIER

1788
Incidence of hepatitis C virus antibody seroconversion among people who inject drugs in Tbilisi, Georgia
Poster Presentation
Presenter: Tengiz Tsertsvadze

1799
Are primary healthcare facilities ready to provide hepatitis delta services in Mongolia: service availability and readiness assessment findings
Poster Presentation
Presenter: Azzaya Oktyabri

1812
Prevalence and incidence of delta hepatitis in HIV-HBV coinfected patients in the Dat’AIDS cohort
Poster Presentation
Presenter: Dulce Alfaiate

1819
Spontaneous clearance of hepatitis C virus infection in the country of Georgia, 2015-2021
Poster Presentation
Presenter: George Kamkamidze

1820
Hepatitis C screening and elimination strategy: implementation of the FOCUS program in Almería, Spain
Poster Presentation
Presenter: Marta Casado

1829
Opt-out testing for hepatitis B and C infections in adults attending the emergency department of a London Hospital
Poster Presentation
Presenter: Jingwei Zeng
1925
Cascade of care among people with an HBV notification in New South Wales, Australia, including diagnosis, specialist assessment, and treatment uptake
Poster Presentation
Presenter: Syed Hassan Bin Usman Shah

1993
Zero-HCV before end stage renal disease (ESRD): a collaborative “treat-all” approach to eliminate HCV in chronic kidney disease population in Taiwan
Poster Presentation
Presenter: Tsung-Hui Hu

1996
Characterizing individuals who remain to be screened and those lost to follow-up from Georgia’s HCV elimination program
Poster Presentation
Presenter: Sophia Surguladze

1997
HCV screening automation at hospitals level based on extrahepatic manifestations and risk profile. Preliminary results from the Hospitals without C programme (hospitales sin C)
Poster Presentation
Presenter: ANTONIO GARCIA HEROLA

1999
Tailored message intervention by nudge theory increases the number of the viral hepatitis screening for Japanese workers and consultation behavior of positive patients - Consideration of 1.7 million general check-up participants
Poster Presentation
Presenter: Masaaki Korenaga

2095
Progress in hepatitis C screening as part of the hepatitis C elimination program in Georgia
Poster Presentation
Presenter: Maia Tsereteli

2114
Innovation linkage model to re-engage lost-to-follow-up individuals in the national hepatitis C elimination program in Georgia
Poster Presentation
Presenter: Vladimer Getia
Screening, confirmation, and treatment rates of hepatitis C virus infections in patients undergoing surgery in a single tertiary academic centre
Poster Presentation
Presenter: Jae Seung Lee

What is the most effective strategy to identify HBV-infected pregnant women eligible for antiviral prophylaxis in Burkina Faso? A modelling study on different testing strategies
Poster Presentation
Presenter: Andréa Gosset

Effectiveness of birth-dose vaccine in preventing mother-to-child transmission of hepatitis B virus in Ethiopia
Poster Presentation
Presenter: Mebrihit Arefaine

Patients with persistently abnormal liver biochemistry are under-investigated and can be rapidly identified using a novel case-finding database
Poster Presentation
Presenter: Almuthana Mohamed

One step closer to the goal: mobile InfoHep centre offering detection, protection, prevention and treatment / linkage-to care services in Croatian penalty institutions
Poster Presentation
Presenter: Tatjana Reic

Hepatitis B, C and D infections among nine high-risk populations in Burkina Faso, West Africa
Poster Presentation
Presenter: Armel Moumouni SANOU

Risk of developing cancer - comparison of HBV, HCV and smoking
Poster Presentation
Presenter: Homie Razavi

Complete and maintained elimination of hepatitis C in patients in methadone substitution program
Poster Presentation
Presenter: Esther Rodríguez Candelaria
Final results of a hepatitis C micro-elimination campaign in a highly endemic, well-defined demographic area of peri-urban Karachi, Pakistan
Presenter: Saeed Sadiq Hamid

Hepatocellular carcinoma associated with chronic hepatitis C: a case for an annual mortality and morbidity review
Presenter: Neil McInnes

The impact of Covid-19 on hepatocellular carcinoma screening in British Columbia
Presenter: Makuza Jean Damascene

Exploring the impacts of the COVID-19 pandemic on access to HCV-related care and support: findings from a survey of people with lived experience of incarceration and/or substance use in British Columbia, Canada
Presenter: Terri Buller-Taylor

Chronic hepatitis B virus infection and risk of stroke types: a prospective cohort study of 0.5 million Chinese adults
Presenter: Elizabeth Hamilton

Reimplementation of a revamped cost-effective national elimination strategy is the only way Brazil moves towards eliminating HCV
Presenter: Alexis Voeller

New tools reaching hepatitis C elimination: automatic hepatitis C virus detection in presurgical evaluations
Presenter: MARINA ELIANA MILLAN LORENZO
Late diagnosis of hepatitis C in Quebec, Canada, 1990-2018: a population-based study
Poster Presentation
Presenter: Ana Maria Passos-Castilho

Metabolic–associated fatty liver disease in socio-economic vulnerable population with chronic hepatitis B and C
Poster Presentation
Presenter: Speranta Iacob

Acceptance and feasibility of hepatitis C screening by assisted self-testing in high-risk and general population: a randomized clinical trial
Poster Presentation
Presenter: Federica Benitez Zafra

Influence of language barrier and cultural differences in hepatitis B disease knowledge in the chinese community of Barcelona
Poster Presentation
Presenter: Anna Pocurull

Cantabria on the way to HCV elimination. Differential prevalence of hepatitis C in Cantabria: @CohorteCantabria vs ETHON cohort
Poster Presentation
Presenter: Joaquin Cabezas

Survey to evaluate the implementation of the recommendations on the comprehensive diagnosis of viral hepatitis in a single extraction: where are we?
Poster Presentation
Presenter: Joaquin Cabezas

The evaluation of people suspected of sexually transmitted diseases requires tools for the comprehensive diagnosis of viral hepatitis and HIV
Poster Presentation
Presenter: Joaquin Cabezas

Impact of hepatitis B family screening, counselling and education program on active case detection: a step towards elimination through preventive hepatology clinic in India
2816
Prevalence of hepatitis B and C viral infections among transgenders and men who have sex with men in Pakistan
Poster Presentation
Presenter: Hassan Mahmood

2822
Strategies to eliminate hepatitis C virus infection in the Americas
Poster Presentation
Presenter: Luis Antonio Diaz

2844
Comparison of HCVRNA results using plasma separation card with gold standard veni-puncture
Poster Presentation
Presenter: Huma Qureshi

2847
Pandemic preparedness and viral hepatitis - Global survey of hepatitis program managers and healthcare providers
Poster Presentation
Presenter: Nida Ali

2981
New hepatitis C diagnoses in 2022. Who and where. Referral efficiency
Poster Presentation
Presenter: Cristina Suárez Montesdeoca

3028
Low coverage of hepatitis D virus testing in individuals with HIV and HBV in the Netherlands: a retrospective, cross-sectional and longitudinal study
Poster Presentation
Presenter: Anders Boyd

3058
The impact of hepatitis C and socio-demographic variables on Health-related quality of life among patients in Pakistan
Poster Presentation
Presenter: Siwaporn Niyomsri

3071
A nationwide study on the core indicators related to elimination of viral hepatitis B and C in Korea
Poster Presentation
Presenter: In Hee Kim

3081
HCV elimination in persons living with HIV (PLWH): the NoCo (No-Coinfection) study of the ICONA network
Poster Presentation
Presenter: Massimo Puoti

3093
Qualitative interviews to assess the impact of chronic hepatitis delta virus infection on health-related quality of life in untreated patients from the US, Italy, Spain, and Germany
Poster Presentation
Presenter: Pietro Lampertico

3105
Cost-effectiveness analysis of a new paradigm to simplify testing, monitoring and treatment of hepatitis C virus in the United States
Poster Presentation
Presenter: Douglas T Dieterich

3131
Results from a community-based intervention to increase viral hepatitis screening among at-risk African migrants in Catalonia, Spain (2020-2022)
Poster Presentation
Presenter: Camila Picchio

3168
An international coalition to eliminate hepatitis B virus (ICE-HBV) survey confirms inadequate HBV/HDV screening and diagnosis diminishing elimination targets in resource limited settings
Poster Presentation
Presenter: Daryl Lau

3305
Tenofovir prophylaxis during pregnancy for the elimination of mother-to-child transmission of hepatitis B virus: a cost-effectiveness analysis
Poster Presentation
Presenter: Pisit Tangkijvanich

3306
Care cascade for children with hepatitis C virus exposure in the United States and implications of early ribonucleic acid testing
Poster Presentation
Presenter: Megan Curtis

3308
A territory-wide opportunistic, hospital-based HCV screening in the general population from northern Italy: the 1969-1989 birth-cohort
Poster Presentation
Presenter: Roberta D'Ambrosio

3328
Hepatitis delta virus infection in Turkey: A meta analysis of prevalence
Poster Presentation
Presenter: Mehlika Toy

3334
Finding undiagnosed hepatitis C cases: using machine learning to identify clinical attributes and social determinants of health to improve the screening-to-diagnosis ratio and improve efficiency and linkage to care
Oral Presentation
Presenter: Linda Chen

3428
Population adjusted prevalence of hepatitis delta virus in 21 countries and territories
Poster Presentation
Presenter: Devin Razavi-Shearer

3457
Trends in hepatitis B and hepatitis C related hepatocellular carcinoma, 2015 to 2030
Poster Presentation
Presenter: Devin Razavi-Shearer

3474
Policy and implementation needs for hepatitis B birth dose in the WHO African region: a survey of national program managers
Poster Presentation
Presenter: Henry Njuguna

3514
Hepatitis C screening program in Lithuania: first results and scenarios for virus elimination
Poster Presentation
Presenter: Limas Kupcinskas

3526
A modelling study of the impact of scaling up of HCV case finding and treatment for people who inject drugs in English region of Bristol and Severn
Poster Presentation
Presenter: Zoe Ward

3529
The first mass reactive vaccination campaign against hepatitis E in Bentiu, South Sudan: feasibility, vaccination coverage and two-dose vaccine effectiveness
Oral Presentation
Presenter: Iza Ciglemecki

3546
Challenges and strategies to improve linkage to care and treatment for hepatitis C in pregnancy: perspectives from a global community of practice
Poster Presentation
Presenter: Neil Gupta

3558
Hepatitis C seroprevalence screening and linkage to care of unknown infected patients admitted to a tertiary care emergency department: on the road to achieve the WHO 2030 virus elimination target
Poster Presentation
Presenter: Roberta Lasco

3565
Estimation of prevalence of chronic HCV infection in EU/EEA countries using multiparameter evidence synthesis
Poster Presentation
Presenter: Georgios Nikolopoulos

3578
Estimating the economic value allocation of the social surplus generated by the utilization of second-generation direct-acting antivirals for hepatitis C in the United States, 2015-2019
Poster Presentation
Presenter: Jens Grueger

3611
Multidisciplinary approaches to increase hepatitis C screening rates in a New York City primary care clinic
Poster Presentation
Presenter: Carolina Villarroel

3612
Microbiological analysis of acute hepatitis of unknown aetiology in children in Spain
Poster Presentation
3698
Consider schistosomiasis screening in hepatitis B patients from endemic regions: a hepatic comorbidity that should not be neglected
Poster Presentation
Presenter: Ana Avellon Calvo

3727
Sofosbuvir/Velpatasvir (S/V) for the treatment of HCV infection among vulnerable inner-city residents: extending the results of clinical trial part 2
Poster Presentation
Presenter: Marie-Noëlle Hilleret

3741
Cascade of care and HCV treatment of inner city populations engaged in care through community pop-up clinics (CPCs)
Poster Presentation
Presenter: Brian CONWAY

3786
Health outcomes of hepatitis C direct-acting antivirals: beyond real life sustained viral response data
Poster Presentation
Presenter: Carmen Alonso Martin

3799
Estimating the residual risk of hepatitis B mother-to-child transmission in The Gambia, 30 years after HBV vaccine implementation
Oral Presentation
Presenter: Rohey Bangura

3807
Automation of hepatitis C screening through electronic health record algorithm
Poster Presentation
Presenter: Vítor Magno Pereira

3822
Emergency department contribution to hepatitis C elimination through opportunistic screening in Cascais, Portugal
Poster Presentation
Presenter: Inês Vaz Pinto
Treatment start resilience but testing decrement in a coordinated statewide HCV treatment program during COVID: lessons learned and future steps
Poster Presentation
Presenter: Yvonne Lynch-Hill

Rare liver diseases (including paediatric and genetic)

38
Effects of tetrathiomolybdate, trientine, and penicillamine on intestinal copper uptake: a randomized placebo-controlled 64Cu PET/CT study
Poster Presentation
Presenter: Frederik Teicher Kirk

40
Understanding the experience of patients with alpha-1 antitrypsin deficiency (AATD)-associated liver disease
Poster Presentation
Presenter: Virginia Clark

41
Differences in the rates of liver-related clinical events in paediatric patients with alpha-1 antitrypsin deficiency-associated liver disease in the United States
Poster Presentation
Presenter: Ed G. Marins

47
Final results from a phase 1/2, 48-month, open-label extension study of givosiran in patients with acute intermittent porphyria
Oral Presentation
Presenter: Eliane Sardh

60
Clinical characteristics and pathogenic mechanism of five new ABCB4 missense mutations in progressive familial intrahepatic cholestasis type 3
Poster Presentation
Presenter: yuhang weng

142
Effects of tetrathiomolybdate on copper distribution and biliary excretion: a controlled 64CuCl2 PET/MRI
Poster Presentation
Presenter: Frederik Teicher Kirk
268
Liver transplantation for Wilson disease: single center experience
Poster Presentation
Presenter: amnah Alhanaee

287
Poster Presentation
Presenter: Lorenz Michael Pammer

303
Targeting CCL24 in primary sclerosing cholangitis with CM101: rationale and study design
Poster Presentation
Presenter: Douglas Thorburn

370
Does earlier introduction of azathioprine result in a reduced cumulative dose of corticosteroid therapy in the treatment of autoimmune hepatitis (AIH) and does this result in the same degree of biochemical response?
Poster Presentation
Presenter: Sital Shah

396
Impact of suffering Wilson disease in Spain: an observational cross-sectional multicenter study
Poster Presentation
Presenter: Zoe Mariño

475
Association of circulating Z-polymer with adverse clinical outcomes and liver fibrosis in adults with the PiZZ alpha-1 antitrypsin deficiency genotype
Poster Presentation
Presenter: Malin Fromme

507
Performance of spleen stiffness measurement by vibration-controlled transient elastography to rule out high-risk varices in patients with porto-sinusoidal vascular disorder
Oral Presentation
Presenter: Lucile Moga

530
The ancestral haplotype HLA-A3 does not influence the likelihood of advanced hepatic fibrosis or cirrhosis in C282Y homozygous hemochromatosis
Poster Presentation
534
Extrahepatic iron loading and disease complications in HFE haemochromatosis
Poster Presentation
Presenter: John Olynyk

664
Identification of correctors for traffic-defective ABCB4 variants by a high-throughput screening approach
Poster Presentation
Presenter: Mounia Lakli

712
Human cytomegalovirus (HCMV) infection of macrophages induced abnormal development of cholangiocytes in an organoid co-culture model for biliary atresia
Poster Presentation
Presenter: Syed Mushfiqur Rahaman

763
Albumin levels are associated with portal hypertension in patients with porto sinusoidal vascular disorder
Poster Presentation
Presenter: Lucia Lapenna

765
Role of gut-derived endotoxins in porto-sinusoidal vascular disease
Poster Presentation
Presenter: Stefania Gioia

834
Fazirsiran reduces liver Z-alpha-1 antitrypsin synthesis, decreases globule burden and improves histological measures of liver disease in adults with alpha-1 antitrypsin deficiency: a randomized placebo-controlled phase 2 study
Oral Presentation
Presenter: Virginia Clark

856
Quality of life in patients with Wilson disease treated with Trientine dihydrochloride: a prospective study
Poster Presentation
Presenter: Karl Heinz Weiss
Four-fold increased mortality rate in patients with Wilson’s disease: a population-based cohort study of 151 patients
Poster Presentation
Presenter: Hannes Hagström

Recent splanchnic vein thrombosis occurring during Sars-Cov-2 infection – The VALDIG study
Poster Presentation
Presenter: Pierre Deltenre

Liver-related clinical events among adult patients with alpha-1 antitrypsin deficiency-associated liver disease: a longitudinal retrospective study using linked insurance claims data and electronic medical records in the United States
Poster Presentation
Presenter: Ed G. Marins

Efficacy and safety outcomes with odevixibat treatment: Pooled data from the phase 3 ASSERT and ASSERT-EXT studies in patients with Alagille syndrome
Poster Presentation
Presenter: Madeleine Aumar

Transcriptomic analysis of biliary atresia finds ongoing hepatic hematopoiesis with elevated IGF2
Poster Presentation
Presenter: Jake Mann

Common, non-pathogenic variants in genes from monogenic disorders confer additional risk of liver injury later in life
Poster Presentation
Presenter: Jake Mann

Deep learning quantification reveals fundamental prognostic role for ductular reaction in biliary atresia
Poster Presentation
Presenter: Iiris Nyholm

Long-term efficacy and safety of odevixibat in patients with progressive familial intrahepatic cholestasis: results with 96 weeks or more of treatment
1017
Odevixibat therapy following liver transplantation in patients with FIC1-deficient progressive familial intrahepatic cholestasis: a retrospective case series
Poster Presentation
Presenter: Ekkehard Sturm

1031
Outcomes in adult patients with progressive familial intrahepatic cholestasis treated with odevixibat: subgroup analysis from the PEDFIC 2 study
Poster Presentation
Presenter: Georg-Friedrich Vogel

1039
Real-world experience of Odevixibat in adults with genetic disorders of cholestasis
Poster Presentation
Presenter: Janis M. Stoll

1052
Porto sinusoidal vascular liver disorder: natural history and long-term outcome
Oral Presentation
Presenter: Marta Magaz

1067
Evaluating pruritus and fatigue in patients with treatment-refractory primary biliary cholangitis
Poster Presentation
Presenter: Marwan Sleiman

1159
Long-term outcomes of patients with Wilson disease: a single center analysis of 361 Korean patients
Poster Presentation
Presenter: Hyo Jin Nam

1190
ARBM-101 as an emerging potent therapeutic option for Wilson disease
Poster Presentation
Presenter: Hans Zischka

1200
In vivo adenine base editing reverts C282Y in an HFE- mouse model and improves iron metabolism
Poster Presentation
1257
Main clinical characteristics and evolutionary events among patients suffering Wilson disease in Spain: first results from the Spanish Wilson registry
Poster Presentation
Presenter: Zoe Mariño

1261
The impact of a complete biochemical response on health-related quality of life in patients with autoimmune hepatitis: a multicentre prospective cross-sectional study
Poster Presentation
Presenter: Romée Snijders

1262
Ultrasonographic liver characteristics among patients with Wilson disease
Poster Presentation
Presenter: Zoe Mariño

1294
Clinical features, histology and outcome of pediatric porto-sinusoidal vascular disease
Poster Presentation
Presenter: Angelo Di Giorgio

1323
Odevixibat therapy in patients with MYO5B mutations: a retrospective case series
Poster Presentation
Presenter: Emmanuel Gonzalès

1325
Inhibition of the renal apical sodium-dependent bile acid transporter prevents cholemic nephropathy
Poster Presentation
Presenter: Ahmed Ghallab

1345
Serum bile acids are associated with native liver survival in patients with Alagille syndrome: results from the GALA study group
Poster Presentation
Presenter: Carla Fiorella Murillo Perez

1383
High-dose oral thiamine was not superior to placebo in reducing fatigue in patients with primary biliary cholangitis: a randomised, double-blinded, placebo-controlled crossover trial
1401
Alpha-1 antitrypsin inclusions sequester 78 kDa glucose-regulated protein in a bile-acid inducible manner
Presenter: Palle Bager

1447
Human induced pluripotent stem cells-derived hepatocytes: a very effective tool for functional studies of rare liver diseases
Presenter: Igor Spivak

1471
Cancer incidence and survival in HFE hemochromatosis – A population-based cohort study
Presenter: Benedetta Blarasin

1492
Symptom severity measured by polycystic liver disease-specific questionnaire score partly correlates with both total number of liver cysts and the presence of dominant cysts
Presenter: Avisnata Das

1509
Patient experience with acute hepatic porphyria before and after long-term givosiran treatment: a qualitative interview study
Presenter: Stephen Lombardelli

1511
Analysis of long-term treatment effects of odevixibat on clinical outcomes in children with progressive familial intrahepatic cholestasis in odevixibat clinical studies vs external controls from the NAPPED database
Presenter: Bettina Hansen

1579
The non-invasive evaluation of vascular liver disease in patients with cystic fibrosis: a prospective cross-sectional study
Presenter: Elton Dajti
Clinical features of portal hypertension and their prognostic implication in patients with Wilson’s disease
Poster Presentation
Presenter: Lukas Burghart

Deep tissue exposure of antibiotics at the target site of infection in patients with cystic liver disease: a randomized pharmacokinetic trial
Poster Presentation
Presenter: Marten A. Lantinga

Novel pathogenic ABCC2 variants identified in patients with Dubin-Johnson syndrome and further functional evidence in abnormal bilirubin metabolism
Poster Presentation
Presenter: Wenting Tan

Metabolomic profiles facilitate differential diagnosis of porto-sinusoidal vascular disorder versus liver cirrhosis
Poster Presentation
Presenter: Bernhard Scheiner

Intrahepatic cholestasis of pregnancy: genetic testing and genotype-phenotype relations in a cohort from a Danish tertiary liver center
Poster Presentation
Presenter: Henning Grønbæk

Acute liver failure due neonatal hemochromatosis: case with fatal outcome despite early diagnosis and treatment
Poster Presentation
Presenter: LIUDMYLA SHOSTAKOVYCH

Exploring pregnancy, breastfeeding and contraception among women with Wilson disease in Spain: results from the Spanish Wilson registry
Poster Presentation
Presenter: Zoe Mariño
1853
Hepatobiliary malignancies in Wilson Disease: data from an Italian national reference centre
Poster Presentation
Presenter: Lorenzo Canova

1911
Demographics, outcomes, and costs of Wilson’s disease hospitalizations: a nationwide cohort study
Poster Presentation
Presenter: Ankoor Patel

1956
Rescue of PKU disease phenotype using hepatic progenitor by cytosine base editor and prime editor in vitro
Poster Presentation
Presenter: Myounghoi Kim

2083
Longitudinal assessment of gut microbiota, metabolome and intestinal barrier dysfunction in biliary atresia
Poster Presentation
Presenter: Vandana Jain

2102
Endogenous ethanol production in biliary atresia and its association with clinical outcomes, liver disease severity, fibrosis, bacterial translocation and intestinal permeability
Poster Presentation
Presenter: Vandana Jain

2152
CD73high biliary tract cancer (BTC): a molecularly-defined subtype with distinct clinical implications
Poster Presentation
Presenter: pietro carotenuto

2212
Longitudinal assessment of plasma immune and bacterial translocation markers in biliary atresia
Poster Presentation
Presenter: Vandana Jain

2305
Efficacy and safety of tiomolibdate choline versus standard of care in patients with Wilson disease with and without compensated cirrhosis: sub-analysis of an ongoing phase 3, randomized, controlled study
Poster Presentation
Presenter: Aftab Ala
Impact of extrahepatic portal vein obstruction on fertility and pregnancy outcomes - a tertiary center experience
Poster Presentation
Presenter: Ankita Singh

Efficacy and safety of tiomolibdate choline in patients with an incomplete or intolerant response to prior Wilson disease therapy: subgroup analysis of the phase 3 FoCus trial
Poster Presentation
Presenter: Karl Heinz Weiss

Immune cell incompetence and hepatocyte differentiation defects explain mild fibrosis in a model of Alagille syndrome
Poster Presentation
Presenter: Jan Mašek

Immortalized patient-derived cell models for analysis of liver disease
Poster Presentation
Presenter: Matthias Weiand

Role of transient elastography to identify Fontan-associated liver disease (FALD) and novel risk-score to predict failing Fontan
Poster Presentation
Presenter: Luisa Cavalletto

Endoscopic ultrasound direct portal pressure measurement in patients with porto-sinusoidal vascular disorder and clinically significant portal hypertension: a comparison with hepatic venous pressure gradient measurement
Poster Presentation
Presenter: Lucia Giuli

Blood markers of immune activation help distinguish paediatric activated T-cell hepatitis from other causes
Poster Presentation
Presenter: Tamir Diamond
2517
SARS-CoV-2 productively infects human hepatocytes and induces cell death
Poster Presentation
Presenter: Cho-Chin Cheng

2522
First nationwide genetic study on Wilson disease (Spanish Wilson registry): high diversity in mutations and in use of genetic evaluation, association with clinical data and influence on diagnosis and health costs
Poster Presentation
Presenter: Pablo Alonso Castellano

2538
Beneficial effect of cystic fibrosis transmembrane conductance regulator modulators on adults with cystic fibrosis liver disease
Poster Presentation
Presenter: Alexandra Alexopoulou

2586
Alkaline phosphatase on admission to the intensive care unit as a new early prognostic biomarker for the development of COVID-19-associated secondary sclerosing cholangitis
Poster Presentation
Presenter: Schmid Stephan

2639
High diagnostic uptake of a targeted panel sequencing in adult patients with chronic hereditary liver disorders
Poster Presentation
Presenter: Luisa Ronzoni

2690
Efficacy and safety of vaccination against SARS-CoV-2 in patients with vascular liver disease
Poster Presentation
Presenter: Valeria Perez-Campuzano

2714
The adequacy and safety of liver biopsy performed during cardiac catheterization in patients with Fontan and non-Fontan heart disease
Poster Presentation
Presenter: Edward Cytryn

2736
Association of liver injury and prognosis in patients with severe fever with thrombocytopenia syndrome
2766
Characterizing the role of human cytomegalovirus infection associated with biliary atresia
Poster Presentation
Presenter: Rui Huang

2809
Digital pathology using stain-free imaging indices as a tool for fibrosis quantification in patients with congestive hepatopathy
Poster Presentation
Presenter: Allen KL Cheung

2818
Proteomics for the study of biomarkers in Wilson's disease
Poster Presentation
Presenter: Matthew Yeh

2900
Risk of cirrhosis and hepatocellular carcinoma in hemochromatosis: a Swedish nationwide cohort study
Poster Presentation
Presenter: Hanne Åström

2921
Impact of alcohol consumption on the liver phenotype in alpha-1 antitrypsin deficiency
Poster Presentation
Presenter: Malin Fromme

2936
Bacterial vesicles associated virulence factors and epitope mimics in autoimmune hepatitis patients
Poster Presentation
Presenter: SWATI THANGARIYAL

3011
Lessons from population genomics for Wilson disease: Prevalence, penetrance of mutations, clinical implications and design of regional screening programmes
Poster Presentation
Presenter: Pablo Alonso Castellano

3014
Schistosoma mansoni infection-associated oxidative stress triggers hepatocellular proliferation
Poster Presentation
Presenter: Verena von Buelow

3050
Online education yields significant gains in gastroenterologists’ knowledge of clinical manifestations of Wilson disease
Poster Presentation
Presenter: Sukhbir Bahra

3109
CRISPR/Cas9-mediated gene correction of Wilson disease H1069Q mutation in an iPS cell model
Poster Presentation
Presenter: Vanessa Sandfort

3155
Genetic findings and magnetic resonance imaging of multiple biliary hamartomas
Poster Presentation
Presenter: Juliana Goediker

3225
Ancillary diagnostic biomarkers in autoimmune hepatitis
Poster Presentation
Presenter: Chhagan Bihari

3281
Progressive familial intrahepatic cholestasis: KFSH & RC
Poster Presentation
Presenter: Muath Najmi

3337
A longitudinal study of epidemiology and treatment management of Wilson disease in France based on the French national claims database SNDS
Poster Presentation
Presenter: Jean Philippe Combal

3382
Current transition management of adolescents and young adults with liver diseases: an European reference network rare liver survey
Poster Presentation
Presenter: Joao Madaleno

3392
Phytoestrogens as a possible hidden driver of cysts proliferation in polycystic liver disease in men and women after menopause
Poster Presentation
Presenter: Miki Scaravaglio

3437
Performance of blood based non-invasive tests for liver fibrosis prediction by transient elastography in Alpha-1 antitrypsin deficiency
Poster Presentation
Presenter: Hassaan Yousuf

3471
Genetic modifiers of liver phenotypes in pediatric Wilson disease: liver biopsy and transient elastography based study
Poster Presentation
Presenter: Marcin Krawczyk

3541
Biliary atresia human cholangiocyte organoids demonstrate increased oxidative stress response
Poster Presentation
Presenter: yara hamody

3563
Modeling Alagille syndrome in vitro using complex induced pluripotent stem cell-derived human liver organoids
Poster Presentation
Presenter: Massimiliano Paganelli

3627
Clinical picture of acute hepatitis in children - single center observations
Poster Presentation
Presenter: Anna Mania

3647
Trans-jugular intrahepatic Porto-systemic shunt for Budd Chiari syndrome: single center experience
Poster Presentation
Presenter: amnah Alhanaee

3661
State of knowledge of alpha 1 anti-trypsin deficiency among practitioners specialized in liver transplantation in France: a national survey
Poster Presentation
Presenter: Manon Evain
3739
Alpha-1 antitrypsin deficiency is underdiagnosed in cirrhotic liver transplant patients: a retrospective multicenter study
Poster Presentation
Presenter: Manon Evain

3753
Surveillance of cystic echinococcosis in France: report of the first 103 cases from the French observatory OFREKYS
Poster Presentation
Presenter: Solange BRESSON-HADNI

3765
Emphysematous pancreatitis: a sporadic sequela of necrotizing pancreatic infections
Poster Presentation
Presenter: Audrey Fonkam

3773
Hepatic alterations in COVID-19: a comparative autopsy study
Poster Presentation
Presenter: Sigurd Lax

3793
Chronic hepatitis B infection and porto-sinusoidal vascular disorder, a non-negligible coexistence
Poster Presentation
Presenter: Pol Olivas Alberch

3813
Myeloproliferative neoplasms and splanchnic vein thrombosis: results of a long-term UK prospective cohort study
Poster Presentation
Presenter: Rupen Hargreaves

3857
Monitoring, dosing and clinical outcomes of CFTR modulator triple combination therapy in children with CF post liver transplantation
Poster Presentation
Presenter: Daniel Leung

Viral Hepatitis: Experimental and pathophysiology

927
Chimeric bio-nanoparticles induce targeted HBeAg seroclearance in a HBV hydrodynamic injection mouse model
Poster Presentation
Presenter: Peter Revill

956
The TLR8 agonist Selgantolimod modulates Kupffer cell differentiation status and indirectly impairs HBV entry into hepatocytes via an IL-6-dependent mechanism
Poster Presentation
Presenter: Armando Andres Soares

1072
COVID-19 vaccination alters NK cell dynamics and transiently reduces HBsAg titers among patients with chronic hepatitis B
Poster Presentation
Presenter: Hyunjae Shin

1118
Rat hepatitis E virus infection in a rat model has multiphasic viral replication kinetics
Poster Presentation
Presenter: Harel Dahari

1121
Intrahepatic characterization of virological and immunological markers in two distinct populations of chronic hepatitis B: baseline assessment of core liver and fine needle aspiration biopsies from the investigational INSIGHT study
Poster Presentation
Presenter: Pietro Lampertico

1242
(N)one size fits all: Genotype-matched analysis of different disease phases of chronic hepatitis B virus infection
Poster Presentation
Presenter: Michael Basic

1268
Automated high-throughput image-based screen discovers members of the Akt serine/threonine kinase family as potential targets for treatment of hepatitis E virus infection
Poster Presentation
Presenter: Mara Klöhn

1280
A PKA-associated liver-tissue rheostat curbs T cell receptor signalling and effector function of virus-specific CD8 T cells in chronic viral hepatitis
Oral Presentation
Presenter: Miriam Bosch

1285
Intrahepatic CD8+ T cells correlate with significant declines in HBV viral load and S antigen following a single vaccination with VRON-0200 in an AAV mouse model
Poster Presentation
Presenter: Hildegund Ertl

1334
Pharmacodynamic durability of ALG-125755, a GalNAc-conjugated siRNA, correlated with total and RNA induced complex (RISC) bound siRNA in mouse liver
Poster Presentation
Presenter: Kusum Gupta

1406
HBsAg level defines different clinical phenotypes of chronic HBV infection eAg(-) related to the quality of the HBV-specific CD8 cell response
Poster Presentation
Presenter: Henar Calvo Sánchez

1489
The hepatitis E virus ORF2 protein forms amyloid-like protein aggregates which may be pathogenic in human neurons
Poster Presentation
Presenter: Jungen Hu

1553
RBD1016 – a novel anti-HBV GalNAc-siRNA drug resulted in sustained HBsAg reduction and seroconversion in mice models
Poster Presentation
Presenter: Li Ming Gan

1653
Identification of resistance-associated variants after sofosbuvir treatment in chronic hepatitis E patients
Poster Presentation
Presenter: Andre Gömer

1880
Hepatitis B pre-genomic RNA level has a prospective supporting role for predicting the outcomes of the hepatitis B virus inactive carrier phase
Poster Presentation
Presenter: Prooksa Ananchuensook
An in vivo duck hepatitis B virus model recapitulates key aspects of nucleic acid polymer treatment outcomes in chronic hepatitis B patients
Poster Presentation
Presenter: Yannick Debing

Epigenetic modulation by DNA methyltransferase inhibition may enhance the effect of immune checkpoint inhibitors to restore HBV-specific T cell responses
Poster Presentation
Presenter: Melanie Urbanek-Quaing

Hepatitis B virus infected hepatocytes are resistant to cell death induction by virus-specific T cells
Poster Presentation
Presenter: Emely Springer

HBsAg kinetics at month 9 after analogue treatment discontinuation in chronic hepatitis B eAg(-) predicts long-term HBV control
Poster Presentation
Presenter: Henar Calvo Sánchez

Rapid functional secretome analysis of HBV-specific T cells to guide clinical management of CHB patients
Poster Presentation
Presenter: Nina Le Bert

Detection and functional analysis of HBV-specific stem cell memory T cells (Tscm)
Poster Presentation
Presenter: Hiromi Abe-Chayama

Quadruple mutation GCAC1809-1812TTCT leads to a better prognosis by decreasing HBV-mediated fibrogenic activity
Poster Presentation
Presenter: Esra Görgülü

A novel imaging approach to investigate hepatitis E virus entry
2219
Identification and functional analysis of miR-4461 associated with hepatitis B-derived hepatocellular carcinomas
Poster Presentation
Presenter: Masaya Sugiyama

2363
Nucleotide analogue therapy does not reverse the hyperexpression of innate-like markers on activated T cells consistent with immunopathology in chronic hepatitis B
Poster Presentation
Presenter: Lung Yi Loey Mak

2420
CTLA4 inhibits anti-HBs secretion by blocking BCR signaling pathway in chronic hepatitis B infection
Poster Presentation
Presenter: Minxin Mao

2437
Reduced hepatic bile acid uptake and blocked hepatitis B viral infection after oral administration of novel small molecule inhibitors of the sodium taurocholate co-transporting polypeptide (NTCP)
Poster Presentation
Presenter: Stan van de Graaf

2458
Fas/Fas-ligand induced apoptosis of CD8(+) lymphocytes in the placenta of women with chronic hepatitis B plays a twofold role in the protection of fetus
Poster Presentation
Presenter: Dionysia Mandilara

2461
A primary human hepatocyte system to evaluate antisense oligonucleotide activity against clinically identified hepatitis B virus variants that contain mismatches in the bepirovirsen binding site
Poster Presentation
Presenter: Alexander Koenig

2530
A potent human PD-L1 siRNA leads to significant reduction of AAV-HBV infected hepatocytes via immune activation in human PD-1/PD-L1 double knock in mice
Poster Presentation
Presenter: Jin Hong
Droplet digital PCR can quantify cccDNA in plasma of naive chronic HBV infected patients with low HBsAg levels
Poster Presentation
Presenter: Ravinder Singh

A new glyco-biomarker for measuring infectious hepatitis B virus targeting surface antigen glycan isomer (HBsAgGi)
Poster Presentation
Presenter: Kiyohiko Angata

The divergent C-terminus of L-HDAg regulates the dynamic life cycle of HDV and the responses to lonafarnib treatment
Poster Presentation
Presenter: Hongbo Guo

Transcriptional analysis of HBV infected liver after treatment with selgantolimod reveals longitudinal changes in both inflammation-related pathways and B cell receptor repertoire
Poster Presentation
Presenter: Nikita Kolhatkar

Serum metabolite reveal mitochondrial dysfunction and energy metabolism disruption in chronic hepatitis C virus infection
Poster Presentation
Presenter: AMAR DEEP

Dating the origin and evolution dynamics of hepatitis D virus
Poster Presentation
Presenter: Wenshi Wang

Pregnancy zone protein as a promising biomarker for HEV-related acute liver failure
Poster Presentation
Presenter: Jian Wu

PD-1 does not suppress effector CD8 T cell differentiation during acute HBV infection and is not required for the induction of HBV-specific CD8 T cell exhaustion in HBV persistent mice
2885
Reduction in quantity and function of HBcAg-specific B cells indicates the response to anti-viral therapy in chronic HBV-infected patients receiving ETV or TDF treatment
Poster Presentation
Presenter: Jia Liu

2912
HBsAg induces mild activation, but not suppression, of intrahepatic immune cells as shown by single-cell RNA sequencing of fine-needle aspirates in chronic HBV patients
Poster Presentation
Presenter: Li Wang

2941
Intrahepatic hepatitis B virus cccDNA amount and transcriptional activity in a well-characterized cohort of Gambian chronically infected patients: correlation with emerging serum viral markers
Poster Presentation
Presenter: Zgjim Osmani

2948
A novel recombinant HBV based selection system allows for a systematic genomic knock-out screening and the identification of host factors involved in HBV infection
Poster Presentation
Presenter: Barbara Testoni

2979
miR-26a targets USP15 to robustly suppress hepatitis E virus replication via the enhancement of RIG-I-mediated type I interferon response
Poster Presentation
Presenter: Wenshi Wang

3032
Application of magnetic nanoparticle on boosting HBV infection system effectiveness
Poster Presentation
Presenter: Bo-Hung Liao

3040
Altered metabolic program initiates immune activation leading to hepatitis B surface antigen seroconversion in mild and severe hepatitis B reactivation patients
Poster Presentation
Presenter: Jayesh Kumar Sevak
Impact of pegylated interferon-alpha in combination with Bulevirtide in HBV/HDV infected humanized mice
Poster Presentation
Presenter: Maura Dandri

Impact of cirrhosis and long-term follow-up on the inflammatory milieu after hepatitis C virus (HCV) elimination by direct-acting antiviral (DAA) therapy
Poster Presentation
Presenter: Moana Witte

HBs-directed T cell engager antibodies foster efficient recruitment of T cells and lead to strong reduction of hepatitis B virus infection in livers of human liver chimeric mice
Poster Presentation
Presenter: Annika Volmari

Identification of unique liver NK cells in HBV and a new perspective on exhaustion-related NK cell phenotypes by single-cell RNA sequencing
Poster Presentation
Presenter: Boris Beudeker

Characterization of biomarker kinetics in a novel in vitro HBV infection model with the cell line HepG2-hNTCP-sec+ revealed stable HBsAg composition during short- and long-term infection up to four weeks
Poster Presentation
Presenter: Maria Pfefferkorn

Preclinical pharmacokinetic, pharmacodynamic and efficacy relationships of ALG-093702, a liver targeted PD-L1 small molecule inhibitor, in different in vivo models
Poster Presentation
Presenter: Tongfei Wu

Growth factor stimulation enhances NTCP expression and improves in vitro HBV infection in hepatoma cells
Poster Presentation
Presenter: Rodrigue Kamga Wouambo
3170
Hepatitis B virus antigens induce a dramatic LPS-like activation of inflammasome dependent on viral variability
Poster Presentation
Presenter: EVE TODESCO

3173
HBV and HDV interaction and variability in a superinfection mouse model: role of type I interferon
Poster Presentation
Presenter: Beatriz Pacín Ruiz

3211
Extracellular vesicle-derived microRNA signature in chronic hepatitis C patients with different stages of liver fibrosis
Poster Presentation
Presenter: Amanda Fernández Rodríguez

3219
Proteomics analysis of HBV cccDNA-bound proteins for therapeutic targeting in liver biopsies from hepatitis B patients
Poster Presentation
Presenter: Purnima Tyagi

3224
The role of gamma delta T cells in chronic hepatitis B virus infection
Poster Presentation
Presenter: Katja Steppich

3226
Baseline plasma lipidome correlates with direct-acting antiviral therapy non-response for HCV in HIV-HCV coinfected patients
Poster Presentation
Presenter: Vasundhra Bindal

3235
Host Sequence snatching identified in-vivo enhances hepatitis E viral replication
Poster Presentation
Presenter: Daniel Todt

3303
A gene editing approach for chronic hepatitis B: elimination of hepatitis B virus in vivo by targeting cccDNA and integrated viral genomes with a sequence-specific ARCUS nuclease
Oral Presentation
Presenter: Cassandra Gorsuch
Low intraindividual viral evolution is linked to disease progression and need of antiviral treatment initiation in chronic hepatitis B
Poster Presentation
Presenter: Magnus Illum Dalegaard

Recombinant hepatitis E viruses harboring a split luciferase tag in the ORF2 capsid protein
Poster Presentation
Presenter: Maliki Ankavay

Thiourea derivatives exhibit antiviral property by inhibiting hepatitis B virus DNA replication and HBx-induced gene transcription
Poster Presentation
Presenter: Jitendra Kumar

Prophylactic vaccine against hepatitis D virus (HDV) superinfection
Poster Presentation
Presenter: Matti Sällberg

HBV infection reshapes host chromatin accessibility and affects choline and iron metabolism
Poster Presentation
Presenter: Vincenzo Alfano

Viral hepatitis A/E: Clinical aspects

Hepatitis A hospitalisations in the United States and risk factors for inpatient mortality: a nationwide population study, 1998-2020
Poster Presentation
Presenter: Paul Wasuwanich

High prevalence of HEV related to the progression and prognosis of patients with acute pancreatitis: a multicentre cross-sectional and cohort study in China
Poster Presentation
Presenter: Jian Wu

Hepatitis E virus infection before and after liver transplantation
Viral hepatitis B and D: Clinical aspects

82
HBsAg seroclearance decreases risk of hepatocellular carcinoma but not hepatic decompensation in nucleos(t)ide analogue-treated cirrhotic patients with complete hepatitis B virus suppression: a territory-wide cohort study
Poster Presentation
Presenter: Petra Dinjar Kujundžić

98
Baseline hepatocyte ballooning is a risk factor for adverse events in patients with chronic hepatitis B complicated with nonalcoholic fatty liver disease
Poster Presentation
Presenter: Terry Cheuk-Fung Yip

199
Neglible 10-year risk of liver-related events in chronic hepatitis B patients with low liver stiffness
Poster Presentation
Presenter: Youwen Tan

214
Molecular epidemiology of hepatitis B virus and hepatitis delta virus coinfection in Sudan
Poster Presentation
Presenter: Lesley Patmore

250
An online web-based calculator accurately diagnoses immune tolerant phase in chronic HBV-infected patients
Poster Presentation
Presenter: Osama Mohamed

315
IP10 and anti-HBc can predict virological relapse and HBsAg loss for chronic hepatitis B patients after nucleos(t)ide analogue discontinuation
Poster Presentation
Presenter: Yandi Xie

344
Epidemiological landscape and clinical spectrum of chronic hepatitis B in East Africa
Poster Presentation
Presenter: abate shewaye
Utilizing machine learning-based predictive models to identify early virological recurrence in Chinese chronic hepatitis B patients following entecavir withdrawal
Poster Presentation
Presenter: Xiaoke Li

Incidence of hepatitis D virus super-infection in HBsAg positive patients (The Inci-D cohort study)
Poster Presentation
Presenter: Ingiliz Patrick

A retrospective observational cohort study of liver-related events among individuals with hepatitis B virus infection with and without hepatitis delta virus infection
Poster Presentation
Presenter: Laura Telep

Passive transfer of hepatitis B core antibody after intravenous immunoglobulin administration in adult patients: a retrospective review
Poster Presentation
Presenter: Sital Shah

Hepatitis D screening in HBsAg positive individuals in Germany: insufficient implementation results in a large number of undiagnosed cases
Poster Presentation
Presenter: Toni Herta

HDV full genome sequencing and sensitive HBV genotyping from a large cohort of HBV/HDV co-infected patients
Poster Presentation
Presenter: Savrina Manhas

Systematic review and meta-analysis: the proportion of chronic hepatitis B patients with different alanine transaminase upper limits and significant hepatic histology
Poster Presentation
Presenter: Yuhao Yao
Secular trends of newly diagnosed chronic hepatitis B in 2000-2022 – a territory-wide study
Poster Presentation
Presenter: Grace Lai-Hung Wong

647
Next generation core inhibitors ABI-H3733 and ABI-4334 have significantly improved potency and target coverage for both antiviral and cccDNA formation activities compared to first-generation core inhibitors
Poster Presentation
Presenter: Kathryn M Kitrinos

672
Epidemiological and clinical profile of HDV infected people in care in Italy: interim analysis from the ongoing PITER cohort
Poster Presentation
Presenter: Loreta Kondili

701
Clinical evaluation of highly sensitive iTACT hepatitis B core-related antigen and hepatitis B surface antigen assays in the management of HBV reactivation
Poster Presentation
Presenter: Takako Inoue

718
Eliminating viral hepatitis one island at a time – the Hainan experience
Poster Presentation
Presenter: Biao Wu

747
Prevalence and predictors of HDV viremia in anti-HDV positive patients of the HEllenic multicenter ReAl-life CLinical Study (HERACLIS-HDV)
Poster Presentation
Presenter: George Papatheodoridis

815
HBcrAg-based risk score predicts HCC better than HBV DNA-based risk scores in HBeAg-negative grey zone patients
Poster Presentation
Presenter: Tai-Chung Tseng

828
Eight weeks or less of tenofovir alafenamide to prevent the perinatal hepatitis B transmission: a multicenter, prospective, randomized study
Poster Presentation
Presenter: Qing-Lei Zeng

851
B cell phenotype, Toll-Like receptor 9 expression and proinflammatory cytokines profile in patients with chronic hepatitis B with HBsAg loss or persistent
Poster Presentation
Presenter: Nour Nasser

890
In patients with chronic hepatitis D, the decline of ≥2log HDV-RNA levels that remain detectable is associated with better clinical outcomes
Poster Presentation
Presenter: Adriana Palom

914
Long-term outcome of hepatitis delta in different regions world-wide: results of the hepatitis delta international network (HDIN)
Poster Presentation
Presenter: Anika Wranke

935
Steadily decline of HBV DNA load under NAs in lymphoma patients and higher level of qAnti-HBc predict HBV reactivation
Poster Presentation
Presenter: Yi-Qi Liu

942
Effect of Tenofovir and Entecavir on occurrence of hepatocellular carcinoma depends on duration of antiviral treatment and hierarchical PAGE-B risk score
Poster Presentation
Presenter: Yi-Hsiang Huang

1032
Self-stigma in chronic hepatitis B: content and psychometric validation of a new patient-reported outcome instrument
Poster Presentation
Presenter: Robert G. Gish

1034
Treatment with siRNA JNJ-73763989 plus nucleos(t)ide analogue (NA) decreases HBsAg and HDV RNA levels in patients with chronic hepatitis D (CHD): part 1 of the REEF-D study
Oral Presentation
Presenter: Heiner Wedemeyer
1141
Programmed cell death protein 1/ligand 1 inhibitor versus tyrosine kinase inhibitor in the efficacy of HBsAg reduction in chronic hepatitis B patients with hepatocellular carcinoma
Poster Presentation
Presenter: Te-Wei Tseng

1265
High prevalence of hepatic steatosis in adults living with hepatitis B, with and without HIV co-infection, in London, UK
Poster Presentation
Presenter: Claire Mullender

1356
Significant disparities in risk of cirrhosis and hepatocellular carcinoma among non-cirrhotic, treatment naïve, e-antigen negative hepatitis B patients with low levels of serum alanine aminotransferase
Poster Presentation
Presenter: Robert Wong

1359
Significant heterogeneity in long-term risks of cirrhosis or hepatocellular carcinoma among a national cohort of U.S. veterans with non-cirrhotic, treatment naïve chronic hepatitis B in the immune tolerant phase
Poster Presentation
Presenter: Robert Wong

1379
Novel serum biomarkers for risk stratification in chronic hepatitis B - what do they bring to the table?
Poster Presentation
Presenter: Louise Downs

1417
Hepatitis flare appeared to be more severe with poorer outcome in chronic hepatitis B patients with recent COVID vaccination during the COVID pandemic
Poster Presentation
Presenter: Jennifer Tai

1430
Extrahepatic malignancies and antiviral drugs for chronic hepatitis B: a nationwide cohort study
Poster Presentation
Presenter: Moon Haeng Hur

1460
Healthcare resource use and costs associated with hepatitis delta virus infection compared to hepatitis B virus monoinfection among commercially insured patients in the US
Poster Presentation
Presenter: Chong Kim

1467
Increased baseline comorbidity burden among commercially insured patients with hepatitis delta virus infection vs hepatitis B virus monoinfection in the United States
Poster Presentation
Presenter: Chong Kim

1469
Significantly higher clinical and economic burden following diagnosis of hepatitis delta virus infection among commercially insured adults with chronic hepatitis B in the United States
Poster Presentation
Presenter: Chong Kim

1475
Hepatitis delta treatment utilization in the United States: an analysis of commercially insured adults with hepatitis delta virus infection
Poster Presentation
Presenter: Chong Kim

1481
Patients with chronic hepatitis delta virus coinfections have higher risk of disease progression than chronic hepatitis B virus monoinfection – results from a Spanish national hospital database
Poster Presentation
Presenter: Chong Kim

1499
Assessment of clinical and patient reported outcome measures in individuals with chronic hepatitis B who clear HBsAg, followed by the Canadian hepatitis B network
Poster Presentation
Presenter: Carla Coffin

1602
Prediction of hepatocellular carcinoma in chronic hepatitis B patients following HBsAg seroclearance: Lage score
Poster Presentation
Presenter: Jonggi Choi

1605
Comparison of HCC incidence between entecavir and tenofovir in a chronic hepatitis B cohort with balanced censoring
1679
Novel, high accuracy prediction models of hepatocellular carcinoma based on longitudinal data and cell-free DNA signatures

Oral Presentation
Presenter: Rong Fan

1774
Liver stiffness measurement as a noninvasive method for the diagnosis of liver cirrhosis in patients with chronic hepatitis D virus infection

Poster Presentation
Presenter: Lisa Sandmann

1785
aMAP score and its combination with liver stiffness measurement accurately assess liver fibrosis in virologically suppressed CHB patients

Poster Presentation
Presenter: Jinlin HOU

1794
Current status of hepatitis delta in Andalusia: multicenter study

Poster Presentation
Presenter: Marta Casado

1886
Persistent detectable serum hepatitis B virus RNA is associated with increased risk of hepatocellular carcinoma in nucleos(t)ide analogues treated patients with chronic hepatitis B

Poster Presentation
Presenter: Shi Liu

1919
Improved prediction for liver fibrosis of Fibrosis-4 using machine learning in patients with chronic hepatitis B

Poster Presentation
Presenter: Zhiyi Zhang

1976
Identification of liver-associated gene signatures from serum exosomes in patients with chronic hepatitis B

Poster Presentation
Presenter: Mario Cortese
1992
Distribution of the natural history stages of pregnant women with chronic hepatitis B virus infection and its association with pregnancy complications and adverse pregnancy outcomes
Poster Presentation
Presenter: Zhihua Liu

2030
Influence of viral load and fibrotic burden on hepatocellular carcinoma risk at phase change to immune-active phase in chronic hepatitis B
Poster Presentation
Presenter: Ho Soo Chun

2067
Identification and external validation of the optimal ALT thresholds for ruling in significant histologic disease in chronic hepatitis B
Poster Presentation
Presenter: Zhiyi Zhang

2107
The impact of hepatitis B infection and advanced liver disease on health utility and health related quality of life in The Gambia: a cross-sectional study
Poster Presentation
Presenter: Yazan Haddadin

2117
Extrahepatic mortality in patients with chronic hepatitis B infection: a large population-based cohort study
Poster Presentation
Presenter: Young Eun Chon

2120
Treatment experience and acceptability in a UK HBV cohort—why personalised regimens may be necessary in chronic hepatitis B
Poster Presentation
Presenter: Jane Abbott

2157
Overcoming barriers to care for Delta infected patients
Poster Presentation
Presenter: Marina Berenguer

2165
Can we better characterize HBeAg-negative chronically infected hepatitis B patients using novel biomarkers?
Poster Presentation
Presenter: Thais Leonel Couto

2269
Dynamic monitoring of HBsAg-specific B cells in CHB patients and its clinical significance in predicting interferon therapy efficacy
Poster Presentation
Presenter: Yu Geng

2332
Comparison of hepatitis B reactivation in patients with resolved hepatitis B infection receiving rituximab or non-rituximab based immunosuppressive therapy: does presence of hepatitis B surface antibody reduce the risk of reactivation?
Poster Presentation
Presenter: Wei-Lun Liou

2356
Predominance of genotype 5 hepatitis delta virus infection in a portuguese centre
Poster Presentation
Presenter: Mariana Cardoso

2365
Contrasting immune fingerprints of chronic hepatitis B Virus infection in adults from South Africa and the United Kingdom
Poster Presentation
Presenter: Marion Delphin

2415
Clinical characteristics and phase transition of chronic hepatitis B patients with HBeAg and anti-HBe coexistence
Poster Presentation
Presenter: Ruifei Xue

2465
Association of liver fibrosis and hypophosphatemia in treatment-naïve patients with chronic hepatitis B
Poster Presentation
Presenter: Jian Wang

2490
Lower HBV DNA levels is associated more severe liver fibrosis in chronic hepatitis B with serological immune-tolerant phase
2507
Stability of Hepatitis B virus RNA in plasma and serum under various storage conditions
Poster Presentation
Presenter: Jian Wang

2582
Novel serum markers of cccDNA transcriptional activity – HBcrAg and pre-genomic RNA and CXCL10 pro-inflammatory chemokine levels can reduce uncertainty of HBeAg-negative chronic hepatitis B phases
Poster Presentation
Presenter: Valerie Ohlendorf

2604
HDV genotypes have an impact on pegylated interferon therapy response and long-term liver disease related outcomes
Poster Presentation
Presenter: Ivana Carey

2613
Treatment eligibility and initiation among chronic hepatitis B patients in a real-world setting in the United States
Poster Presentation
Presenter: Mark A Schmidt

2678
Long-term outcomes of patients with chronic HBsAg positive/HBe-negative infection: differences and transition between inactive carriers and low viremic carriers
Poster Presentation
Presenter: Giacomo Emanuele Maria Rizzo

2700
Distinct virologic trajectories in chronic hepatitis B patients identify heterogeneity in response to nucleotide analogue therapy
Poster Presentation
Presenter: Tingyan Wang

2708
The performance of the cobas® HBV RNA assay for use on the cobas® 5800/6800/8800 Systems (RUO) against genomic variants and transcript heterogeneity
Poster Presentation
Presenter: Thomas Meister
2765
HBV infected pregnant woman received antiviral treatment and discontinued it postpartum can benefit from retreatment
Poster Presentation
Presenter: Qiao Tang

2767
Effects of tenofovir alafenamide fumarate on serum lipids in patients with chronic hepatitis B
Poster Presentation
Presenter: Yilin Liu

2770
Higher risk of disease progression in the gray zone relative to hepatitis B e antigen negative chronic hepatitis B infection
Poster Presentation
Presenter: YunLing Xue

2771
A novel nomogram for predicting HBeAg clearance in HBeAg-positive chronic hepatitis B patients after nucleos(t)ide analogues treatment
Poster Presentation
Presenter: Yan Gu

2815
Analysis of disease progression in patients with chronic hepatitis B using a large nationwide database
Poster Presentation
Presenter: Nobuharu Tamaki

2826
Serum CXCL16 serves as the predictor for liver inflammation functioning through a NKT cell-depend way in chronic hepatitis B patients
Poster Presentation
Presenter: Yawen Wan

2962
Hepatitis delta virus (HDV) infection: frequency and outcome in persons living with HIV (PLWH). Data from the ICONA (Italian cohort of naïve for antiretrovirals) cohort
Poster Presentation
Presenter: Massimo Puoti

3089
Systematic screening for hepatitis B at emergency department and linkage to care in Barcelona, Spain
Poster Presentation
Presenter: Juan Carlos Ruíz-Cobo

3177
Detection of hepatitis delta virus in seminal fluid and female genital tract
Poster Presentation
Presenter: Naranjargal Dashdorj

3213
Off-therapy events in hepatitis B e antigen-negative patients with sustained HBV surface antigen <100 and <50 IU/mL
Poster Presentation
Presenter: Yen-Chun Liu

3217
Impact of fatty liver on long-term outcomes in chronic hepatitis B: a systematic review and matched analysis of individual patient data meta-analysis
Poster Presentation
Presenter: Yu Jun Wong

3227
Aspirin use and risk of hepatocellular carcinoma and gastrointestinal bleeding in patients with HBV-related cirrhosis: a landmark analysis
Poster Presentation
Presenter: Mi Na Kim

3236
Association of TLR7 polymorphisms in Caucasians with disease stages and HBsAg loss in hepatitis virus B infections
Poster Presentation
Presenter: Janett Fischer

3238
Stable temporal trend of HDV seroprevalence in central Italy across the last two decades with the circulation of HDV sub-genotypes 1 inducing different inflammatory stimuli
Poster Presentation
Presenter: Lorenzo Piermatteo

3252
Dried blood spot (DBS): a new tool for screening, diagnosis and monitoring of hepatitis D virus (HDV) infection
Poster Presentation
Presenter: Rola Matar
3258
Higher levels of three HBsAg forms (Large, Middle and Small HBsAg) are associated with HDV replication and with the degree of disease and liver damage
Poster Presentation
Presenter: Leonardo Duca

3261
Driving improvements in hepatitis B care in Africa: profile of the hepatitis B in Africa collaborative network (HEPSANET)
Poster Presentation
Presenter: Asgeir Johannessen

3288
The comparisons of clinical relapse timing and severity after cessation of prophylactic nucleos(t)ide analogue between chronic hepatitis B patients with lymphoma receiving chemotherapy with and without Rituximab
Poster Presentation
Presenter: Yen-Chun Liu

3298
Long-term outcomes of untreated chronic hepatitis B patients with persistent HBsAg <100 IU/mL
Poster Presentation
Presenter: Rachel Wen-Juei Jeng

3341
The prognosis of hepatitis delta infections in Belgium is poor and determined by the hepatitis delta viremia
Poster Presentation
Presenter: Arno Furquim d’Almeida

3364
Serum thrombospondin-2 for predicting liver fibrosis in patients with chronic hepatitis B virus infection
Poster Presentation
Presenter: Yun Chen

3366
The intrahepatic activity of Hepatitis Delta virus is sustained by an abundant production of HBs transcripts, mainly derived from integrated HBV-DNA, and is not strictly related to the extent of HBV reservoir
Poster Presentation
Presenter: Romina Salpini
3367
Risk factors for viral reactivation in patients with overt or occult HepatitisB Virus infection receiving immunosuppressive treatments: a systematic review and meta-analysis
Poster Presentation
Presenter: Ciro Celsa

3384
Characterizing chronic hepatitis delta in Spain and the gaps in its management
Poster Presentation
Presenter: Sergio Rodriguez-Tajes

3438
Ultrasensitive HBV-RNA quantification by droplet digital PCR is a promising biomarker to optimize the staging of chronic HBV infection and to identify minimal viral activity under prolonged virological suppression
Poster Presentation
Presenter: Romina Salpini

3469
The benefit of a local hepatitis B reactivation guideline to improve screening and prophylaxis for patients initiated on rituximab
Poster Presentation
Presenter: Helen Boothman

3490
Study of hepatitis delta virus replication markers in anti-HBc positive patients with chronic hepatitis C
Poster Presentation
Presenter: Francisco Javier Garcia-Samaniego Rey

3622
Barriers to hepatitis B treatment from the patient’s perspectives: survey study by the canadian hepatitis B network
Poster Presentation
Presenter: Hin HIn Ko

3660
Ten years follow-up of patients with chronic hepatitis B and hepatitis D infection
Poster Presentation
Presenter: Andreea Dobroaia

3730
The role of PAGE-B score in predicting the development of hepatocellular cancer in patients with chronic delta hepatitis
Poster Presentation
T-cell responses to PreS1 and PreS2 are correlated to anti-HBs antibody titres, which are higher and persist longer in volunteers vaccinated with 3-antigen than with 1-antigen hepatitis B vaccine in the PROTECT Study: 3.5 year follow up
Poster Presentation
Presenter: Francisco Diaz-Mitoma

Clinical phenotypes of hepatocellular carcinoma in patients with chronic hepatitis D compared to patients with chronic hepatitis B
Poster Presentation
Presenter: Christoph Schramm

HDV RNA levels <1000 IU/ml and total anti-HDV titers <1:1000 identify chronic hepatitis D subjects without active liver disease
Poster Presentation
Presenter: Gabriele Ricco

Risk stratification for hepatocellular carcinoma in patients with chronic hepatitis D
Poster Presentation
Presenter: Christoph Schramm

Relationship of hepatitis D viral load, ALT levels, and liver stiffness in untreated patients with chronic hepatitis D
Poster Presentation
Presenter: Soo Aleman

Long-term outcomes of a population-based cohort of chronic hepatitis B (CHB) patients in West Africa
Poster Presentation
Presenter: Gibril Ndow

Viral Hepatitis B and D: Current therapies

Predictors of severe flares after nucleos(t)ide analogue cessation - results of a global cohort study (RETRACT-B study)
Oral Presentation
Presenter: Edo Dongelmans

725
Five years follow-up of 96 weeks peginterferon plus tenofovir disoproxil fumarate in hepatitis D
Poster Presentation
Presenter: Heiner Wedemeyer

855
Low HBV DNA and HBsAg levels at 24 weeks off-treatment predict sustained response and HBsAg loss in patients who discontinued antiviral therapy
Poster Presentation
Presenter: Milan Sonneveld

923
Stopping bulevirtide in long-term HDV-RNA suppressed patients seems safe and may enable long treatment-free intervals
Poster Presentation
Presenter: Mathias Jachs

1073
NTCP genetic variants may influence early virological response to bulevirtide monotherapy in patients with HDV related cirrhosis
Poster Presentation
Presenter: Pierluigi Toniutto

1123
Association of post-treatment virologic relapse and biochemical flares with HBV serum biomarkers in long-term virologically suppressed HBeAg-negative patients stopping NA treatment: Exploratory analyses from the control arm of the REEF-2 study
Poster Presentation
Presenter: Florian van Bömmel

1169
Tenofovir is associated with a better prognosis of hepatocellular carcinoma compared with entecavir in patients with chronic hepatitis B
Poster Presentation
Presenter: Hyun Jun Um

1237
Comparable risk of cardiovascular events in chronic hepatitis B patients treated with tenofovir disoproxil fumarate or tenofovir alafenamide
Poster Presentation
Presenter: Hyeyeon Hong
Comparison of body weight and lipid profiles following tenofovir disoproxil fumarate or entecavir switching to tenofovir alafenamide in chronic hepatitis B patients
Poster Presentation
Presenter: Pin-Nan Cheng

HDV-RNA decline less than 1 log after 6 months of BLV 2mg monotherapy could define poor response and lead to therapeutic decision. Data from real-life cohort
Oral Presentation
Presenter: Victor de Lédinghen

The different immune response of B cells specific for hepatitis B virus core and envelope antigen in chronic hepatitis B patients with pegylated interferon-alpha treatment
Poster Presentation
Presenter: Qi Zheng

Hepatitis B surface antigen loss rate and safety and discontinuations with pegylated interferon alpha in chronic hepatitis B virus infection, a systematic review
Poster Presentation
Presenter: Vera Gielen

Model-based meta-analysis of pegylated IFN-alpha induced HBsAg loss at end of treatment and 24 weeks post treatment in chronic hepatitis B virus infection
Poster Presentation
Presenter: Vera Gielen

Improvements in ALT levels during Bulevirtide treatment for hepatitis D are seen regardless of virologic response
Poster Presentation
Presenter: Katja Deterding

Switching to Besifovir in chronic hepatitis B patients receiving Tenofovir Disoproxil Fumarate: 96 weeks results of phase 4 trial
Poster Presentation
Presenter: Hyung Joon Yim
2187
Effect of first-line nucleoside analogues on blood lipids in patients with chronic hepatitis B: a network meta-analysis
Poster Presentation
Presenter: Kexin Tong

2199
Comparison of kidney function decline between chronic hepatitis B patients with versus without antiviral therapy
Poster Presentation
Presenter: Jae Seung Lee

2318
Predictors of Baveno VII criteria for recompensation in patients with hepatitis B-related decompensated cirrhosis
Poster Presentation
Presenter: Vicki Wing-Ki HUI

2371
Long-term efficacy of tenofovir alafenamide in HBeAg-positive and -negative chronic hepatitis B patients treated for up to 8 years in 2 phase 3 studies
Oral Presentation
Presenter: Maria Buti

2373
The efficacy of peginterferon alpha in Chinese inactive hepatitis B carriers and nucleoside analogs-experienced patients: a real world research
Poster Presentation
Presenter: Chaojing Wen

2380
Kinetics of HBsAg forms in chronic hepatitis delta patients treated with bulevirtide for 48 weeks: correlation with virological response
Poster Presentation
Presenter: Stefano D'Anna

2448
Long-term safety profile of tenofovir alafenamide in chronic hepatitis B patients; final 8-year results of 2 Phase 3 studies
Poster Presentation
Presenter: Young-Suk Lim

2727
Incomplete response with/without genotypic resistance to prior antivirals is not associated with a higher risk of hepatocellular carcinoma during tenofovir treatment for chronic hepatitis B
Poster Presentation
Presenter: Ju Yeon Kim

2814
Utility of partial cure as an endpoint after nucleos(t)ide analogue withdrawal among chronic hepatitis B patients (RETRACT-B study)
Poster Presentation
Presenter: Grishma Hirode

2959
Effects of tenofovir disoproxil fumarate versus tenofovir alafenamide on risk of osteoporotic fracture in patients with chronic hepatitis B: a nationwide claims study
Poster Presentation
Presenter: Eunju Kim

3323
Similarly low risk of chronic kidney disease (CKD) progression in chronic hepatitis B patients with Stage 2 CKD on tenofovir alafenamide versus entecavir
Poster Presentation
Presenter: Yan Liang

3567
Effects of interferon-based therapies in functional cure and hepatocellular carcinoma risk reduction in patients with chronic hepatitis B: real-world evidence from 2-year data of OASIS project
Poster Presentation
Presenter: Qiran Zhang

3734
Efficacy and safety at 96 weeks of bulevirtide 2 mg or 10 mg monotherapy for chronic hepatitis D: results from an interim analysis of a phase 3 randomized study
Oral Presentation
Presenter: Heiner Wedemeyer

Viral Hepatitis B and D: New therapies, unapproved therapies or strategies

239
Consolidation treatment with Tiaogan-Buxu-Jiedu granule (Traditional Chinese Medicine compound) plus entecavir reduces virological relapse following entecavir withdrawal in Chinese patients with chronic hepatitis B: a randomized, controlled trial
Poster Presentation
Presenter: Xiaoke Li
Safety, pharmacokinetics, and antiviral activity of the next-generation hepatitis B core inhibitor ABI-H3733 in patients with hepatitis B e antigen negative chronic hepatitis B infection: preliminary results from a randomized, blinded, Phase 1b study
Poster Presentation
Presenter: Edward Gane

The safety and pharmacokinetics of ABI-4334, a novel next-generation HBV core inhibitor: interim results from a phase 1 study in healthy volunteers
Poster Presentation
Presenter: Edward Gane

A novel class of orally-available small molecules potently inhibiting hepatitis B and D virus entry
Poster Presentation
Presenter: Marc Windisch

Vebicorvir, entecavir, and pegylated interferon in patients with hepatitis B e antigen positive chronic hepatitis B virus infection: findings from a phase 2, randomized open-label study in China
Poster Presentation
Presenter: Grace Wang

Efficacy and safety of celecoxib add on nucleos(t)ide analogues on the hepatitis B surface antigen of virally suppressed patients with chronic hepatitis B - interim analysis
Poster Presentation
Presenter: Feng Xue

Treatment for up to 24 weeks with the capsid assembly modulator ALG-000184 results in dose related reductions in HBsAg in subjects with HBeAg positive chronic hepatitis B
Poster Presentation
Presenter: Jinlin HOU

Is treatment with Bulevirtide 10 mg useful in poor responder patients to 2 mg? Results from the French multicenter early access program
Poster Presentation
Presenter: Victor de Lédinghen
1270
Cell-mediated immunity analysis to assess the characteristics of immune response to bepirovirsen: Examples from the B-Clear study
Poster Presentation
Presenter: Jenn Singh

1273
Safety and antiviral activity of short-duration combinations of the investigational small interfering ribonucleic acid VIR-2218 with the neutralizing, vaccinal monoclonal antibody VIR-3434: post-treatment follow-up from the Phase 2 MARCH trial
Oral Presentation
Presenter: Edward Gane

1281
Hepatitis B virus core protein variant profiles observed in chronic hepatitis B patients treated with capsid inhibitor AB-836
Poster Presentation
Presenter: Christine L. Espiritu

1305
Single dose pharmacokinetics of VIR-3434, a novel neutralizing monoclonal antibody, in participants with chronic hepatitis B virus infection
Poster Presentation
Presenter: Sneha V. Gupta

1333
VIR-2218 and VIR-3434 therapy is efficacious in preclinical models of hepatitis delta virus infection
Poster Presentation
Presenter: Florian Lempp

1543
Efficacy and prediction analysis of pegylated interferon alpha-2b in treatment-naive HBeAg negative chronic hepatitis B patients with normal ALT: a multicenter real-world study (Ice-breakting Project in China) - Interim analysis
Poster Presentation
Presenter: Chong Zhang

1650
Week 48 results of the phase 3 D-LIVR study, a randomized double-blind, placebo-controlled trial evaluating the safety and efficacy of Lonafarnib-boosted with Ritonavir with or without Peginterferon Alfa in patients with chronic hepatitis delta
Oral Presentation
Presenter: Ohad Etzion
1703
The safety and efficacy of hepalatide (L47) treatment combined with pegylated interferon-alpha 2a in patients with chronic hepatitis B: the preliminary data from a double-blind, RCT phase II trial
Poster Presentation
Presenter: Xiaolu Tang

2024
The Nuc-Stop study: an open-label, randomized trial of different re-start strategies after treatment withdrawal in HBeAg negative chronic hepatitis B patients
Poster Presentation
Presenter: Asgeir Johannessen

2113
Quantification of serum HDV RNA in untreated and Bulevirtide-treated patients with CHD: a comparison between Robogene 2.0 and Eurobioplex
Poster Presentation
Presenter: Maria Paola Anolli

2324
Significant improvement of non-invasive fibrosis tests in HDV compensated cirrhotic patients with clinically significant portal hypertension treated with BLV monotherapy up to 96 weeks
Poster Presentation
Presenter: Elisabetta Degasperi

2328
Switching to peginterferon for chronic hepatitis B patients with hepatitis B e antigen seroconversion on entecavir - a long term follow-up study
Poster Presentation
Presenter: Che To Lai

2359
Kinetics of hepatitis B core related antigen in patients with compensated HDV cirrhosis treated with Bulevirtide monotherapy for 72 weeks: a single-center study
Poster Presentation
Presenter: Elisabetta Degasperi

2399
Modeling-based response-guided therapy with bulevirtide monotherapy for chronic hepatitis D to identify patients for finite treatment duration
Poster Presentation
Presenter: Harel Dahari

2432
Treatment with Bulevirtide, with or without PEG-interferon, in HIV-HBV/HDV co-infected patients in a real-life setting
Poster Presentation
Presenter: Victor de Lédinghen

2441
Positive impact of reflex testing in performing hepatitis delta serology in HBsAg+ patients
Poster Presentation
Presenter: Régine Truchi

2492
Deep learning cluster analysis reveals subtypes in response to antisense oligonucleotide therapy in chronic hepatitis B
Poster Presentation
Presenter: Caroline Weis

2515
Therapeutic vaccine candidate CLB-3000 (CLB-405 and CLB-505 adjuvanted with Alhydrogel): a Good Laboratory Practice (GLP)-compliant 15-week intramuscular toxicity study in rabbits with a 4-week recovery
Poster Presentation
Presenter: Aileen Rubio

2543
A monoclonal antibody 4G2 exhibits anti-viral activity in mouse models of chronic hepatitis B
Poster Presentation
Presenter: Aditi Deshpande

2588
Safety, pharmacokinetics, and antiviral activity of single ascending doses of ALG-125755, a GlcNAc-conjugated small interfering RNA, in subjects with chronic hepatitis B
Poster Presentation
Presenter: Alina Jucov

2668
Increasing functional cure rate beyond 96 weeks after discontinuation of nucleos(t)ide analogue treatment in HBeAg-negative chronic hepatitis B: follow-up of the stop-NUC trial
Poster Presentation
Presenter: Florian van Bömmel

2841
Safety and antiviral activity of RBD1016, a RNAi therapeutic, in chinese subjects with chronic hepatitis B virus (HBV) infection
Poster Presentation
Presenter: Wai-Kay Seto

2887
A phase 2 study of ASC42, a novel farnesoid X receptor (FXR) agonist, in combination with PEGylated interferon (PEG-IFN) and entecavir (ETV) in chronic hepatitis B patients with 12-week treatment
Poster Presentation
Presenter: Jinlin HOU

2944
AHB-137, a novel hepatitis B virus antisense oligonucleotide with substantially enhanced in vitro and in vivo antiviral activity
Poster Presentation
Presenter: Xiaoli Wu

3022
Phase 1b/2a study of heterologous ChAdOx1-HBV/MVA-HBV immunotherapy (VTP-300) combined with low-dose nivolumab (LDN) in virally suppressed patients with CHB on nucleos(t)ide analogues
Poster Presentation
Presenter: Tom Evans

3039
AHB-137, a novel and potent hepatitis B virus antisense oligonucleotide with a favorable preclinical pharmacokinetics and safety profile
Poster Presentation
Presenter: Tingting Lu

3257
Pretreatment and on-therapy HDV RNA levels predict response to Bulevirtide monotherapy in HDV compensated cirrhotic patients treated up to 96 weeks
Poster Presentation
Presenter: Elisabetta Degasperi

3352
Frequency of bepivirsen binding site nucleotide polymorphisms at baseline and impact on end of treatment response to bepivirsen (Phase 2b B-Clear study)
Poster Presentation
Presenter: Jerome Bouquet

3424
Rescue of cirrhotic HBV / HDV infection from bulevirtide failure by subcutaneous REP 2139-Mg
Poster Presentation
Presenter: Marc Bourliere
Preliminary results of a Phase 1b, open-label, multicenter study of selgantolimod (GS-9688) in special populations of patients with chronic hepatitis B
Poster Presentation
Presenter: Kosh Agarwal

Analysis of HBV genotype association to bepirovirsen treatment response in patients with chronic HBV infection (Phase 2b B-Clear study)
Poster Presentation
Presenter: Jerome Bouquet

Safety and efficacy of REP 2139-Mg in association with TDF in chronic hepatitis delta patients with decompensated cirrhosis
Poster Presentation
Presenter: Christiane Stern

Viral Hepatitis C: Clinical aspects including follow up after SVR

Predicting vertical transmission of hepatitis C in pregnant women using a composite score: a multicenter study
Poster Presentation
Presenter: Paul Wasuwanich

Serum myostatin decreased after direct acting antivirals for cirrhotic patients
Poster Presentation
Presenter: Tomoyuki Suehiro

Most vulnerable HCV patient groups treated with direct acting antivirals achieve high response rates and gain quality of life – data from the German hepatitis C-registry (DHC-R)
Poster Presentation
Presenter: Stefan Christensen

Real-world data on long-term quality of life after Glecaprevir/Pibrentasvir therapy: data from the German hepatitis C registry (DHC-R)
Poster Presentation
Presenter: Markus Cornberg
207
Results of the hepatitis B and C screening within the “Check-Up35+” in the German primary care setting one year after implementation by the federal joint committee
Poster Presentation
Presenter: Johannes Wiegand

253
The impact of HCV cure on glycemic indices in patients using glecaprevir/pibrentasvir from nationwide Taiwan HCV registry
Poster Presentation
Presenter: Chung-Feng Huang

312
Impact of direct-acting antiviral therapy on tumor progression and survival in intermediate to advanced hepatocellular carcinoma patient with HCV infection
Poster Presentation
Presenter: Chen-Ta Chi

441
Evaluation of patients treated with direct-acting anti-viral therapy for chronic hepatitis C and their risk of hepatocellular carcinoma in Hong Kong
Poster Presentation
Presenter: Victor Yung Sin Chow

650
Coadministration of hepatitis C direct-acting antivirals and enzyme-inducing antiepileptic drugs: real-world experience from a multi-centre case series
Poster Presentation
Presenter: Alison Boyle

721
Sustained virologic response outcomes in patient with hemodialysis - hepatitis c receiving treatment with direct-acting antivirals agents
Poster Presentation
Presenter: Fardhah Akil

752
Ethnic disparity in mortality related to extrahepatic manifestations among people with chronic HCV infection: a large, linked administrative population-based study in British Columbia, Canada
Poster Presentation
Presenter: Dahn Jeong

759
Analysis of mortality rate in the patients after hepatitis C virus elimination using direct acting antivirals and comparison with the general population
Poster Presentation
Presenter: Satoshi Miuma

798
Impact of direct-acting antiviral therapy on survival in patients with liver cirrhosis and ascites. Data from the hepa-C registry
Poster Presentation
Presenter: Álvaro Hidalgo Romero

848
The prevalence of hepatitis C virus infection in high-risk patients with high normal alanine aminotransferase (ALT) in Israel: a bio bank analysis
Poster Presentation
Presenter: Amir Shlomai

875
The impact of 5 years of testing for hepatitis C in prisons in the north east of England
Poster Presentation
Presenter: Amy Johnson

1014
Clinical outcomes after hepatitis C treatment in patients with advanced chronic liver disease
Poster Presentation
Presenter: Fabio Correia

1170
Mortality risk following HCV cure among people with HIV coinfection
Poster Presentation
Presenter: Naveed Janjua

1299
HCV screening rates in reproductive age women after universal screening guidelines
Poster Presentation
Presenter: Roshni Singh

1321
Network transmission of hepatitis C genotype 2c and 4d in men who have sex with men in Cape Town, South Africa
Poster Presentation
Presenter: Mark Sonderup
1404
External validation of models to predict hepatocellular carcinoma (HCC) in HCV SVR F3-F4 patients
Poster Presentation
Presenter: Marina Berenguer

1494
What is the impact of a Hepatitis C ‘test and trace’ pilot using peer workers?
Poster Presentation
Presenter: Stuart Mcpherson

1559
Post-treatment liver function, but not baseline liver function, predicts survival in hepatitis C virus patients with decompensated cirrhosis after direct-acting antiviral treatment
Poster Presentation
Presenter: Yuki Tahata

1569
Achieving a hepatitis C cure in those with hepatocellular carcinoma is associated with an improvement in overall survival: real world data
Oral Presentation
Presenter: Maria Guerra Veloz

1603
Hepatitis C virus (HCV) infection and neurocognitive impairment in subjects with mild liver disease
Poster Presentation
Presenter: Marcia Maria Amendola Pires

1609
Prognostic factors of post-sustained virological response outcome in patients with chronic hepatitis C treated with direct-acting antivirals
Poster Presentation
Presenter: Won Sohn

1637
Long term normalization of systemic inflammation and endothelial activation after hepatitis C virus (HCV) eradication in HIV/HCV coinfected, HCV monoinfected patients and HCV-infected liver transplant recipients
Poster Presentation
Presenter: laura benitez gutierrez

1733
Direct-acting antivirals reduce disease burden in patients with chronic hepatitis C: a Korean nationwide, multicentre, retrospective cohort study
Poster Presentation
1741
The PNPLA3 genotype is the main driver of weight gain after the hepatitis C cure
Poster Presentation
Presenter: Veronika Pitova

1790
The influence of direct acting antiviral treatment in chronic hepatitis C virus infection on arterial stiffness
Poster Presentation
Presenter: Mircea Istrate

1926
A large-scale, centralized viral hepatitis screening model in Hainan province of China during the COVID-19 pandemic
Poster Presentation
Presenter: Tao Wu

1969
Usefulness of serum CCL20 as a post sustained viral response biomarker for HCV-associated liver fibrosis
Poster Presentation
Presenter: Atsumasa Komori

2021
Hepatitis C micro-elimination program in Zhuhai: a concerted citywide effort to eliminate hepatitis C by 2030
Poster Presentation
Presenter: Xinchun Zheng

2046
Evaluation of the follow-up in patients with advanced fibrosis after achieve sustained viral response with direct-acting antivirals. Screening and risk of hepatocellular carcinoma
Poster Presentation
Presenter: Vanesa Bernal Monterde

2366
HCV screening: shortening read time of point-of-care rapid diagnostic test does not effect detection rates of antibodies against hepatitis C virus
Poster Presentation
Presenter: Muhammad Nabeel Shafqat
2430
Achieving hepatitis C micro-eliminating in 4 female prisons through a nurse led test and treat approach of pathway optimisation and whole prison testing
Poster Presentation
Presenter: Nichola Royal

2460
MAFLD (metabolic associated fatty liver disease) outperforms ultrasonographic steatosis to stratify hepatocellular carcinoma risk in patients with advanced hepatitis C cured with direct antiviral agents
Poster Presentation
Presenter: Serena Pelusi

2601
Cholestatic HCV-related cryoglobulinemia, a new clinical and pathological entity: a case-control study
Poster Presentation
Presenter: Sara Romeo

2605
Hepatitis C virus (HCV) infection and neurocognitive impairment in subjects with mild liver disease: the role of neuropsychological and cognitive provoked P300 tests
Poster Presentation
Presenter: CARLOS BRANDÃO-MELLO

2621
HCV elimination: reengagement of previously diagnosed but unlinked patients with chronic hepatitis C to initiate treatment
Poster Presentation
Presenter: Maria Guerra Veloz

2634
The risks of first hepatic decompensation and HCC remain constant during long-term follow-up and can be stratified by a one-time assessment after HCV-cure
Oral Presentation
Presenter: Georg Semmler

2676
Chronic hepatitis C and aging: search for cognitive changes
Poster Presentation
Presenter: CARLOS BRANDÃO-MELLO

2704
Hospitalisation - missing an opportunity to link to hepatitis C care: a retrospective study at a regional Australian health service
Poster Presentation
Presenter: Joseph DOYLE

2953
Utilising peer support workers in hepatitis C screening in emergency departments: a pilot study
Poster Presentation
Presenter: Alex Caulder

3033
Hepatitis C virus infection follow-up of people who use drugs in the Balearic Islands, Spain
Poster Presentation
Presenter: Jeffrey Lazarus

3422
Impact of hepatitis C treatment on biochemical and metabolic parameters in HIV/HCV coinfected patient
Poster Presentation
Presenter: Misael Osmar Garcia Martin

3456
Clinical outcomes after therapy with direct acting antiviral in patients with HCV-related B-cell Non-Hodgkin lymphomas and/or mixed cryoglobulinemia
Poster Presentation
Presenter: Marco Tizzani

3519
Digital pathology quantification of cirrhosis severity continuum in human HCV liver biopsies and its correspondence with Laennec and Beijing stages
Poster Presentation
Presenter: Louis Petitjean

3531
Differences in baseline characteristics of direct acting antiviral (DAA)- treated Greek HCV patients according to source of infection
Poster Presentation
Presenter: Spyridon (Spyros) SIAKAVELLAS

3542
One year of HCV/HBV/HIV screening in a psychiatric population consulting in the emergency room (Beaujon Hol/REVHEPAT)
Poster Presentation
Presenter: Tarik Asselah

3551
Hepatitis C and monoclonal gammopathy of undetermined significance: clinical and hematological outcome after eradication with direct acting antivirals
Poster Presentation
Presenter: Rosa Claudia Stasio

3572
A prospective, pragmatic post-authorisation safety study of early recurrence of hepatocellular carcinoma in hepatitis C virus-infected patients after direct-acting antiviral (DAA) therapy: DAA-PASS
Poster Presentation
Presenter: Amit Singal

3748
Incidence and associations of HCV reinfection in the era of direct acting antivirals
Poster Presentation
Presenter: Sofia Vasileiadi

3810
HCV micro-elimination strategy in a tertiary hospital: identification of lost cases and linkage to care
Poster Presentation
Presenter: Maria Torner

Viral hepatitis C: Therapy and resistance

83
Retreatment of patients experiencing failure with Hepatitis C direct-acting antivirals
Poster Presentation
Presenter: Nessa Quinn

335
Progress towards achieving hepatitis C elimination in the country of Georgia, April 2015 – December 2022
Poster Presentation
Presenter: Tengiz Tsertsvadze

409
Efficacy of direct-acting antivirals in patients with hepatitis C virus-associated cryoglobulinemia and monoclonal gammopathy
Poster Presentation
Presenter: Sofia Gavrisheva

570
An algorithm for simplified hepatitis C virus treatment with non-specialist care based on real-world data from a nationwide registry in Taiwan
Poster Presentation
Presenter: Ming-Lung Yu

1012
The most difficult to cure with pangenotypic regimens HCV infected population
Poster Presentation
Presenter: Robert Flisiak

1449
Unusual HCV subtypes and retreatment outcomes in a cohort of European DAA-experienced patients
Oral Presentation
Presenter: Julia Dietz

1828
Real-world effectiveness of voxilaprevir/velpatasvir/sofosbuvir in hepatitis C patients with prior failure to DAA treatment
Oral Presentation
Presenter: Christiana Graf

1846
Efficacy and safety of Sofosbuvir Plus Daclatasvir bilayer tablet with or without Ribavirin in patients with chronic hepatitis C genotype 4 Infection
Poster Presentation
Presenter: Mohamed Hassany

2738
Sofosbuvir/Velpatasvir plus Ribavirin for chronic hepatitis C virus genotype 3 infected cirrhotic patients with or without HIV or HBV coinfection: real-world experience from southwest China
Poster Presentation
Presenter: Yongrui Yang

2785
Evaluating utilization and management of comediations with potential for drug-drug interactions among patients with chronic hepatitis C initiating treatment with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir
Poster Presentation
Presenter: Stuart C Gordon

2965
Sofosbuvir/Velpatasvir/Voxilaprevir for re-treatment in direct-acting antiviral experienced hepatitis C virus patients: a systematic review and meta-analysis
Poster Presentation
Presenter: Devan Pooja
3031
Concomitant use of proton pump inhibitors and Sofosbuvir/Velpatasvir: evidence from randomized clinical trials and real-world data
Poster Presentation
Presenter: Maria Buti

3140
Real-life effectiveness of voxilaprevir/sofosbuvir/velpatasvir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir
Poster Presentation
Presenter: Juan Carlos Ruíz-Cobo

3221
Outcomes of early vs late treatment initiation in solid organ transplantation from HCV NAT+ donors to HCV-uninfected recipients: results from the HCV-TARGET study
Oral Presentation
Presenter: Wesam Aleyadeh

3802
Resistance-associated substitutions described after failure of anti-NSSA direct-acting antiviral treatment in 58 hepatitis C virus (HCV) infected patients in cameroon
Poster Presentation
Presenter: serge Tchamgoue